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Chapter 1 
General Introduction 
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To truly understand biology, we need to study it as a system [1]. From a technical perspective, a stable 
system is characterized by feedback loops and a large degree of redundancy, and biological systems are 
no exception. Changing a single input, such as the activity of a protein due to a mutation, will generally 
have only a small impact on the observed phenotype of the biological system, but will affect several 
biological pathways regardless. This becomes complicated when studying complex traits, such as cancer, 
which is characterized by a global deregulation of genetic and epigenetic processes, affecting a whole 
network of intertwined biological pathways [2]. The same goes for nutrition, as food consists of complex 
mixture of various bioactive compounds, influencing a plethora of processes [3,4]. The only way to 
unravel such complex interactions, is to use so-called systems biology approaches. Technology wise, this 
requires high-throughput genome wide methods. No longer focusing on measurements of single entities, 
biological research now encompasses measurements on multiple molecular levels using so-called omics 
approaches, to study gene transcription [5], protein and metabolite levels [6], protein-protein interactions 
[7], protein-DNA interactions [8], genetic variation [9] and many other levels in a single integrative 
biological framework.  With these approaches, not only the amount of data in biological research has 
exploded, but also the complexity thereof, severely hampering biological interpretation. The major 
challenge of bioinformatics has been to develop computational approaches to distill biology from this 
broth of ones and zeros and as such has become one of the cornerstones in modern systems biology 
research.   
 
Arguably, the most successful omics technology of the last decade has been transcriptomics, to study 
gene expression in a genome-wide setting [10]. Yet, more and more we realize that we are not only 
interested in identifying changes in gene expression between conditions, but also in the complex 
regulatory events behind such changes. This thesis focuses on the bioinformatics challenges of studying 
regulatory events originating from the cistrome and the epigenome. The cistrome is defined as the 
complete genome-wide set of cis-acting target sites on the DNA, such as transcription factor binding 
sites, of a trans-acting factor, such as a transcription factor. The complete genome-wide set of epigenetic 
marks is known as the epigenome. Such epigenetic marks are heritable chromatin modifications other 
than changes in the actual underlying DNA sequence, that influence gene expression and more generally 
phenotype. The study of the cistrome and epigenome in biological systems in a genome-wide fashion 
using high-throughput technology, is referred to as cistromics and epigenomics, respectively [2, 11, 12].   
Epigenetic marks influence gene expression by remodeling the chromatin to be in either an open active 
state, known as euchromatin, or a closed, densely packed silenced state known as heterochromatin [13]. 
Epigenetic marks do not only impact the condition of a biological system, but since these marks are 
intrinsically plastic, they are also affected by impacts on the biological system, such as disease and the 
environment. It has been suggested that if such impacts are severe, for example during a long period of 
famine [14], they are passed on to future generations, thereby contributing to the adaptability of 
 9 
organisms. In this view, changes in epigenetic marks are considered “epigenetic scarring”: significant 
events in life leave their mark on the genome for future generations.  
 
 
Figure 1: An overview of Epigenetic Mechanisms (Originally published in Nature [13], used with 
permission). 
 
The most studied epigenetic marks are DNA methylation and modification of histone tails (figure 1). DNA 
methylation occurs mostly at CpG di-nucleotides, adding a methyl-group to cytosine to form 5-
methylcytosine. Loci with a large amount of CpGs are known as CpG islands, which are overrepresented 
in regions in the DNA associated to genes. When a CpG island becomes methylated, it causes the 
nearby gene to become silenced by impeding the binding of required transcription factors and co-
regulators. This can occur either directly by decreased binding affinity on methylated CpGs, or by a more 
permanent mechanism based on attracting methyl-CpG-binding domain proteins (MBD), that 
subsequently recruit chromatin remodeling complexes, leading to histone modifications that remodel the 
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chromatin to become silenced. This illustrates that DNA methylation and histone modifications are part of 
the same larger epigenetic mechanism.   
Histones are proteins that act as spools around which DNA winds in segments of 147 base pairs, to form 
structural units called nucleosomes. A single histone is a complex consisting of histone sub-units known 
as H1/H5, H2A, H2B, H3, and H4. These sub-units have tails that extend from the complex and are 
susceptible to chemical modifications (figure 1). These histone modifications influence gene transcription, 
by inducing a specific chromatin state. The canonical modification associated with active chromatin and 
active transcription is tri-methylation of lysine 4 on histone H3 (H3K4me3). This modification is required at 
only a few nucleosomes surrounding the transcription start site of a gene to enable transcription. 
Conversely, tri-methylation of lysine 27 of histone H3 (H3K27me3) is associated with silenced chromatin 
and silencing of gene transcription, and tends to affect a large number of nucleosomes to cover the entire 
locus of a gene. This spreading out of H3K27me3 modifications is known as “blanketing”.  
 
The foremost technology to study the epigenome and the cistrome is based on combining chromatin 
immunoprecipitation with microarrays (ChIP-on-chip [15]) or more recently high-throughput sequencing 
(ChIP-seq [16,17]). In short, pieces of chromatin bound by a protein or with a specific epigenetic mark, 
are extracted by using an anti-body (figure 2 left). The resulting enriched sample, commonly referred to 
as the experimental DNA sample, is purified thereby creating a sample consisting of short pieces of DNA. 
These pieces of DNA are then hybridized to a microarray containing complementary probes for either the 
whole genome or specific regions of interests, such as gene promoters, or the sample can be analyzed 
directly using high-throughput sequencing. Using this technology together with bioinformatics tools, 
genome-wide maps can be constructed of enrichment for specific DNA interacting proteins, histone 
modifications or DNA methylation, as long as a suitable anti-body is available.  
For DNA methylation research, an anti-body is used that directly targets methylated CpGs and the 
procedure is referred to as methylation dependent immunoprecipitation (MeDIP [18]). Other options for 
DNA methylation include using methylation specific restriction enzymes, such as in the McrBC approach 
[19] (figure 2 right), or more recently, by using an antibody against MBD protein bound to methylated 
DNA regions [20]. Each approach has its own strengths and weaknesses. MeDIP for example is biased 
towards highly methylated, CpG rich regions, such as CpG islands and less sensitive in picking up high 
methylation in CpG poor regions, while the MBD approach is more sensitive to highly methylated regions 
with moderate CpG density [21]. As such, these technologies are complementary and can be used 
conjointly in an experiment [22].  
 
What is clearly lacking in the field are standardized data processing and interpretation procedures for 
epigenomics and cistromics data and the lack of a comprehensive toolset to perform these analyses in. 
Standardization is absolutely essential to support the dissemination of this technology outside the 
confined space of the academic laboratory and pave the way towards clinical applications [23]. Hence, 
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the main aim of this thesis is to improve cistromics and epigenomics data interpretation through 
development of standardized analysis approaches, hereby addressing existing issues in every step of the 
analysis process, from raw data preprocessing to biological interpretation of the results. In each chapter, 
a specific issue is addressed and solutions proposed. 
 
 
Figure 2: An overview of two protocols to perform cistromics and epigenomics analyses. The general 
assay for ChIP and MeDIP studies is shown on the left, whereas the assay for DNA methylation based on 
methylation specific restriction enzymes is shown on the right.  
 
Chapter 2 formulates the requirements of a cistromics and epigenomics work-flow and the novel enrichR 
toolkit that enables to perform such analyses swiftly and thoroughly. As with any omics technology, 
cistromics and epigenomics data are inherently noisy. Due to this nature, microarray based approaches 
are intended for exploratory data analysis to generate hypotheses to validate in the lab. To enhance 
interpretation, ideally multiple lines of evidence are used, combining measurements from various omics 
technologies as well as multiple in silico analysis approaches. For cistromics and epigenomics we are 
interested in regulation of gene transcription. Thus, the primary requirement for a meaningful data 
interpretation is integration with transcriptomics data. Additionally, we are interested in uncovering cis-
acting motifs present in the underlying DNA sequences of the identified enriched regions that potentially 
direct the binding of DNA interacting proteins. The software of choice for any omics data analysis is 
Bioconductor [24], which is a comprehensive, open-source collection of bioinformatics analysis packages. 
EnrichR has been built using this framework and in accordance with its core philosophy is available as 
open-source. 
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The first step in any analysis using high-throughput technology is pre-processing of the raw 
measurements to correct for variance that is of technical rather than biological nature. In chapter 3, 
preprocessing issues for ChIP-on-chip and MeDIP-on-chip microarray data are discussed. Although 
derived from transcriptomics technology, there are key differences in the analysis of ChIP-on-chip and 
MeDIP-on-chip microarray data. Most commonly performed on two-channel microarray technology, one 
channel contains the enriched sample, while the other contains a total DNA sample that contains all the 
sequence content from the studied biological system as a reference. The ratio between the channels is 
used as the measure to determine enriched regions in the genome, corresponding to DNA interacting 
protein binding sites or sites with specific epigenetic modifications. This setup is different from two-
channel transcriptomics microarrays, where both channels contain amplified transcript samples usually 
corresponding to two different conditions. The general assumption in transcriptomics studies is that the 
majority of genes are unchanged between conditions [25,26,27], and hence the majority of spots on a 
microarray will have a comparable signal between channels as well. In epigenomics and cistromics 
studies however, this assumption does not hold since the samples comprising the two channels are so 
fundamentally different, which suggests that many approaches developed for two-channel transcriptomics 
microarray data may not be suitable. To determine whether this is indeed the case, we evaluated the 
performance of several well-known transcriptomics normalization strategies when used for ChIP-on-chip 
and MeDIP-on-chip technology. The results are discussed in chapter 3, where we see that T-quantile 
normalization applied separately on the channels and Tukey’s biweight scaling are the only approaches 
consistently yielding the best results, where in contrast, popular normalization approaches, like quantile 
and LOWESS normalization, impact the reliability of the downstream analysis substantially.  
In chapter 4 we apply the lessons learned from ChIP-on-chip and MeDIP-on-chip technology to construct 
an optimal processing protocol for H3K27me3 histone modification ChIP-seq data. There are specific 
challenges for studying this histone modification in dynamical biological systems, in which a considerable 
amount of epigenetic changes are expected to occur, both in location as well as in total amount. Firstly, 
enrichment finding algorithms for ChIP-seq data are optimized for locating sharply defined peaks [28], but 
due to blanketing [29,30,31], the H3K27me3 enrichment signal is spread out instead. Secondly, like ChIP-
on-chip, MeDIP-on-chip and any other high-throughput technology, ChIP-seq data requires normalization 
to correct for technical bias and enable quantitative comparisons between samples. When studying 
dynamical biological systems, the only suitable approach is scaling the data based on regions in the 
genome where enrichment is stable between conditions. It is however difficult to define a priori which 
regions are prone to have such stable enrichment, as this depends heavily on the biological system 
studied [32]. With these difficulties in mind, we have developed a standardized protocol for the processing 
of H3K27me3 ChIP-seq data. The protocol enables robust detection of H3K27me3 blanketing and allows 
for quantitative data comparison. As such, our protocol complements previous efforts to create the first 
fully standardized analysis pipeline for H3K27me3 enriched ChIP-seq data. We have used this protocol to 
map enrichment of H3K27me3 histone modifications genome-wide in breast cancer cells that are 
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exposed to hypoxic conditions, serving as a model for dynamic effects occurring in response to hypoxia in 
solid tumors.  
 
After raw data has been processed, biology finally comes into view. In chapter 5 we compare the entries 
for several pathways associated with fatty acid metabolism and assess their quality by expanding them 
with current literature and subsequently having them curated by experts. There is a tremendous body of 
biological knowledge already available in biological databases in the form of relations between bioactive 
molecules. This information can be stored as single biochemical interactions [33] or as networks of 
biochemical interactions [34, 35]. When such a network comprises a more or less defined biological 
process with a sense of direction [36], it is called a pathway. An important step in data interpretation is 
integrating knowledge from biological databases. One of the most common approaches for this is 
pathway analysis, which maps gene related data, such as expression data, onto existing biological 
pathways, allowing a straight-forward visual interpretation [37]. Pathways such as the one in figure 3 are 
static representations of biological processes. However, the quality of the content depends highly on the 
knowledge of its creators and the time since it was last updated. During the assessment presented in 
chapter 5, we discovered major differences between the content of databases, and created updated, 
comprehensive pathways of fatty acid metabolism which can be found on WikiPathways [34].  
 
 
Figure 3: An example of a pathway with mapped transcriptomics data. Red colored gene boxes indicate 
up-regulation of the associated transcript, while green indicates down regulation. The pathway was 
downloaded from WikiPathways (http://wikipathways.org/index.php/Pathway:WP241) and data was 
mapped using Pathvisio [37].  
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Chapters 6 and 7 serve as demonstrations in a biological setting of the approaches discussed in chapters 
2, 3 and 4. Chapter 6 describes the analysis and results of an estrogen-receptor α (ER-α) ChIP-on-chip 
dataset aimed at the dissection of the molecular mechanisms of the mitogenic action of estrogen in the 
human endometrium and the breast. Chapter 7 meanwhile describes the results of a ChIP-seq data 
analysis on the enrichment of activating H3K4me3 and silencing H3K27me3 histone modifications. The 
studied system is an MCF7 breast cancer cell line that is exposed to hypoxic conditions, as a model of 
effects occurring in the cores of solid tumors. Cancer cells are characterized by many epigenetic 
deregulations. Understanding the changes in histone modifications in such a dynamical system is key to 
understanding the molecular mechanisms underlying cancer and for the development of future cancer 
treatment. These applications show the importance of the developed approaches and the power of 
integrating cistromics and epigenomics technology in systems biology research. 
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Abstract 
Advances in epigenomics and cistromics have made it possible to study gene transcription regulation on 
a genome wide level. ChIP-on-chip is used to determine binding locations of DNA interacting proteins 
genome wide, be it transcription factors or histones with specific modifications. The same microarray 
technology and analogous protocols can be applied to detect the DNA methylation status of thousands of 
CpG rich regions in one go. The DNA enrichment data arising from these technologies opens up 
tremendous opportunities for unraveling gene transcription regulation. But no matter how stringent the 
statistics, validation of potential regulated genes is essential, using multiple lines of evidence from various 
bioinformatics analysis approaches and additional assays to robustly characterize regulated targets. 
Since such a work flow requires a flexible and extendible framework, we used R and the Bioconductor 
framework to develop enrichR, a toolbox for integrative analysis of ChIP-on-chip and DNA methylation 
microarray data, optimized for the popular NimbleGen platform. The software is fully open-source with a 
focus on high-level functions to accommodate users from any experience level, enabling a full biological 
interpretation in minutes instead of days. As an illustration of enrichR, we have performed an integrative 
analysis of a public estrogen-receptor α (ER-α) ChIP-on-chip dataset and corresponding transcriptomics 
dataset, aimed at dissection of the molecular mechanisms of the mitogenic action of estrogen in the 
human endometrium and the breast.  
 
Introduction 
Over the years, it has become clear that to understand biology, we need to study it as a system [1]. Many 
genome wide technologies have been developed to study biological systems, of which microarray 
technology is the most established. Although microarray technology to measure gene transcription has 
been around since the turn of the millennium, to characterize a system, we need to characterize its 
regulators. Chromatin immunoprecipitation followed by array hybridization (ChIP-on-chip) [2] or, more 
recently, followed by high-throughput sequencing (ChIP-seq), is used to determine genome wide binding 
locations of DNA interacting proteins, such as transcription factors or histones. The same microarray 
technology and analogous protocols can be applied to detect the DNA methylation status of thousands of 
CpG rich regions, such as CpG islands, in one go [3]. The data arising from these technologies, 
henceforth referred to as DNA enrichment data, open up tremendous opportunities for unraveling gene 
transcription regulation and there are many studies that, using such approaches, have given relevant 
contributions to our understanding of the molecular mechanisms underlying gene transcription, cell 
differentiation and cell lineage maintenance [4,5,6,7,8].  
 
In spite of this popularity, analysis approaches for DNA enrichment microarrays are not as standardized 
as for instance for transcriptomics microarray analysis. There are several reasons for this. First and 
foremost, the underlying technology and study designs of these types of microarray analyses are 
extremely diverse. The second reason is that most popular technology for DNA enrichment analysis is 
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based on two-channel microarray technology. This means that there will always be two samples on each 
array, with the golden standard being input DNA in one channel, comprising all DNA sequences present 
in a sample, and an immunoprecipitated DNA sample in the other, which is enriched for regions of 
interest, such as binding locations of a DNA interacting protein. Depending on the research question, 
other designs may yield more robust results for less costs. If for instance the goal is to identify binding 
regions that differ between two samples, or differences in degrees of methylation, hybridizing them 
together on one chip but in different channels is a good approach [9].  
Apart from these technical issues, there are specific problems in the analysis of DNA enrichment 
microarray data. With respect to data normalization, since samples on this two-color technology differ to 
such a large extent, standard microarray normalization procedures can be very destructive on the power 
to identify enrichment and differences therein [10]. Although this is less of an issue for the identification of 
strongly enriched regions, this becomes a major limitation when small differences or moderate enrichment 
is expected, which is frequently the case for transcription factors which only mildly and transiently 
associate to chromatin. Destructive normalization will hamper the identification of such differences.  
This problem is intensified by the fact that the number of expected enriched regions is in most cases 
unknown and may differ to considerable extents between experimental conditions. Therefore, a suitable 
positive or reference control is missing. Most approaches to identify enriched regions are within-sample 
approaches, leading to relative enrichment scores, which are difficult to interpret [11,12]. Since there is a 
definite but unknown correlation between FDR values and relative amount of binding or DNA methylation, 
depending on the amount of enriched regions present in the sample, this paves the way for arbitrary cut-
offs to assess significant enrichment. 
 
With respect to the last step in the analysis process, biological interpretation, enrichment and differences 
therein may not have a measurable effect on gene transcription, even when this difference is classified as 
statistically significant. In general, DNA methylation is known to silence gene transcription, which would 
imply a negative correlation between changes in DNA methylation and changes in gene transcription. 
This model is too simple though, as a decrease in DNA methylation of a gene’s promoter does not 
impose that gene to become activated, as a suitable set of transcription factors is still needed, as is an 
active chromatin structure, guided by the necessary histone modifications. On top of that, small changes 
in efficiency of protein binding or DNA methylation across a tissue can be completely counteracted by 
changes in the levels of available transcription co-regulators. If for instance a gene is hypermethylated in 
a specific tissue, this means that the average degree of methylation of this gene across multiple copies of 
that gene is increased. This implies that the gene is not silenced in all cells of such a sample and are 
exposed for regulation by transcription factors in cells with unmethylated DNA.  
DNA interacting proteins can repress gene transcription, activate it or both, depending on available co-
regulators that are assembled in the multi-protein complexes associated with chromatin [13]. Since 
inactive chromatin hampers the formation of DNA protein complexes, histone modifications are usually 
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less of an issue in the process of target identification in ChIP-on-chip experiments. This changes 
dramatically of course, when using ChIP technology to measure such histone modifications. Then similar 
effects occur as with DNA methylation microarray data, where the effect on gene transcription of a 
change in a particular activating or silencing modification is subject to availability of required co-
regulators.  
 
These observations imply that results DNA enrichment experiments on itself are extremely ambiguous 
and interpretation of such results is severely hampered by lack of additional lines of evidence. Hence, 
more than with any other type of technology, systems biology approaches are essential to get the biology 
out of DNA enrichment data. Therefore, a work flow is needed that implements multiple lines of evidence 
from various bioinformatics analysis approaches and additional assays to robustly characterize regulated 
targets. We have designed such a work flow to maximize biological output of DNA enrichment data, and 
to do it fast and concise (figure 1).  
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Figure 1: Integrative work flow for DNA enrichment microarray data: from raw data (red), through data 
analysis (yellow), to biological interpretation (green).  
 
The essential step is integration with transcriptomics data, ideally running a gene expression assay in 
parallel to the DNA enrichment analysis. Alternatively, online data repositories such as ArrayExpress [14] 
house over a decade of transcriptomics datasets, which therefore bound to include a suitable dataset for 
integration. Based on the integration, genes are split in multiple groups, depending on their relative 
expression and DNA enrichment trends. This step is the least generic in the entire work flow, since it 
depends on the biology behind the experiment and is therefore strongly data driven. An example is given 
in figure 2 where the differences in DNA methylation between group A and group B are plotted against 
the differences in gene expression of all significantly regulated genes, leading to four distinct groups. 
These groups can be biologically characterized by performing biological process enrichment analysis, 
either using Gene Ontology enrichment analysis [15] or using pathway analysis tools [16], and based on 
the results sub-divided into groups. Transcription factors need co-regulators to form complexes and 
influence gene transcription and hence the binding of a single transcription factor is an uninformative 
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indicator of regulation [8]. Hence, a subsequent essential in silico validation step when studying 
transcription factor binding is sequence motif analysis of enriched regions  [17,18,19], to identify 
discriminating motifs between groups, such as the overrepresentation of a set of transcription factor 
binding sites in one group compared to another. For DNA methylation studies, such motif analysis would 
seem less informative, but specific classes of CpG rich regions with tissue and phenotype specific 
methylation are often characterized by enrichment for specific motifs, suggesting that cis-regulatory 
elements may facilitate differential methylation at such CpG islands [20,21,22]. 
 
Figure 2: Scatterplot of changes in DNA methylation versus changes in gene expression of simulated 
DNA enrichment data. 
 
The work flow of figure 1 imposes several requirements on the software used to perform the analyses. It 
should be flexible and well suited to multiple types of data from multiple technologies. Also, it needs to be 
able to retrieve sequence information, since probes are short, often non-overlapping, so gaps need to be 
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filled to be able to perform sequence motif analysis. A tool that lends itself well to integrative systems 
biology approaches is R [34]. R is an open source statistical analysis environment and programming 
language. It is easily extended with additional functionality through packages. The Bioconductor project is 
a great example of this, which is a collection of packages to suit all bioinformatics and biostatistics needs. 
R combined with Bioconductor is the de facto open source standard for genome wide data analysis, 
which makes R a logical choice for ChIP and DNA methylation microarray analysis. There are however 
many minor and major annoyances in R. Although it is flexible, it is also unstable and ever changing. 
Packages that your analysis work flow relied on previously may be altered beyond recognition in an 
updated version. In addition, some essential functionality for ChIP and DNA methylation microarray 
analysis is often missing or suffering from cluttered interfaces, such as retrieving sequences of enriched 
regions from a sequence database. It is like an analog synthesizer: it can make any sound on the planet, 
but enabling it to do so requires an advanced level of programming knowledge.  
With this in mind, we have created enrichR, a toolbox to facilitate any type of enrichment analysis, be it 
ChIP-on-chip, DNA methylation or any other type of enrichment microarray technology. It combines 
several well established Bioconductor packages and adds to them what we found missing, creating a 
framework for robust multiple validation analysis. The package wraps around a collection of well 
established and stable Bioconductor packages. To accommodate users from any experience level, we 
optimized and automated our toolkit for the popular NimbleGen platform, creating several high-level 
functions. Most importantly, we focused on promoter report data, the data received back from NimbleGen, 
enabling to perform a full biological interpretation in minutes instead of days. Our toolkit has formed the 
basis for the bioinformatics analysis of several papers [9,13,23] and has been used extensively for 
education purposes [24].  
 
To demonstrate our work flow and toolkit, we reanalyzed a study on estrogen receptor α targets, aimed at 
dissection of the molecular mechanisms of the mitogenic action of estrogen in the human endometrium 
and the breast [13]. Estrogens are  one  of  the most  frequently  prescribed  drugs worldwide [25].  All 
major actions of estrogen are mediated by the estrogen receptors of which ER-α is responsible for 
proliferation and cell homeoastasis in gynaecologic tissues. Ligand activated ER-α binds to promoters of  
target genes and depending on the availability of co-activators  or  co-repressors, the transcription of the 
target genes is induced or repressed [13, 26, 27]. 
Compounds with estrogen agonistic action protect against osteoporosis, are beneficial for a number of 
physiological functions (cardiovascular, lipid profile) and are used in hormone replacement therapy 
(HRT). On the contrary, estrogen antagonists are used in breast cancer therapy. These drugs, however, 
lead to unwanted side effects, because agonists used in HRT are mitogenic factors in the breast and the 
endometrium and may cause endometrial or breast cancer, whereas antagonists increase the risk for 
osteoporosis and cardiovascular events. The pharmaceutical industry has developed compounds known 
as selective estrogen receptor modulators (SERMs [28]), which, in contrast to pure agonists or  
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antagonists, display tissue-specific agonistic/antagonistic activities. Therefore, potentially, the ideal SERM 
would be antagonists in gynaecologic tissues and the breast, and agonist in the bone and the 
cardiovascular system. However, such a SERM is not available yet, and the use of these medications is 
still confronted with important clinical problems. For instance, tamoxifen, which is used to treat breast 
cancer with excellent results, induces cell proliferation in the uterus, thus increasing the risk for benign 
and malignant endometrial lesions. The inability to predict the tissue specific response to estrogens and 
SERMs is due to the fact that the mechanism of action of ER-α and SERMs is poorly understood. 
Therefore, the recruitment of distinct co-regulators by tamoxifen-activated ER-α in the breast compared to 
the endometrium would lead to distinct transcriptional activation of target genes, hence distinct 
agonistic/antagonistic responses. Therefore, by dissecting differential co-regulator recruitment, it will be 
possible to predict the action of novel SERMs in the human endometrium and other tissues or to identify 
patients who will benefit from hormonal therapies.   
 
Results 
As an illustration of enrichR and our work flow, we have performed an integrative analysis of an estrogen-
receptor α (ER-α) ChIP-on-chip dataset aimed at dissection of the molecular mechanisms of the 
mitogenic action of estrogen in the human endometrium and the breast [13]. We have combined the 
original ChIP-on-chip data with public transcriptomics datasets, and defined distinct groups of targets 
based on the integrated results. We analyzed these groups separately, providing them with a biological 
context by performing biological process enrichment analysis using Gene Ontology and exploring the 
presence of discriminative sequence motifs in and surrounding the enriched regions and promoters of 
target genes.  
The study consisted of a ChIP-on-chip assay. Briefly, estrogen responsive T47D breast cancer cells were 
treated with 17-β-estradiol  or with  vehicle alone (ethanol). Chromatin-immunoprecipitation using an ER-α  
specific antibody was performed 50 minutes after induction, when gene promoters are targeted by the 
activated receptor. Precipitated DNA sequences were subsequently amplified, labeled and hybridized to  
a  NimbleGen Human HGS17 minimal promoter array containing 24134 putative gene promoters. Targets 
were identified as previously described [13].  
Next, we integrated the results with gene expression data from a study investigating gene expression in 
T47D cells in response to 17-β-estradiol stimulation [29]. Briefly, T47D cells were cultured in culture 
medium which was supplemented with 17-β-estradiol. Gene expression profiles were taken at 0, 1, 2, 4, 
8, 12 and 24 hours, using Affymetrix Human Genome U133A 2.0 GeneChips. 
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Figure 3: Clusters of significantly regulated genes, based solely on the transcriptomics data.  
From the transcriptomics results, we created profiles or clusters of significantly differentially regulated 
genes. From these clusters, we defined two categories that showed the largest difference between time 
point 0 and 1: one of down-regulated genes (figure 3, top left), one of up-regulated genes (figure 3, 
others) and performed Gene Ontology enrichment analysis on this set of genes. Although these clusters 
will encompass both direct effects by binding of 17-β-estradiol activated estrogen receptor α and indirect 
effects by downstream regulation, the effects are in any case due to estrogen stimulation, and hence the 
results from this biological process enrichment are expected to be insightful.  
The results show that up-regulated genes are involved mainly in cell cycle and gene transcription 
regulation, indicating that 17-β-estradiol stimulation indeed leads to stimulation of cell cycle inducers 
(table 1). The down-regulated genes are involved in regulation of metabolism and negative regulation of 
transcription, indicating that 17-β-estradiol stimulation leads to down regulation of genes involved in 
metabolism and transcriptional repression (table 1). Interestingly, some down-regulated genes are also 
involved in positive regulation of transcription, indicating silencing of some transcriptional inducers.  
 
To analyze direct ER-α targets more closely, we assessed the expression of targets identified in the 
ChIP-on-chip study and chose those that show significant changes in expression over time and show a 
absolute fold change larger than 1.4 from time point 0 hours to time point 1 hour. Using these settings, we 
identified 47 up-regulated targets and 16 down-regulated targets.  
Based on that selection, we retrieved the promoter regions of these genes close to the TSS (500 bp 
upstream, 100 downstream of TSS) and scanned them for presence of CpG islands and ER-α motifs 
using cosmo [17].  Using strict settings (CpG ratio of 0.65, GC-content of 55% and a minimum length of 
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500 bp [30]), we found that of the 47 promoters of up-regulated promoters, 29 contain a CpG island 
(62%). Of the 16 promoters of the down-regulated targets, 9 contain a CpG island (56%).  
 
  
GO term 
 
# genes with 
GO term 
 
p-value 
Up-regulated genes GO:0006350| transcription 125 <0.01 
GO:0045449| regulation of transcription 117 0.04 
GO:0007049| cell cycle 74 <0.01 
GO:0015031| protein transport 59 <0.01 
GO:0008283| cell proliferation 58 <0.01 
GO:0042981| regulation of apoptosis 53 <0.01 
GO:0006461| protein complex assembly 49 0.01 
GO:0050790| regulation of catalytic activity 48 0.01 
GO:0006412| translation 40 <0.01 
Down-regulated genes GO:0019222| regulation of metabolic process 54 0.03 
GO:0045893| positive regulation of transcription, DNA-dependent 15 0.01 
GO:0045892| negative regulation of transcription, DNA-dependent 13 0.01 
GO:0000122| negative regulation of transcription from RNA 
polymerase II promoter 
9 <0.01 
GO:0007264| small GTPase mediated signal transduction 9 0.03 
GO:0045944| positive regulation of transcription from RNA 
polymerase II promoter 
9 0.01 
 
Table 1: Gene ontology enrichment results for the clusters of significantly regulated genes, based solely 
on the transcriptomics data. Results only reported back for categories with more than 5% of the total 
number of genes.  
 
ER-α can bind to specific estrogen response elements (EREs) or to other motifs when forming a complex 
with other transcription factors. The ERE consensus sequence, an inverted repeat of the sequence 
(GGTCA) separated by 3 bp, rarely occurs in nature [6, 27]; however, the imperfect ERE 
(GGTCANNNTNNCY) and ERE half-site (AGGTCA) are widely accepted as alternative binding sites [27]. 
When ER-α forms a complex with other transcription factors, the resulting binding motif depends on which 
proteins interact directly with the chromatin. Using cosmo, we scanned for motifs containing at least the 
ERE half-site (AGGTCA), using settings that favor a low-stringency palindromic motif. Interestingly, the 
results show that up-regulated genes are characterized by a ERE half-site, while the down-regulated 
genes are characterized by a motif more resembling the ERE palindrome (figure 4).  
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Figure 4: ER-α motifs: canonical palindromic motif (left) and the overrepresented motifs found in up-
regulated and down-regulated targets (right) 
Discussion 
The enrichR toolkit presented here consists of a set of tools to ease ChIP-on-chip and DNA methylation 
microarray analysis and is able to perform complex tasks in just a few lines of code. Galaxy [33] has put 
emphasis on smaller, easy to integrate tools that together comprise a work flow that is adaptable to any 
biological question. The enrichR toolkit fits into this trend very well and since Galaxy is fully compatible 
with R, enrichR can be easily implemented into new and existing Galaxy work flows. Although the enrichR 
toolkit is designed for epigenomics and cistromics microarray data, the functionality is easily translated to 
epigenomics and cistromics analyses performed on high-throughput sequencing technology.  
Although there are many tools available for DNA enrichment analysis, most of these are directed towards 
ChIP-on-chip experiments. Examples of these are the Bioconductor [34] packages Ringo [35], which is 
focused on ChIP-on-chip data analysis for the NimbleGen platform, and Starr [36], which is focused on 
single-channel Affymetrix ChIP-on-chip data. Examples of stand-alone tools are CisGenome [37], which 
is suited for both ChIP-on-chip as well as ChIP-seq data, and CoCAS [38], which is again focused on only 
ChIP-on-chip data. There are also numerous packages for DNA methylation analysis. Examples are the 
MEDME package [39] in Bioconductor which can estimate DNA methylation percentages for all regions 
present on an array, but to calculate these, imposes strict requirements on the wet-lab side of the 
experiment, requiring a fully methylated sample for comparison. BATMAN [40] promises similar things, 
but sports a Spartan command line interface, requiring extensive knowledge of both Java and database 
setup to be able to analyze DNA methylation microarray data. Regardless, all these tools are very 
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powerful on their own, but they all stop when it gets interesting: when we want to go back to biology. Also, 
the stand-alone tools are hampered by their inability to integrate other types of data or perform additional 
analyses once enriched regions have been identified.  
 
One of the most important analyses for DNA enrichment data is conserved motif analysis. Such an 
analysis can be directed or undirected. Directed sequence motif analysis would try to validate identified 
targets as a having regulatory motifs associated with the transcription factor of interest or some other 
combination of motifs, while undirected would encompass searching for motifs of interest in all measured 
regulatory regions and comparing this to the outcome of the DNA enrichment experiment, potentially 
looking at additional regions that did not make the cut before. This leads to the important observation that 
instead of filtering out all regions that do not exhibit significant enrichment, all regions should always be 
reported back. Even regions of low methylation for instance are of interest, and although they are difficult 
if not impossible to identify by standard enrichment finding procedures, combining such procedures with 
additional validation steps will enable the identification of such regions of interest and distinguishing them 
from false positives or background noise. This brings us to the important conclusion that a data driven, 
multiple validation approach negates the potential for overfitting in model based enrichment finding 
algorithms [1,12,39,40,31]. The MPEAK algorithm for instance searches for regions that show triangular 
shaped enrichment, assuming a Poisson distribution around potential transcription factor binding sites [1]. 
Although this is a sensible approach, putting such a shape constraint on the data can be dangerous, as it 
does not take probe sequence or spacing effects or other technical or biological effects into account. 
Such a biological effect might for instance be that the transcription factor of interest binds in a complex of 
other transcription factors to the DNA, increasing the total length of the binding site and truncating or 
skewing the triangular shape. This is for instance the case when studying certain histone modifications 
with ChIP-on-chip and ChIP-seq assays, where the H3K27me3 enriched sites, instead of sharply defined 
peaks, consist of broad, spread out signals, often referred to as blanketing [32]. 
 
We have demonstrated the power of a multiple validation work flow and the enrichR toolkit by performing 
an integrative analysis of a ChIP-on-chip dataset on estrogen receptor α. We extended the biological 
interpretation of the list of targets identified previously, and build evidence for a potential mechanism 
involving co-regulators in estrogen receptor α mediated gene regulation. All of this was done using 
existing data from online repositories and open source tools. By integrating the list of potential estrogen 
receptor α targets with gene expression data, we distinguished two classes of targets. The first class 
includes those targets that are induced upon binding of estrogen receptor α. Analysis of the promoter of 
these targets showed that ERE half sites are present. A gene ontology analysis on this set of targets 
indicated that these targets are mainly involved in processed linked to cell cycle and proliferation, in 
accordance with observations made previously. The second group of targets were those that upon 
binding of ER α are repressed. Motif analysis of these targets revealed ERE motifs more resembling the 
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canonical ERE motif, differing from the motif found in induced targets. Gene ontology enrichment analysis 
showed that these targets are mostly involved in metabolism and regulation of transcription. This 
suggests that the binding event of activated ER-α on the promoter is different for induced targets then it is 
for repressed targets. It is known from literature that endometrial proliferation is induced because 
activated ER-α recruits specific co-regulators at promoters of genes involved in the cell cycle regulation, 
which can be distinguished from co-regulators recruited/genes targeted by ER-α when its activation is not 
coupled to proliferation [6,7,8,13,26,27]. Our observations on the limited set presented here comply with 
these observations. 
 
The enrichR software, a full description of all functions and required packages, in addition to the tables 
and script used for the analysis is freely available from 
http://www.bigcat.unimaas.nl/wiki/index.php/EnrichR. 
 
Methods 
enrichR 
In general, the analysis of DNA enrichment microarray data comprises the following five steps: 
 Data QC: Data quality control (QC) is no different from QC on other two-channel microarray 
technology and many free solutions have been developed and are readily available in R, of which 
the arrayQualityMetrics package is the a comprehensive and elegant solution [41].  
 Data preprocessing: There are several key differences with other two-channel microarray 
technology, because many assumptions underlying the various approaches do not hold for DNA 
enrichment data [10]. 
 Enrichment finding: Enrichment finding is based on the assumption that it is possible to 
distinguish genuine enrichment from random effects within each sample. Most approaches are 
sliding window based and consist of at least two steps. The first is finding regions of enrichment, 
that is windows where the probes have a significantly higher signal  distribution compared to the 
whole signal distribution of the microarray. The second is determining the false discovery rate of 
such an enrichment call, which in most cases determines how many times a window with a 
specific enrichment confidence level has that or a better confidence level through several data 
permutations. When the number of permutations is sufficient, this allows the estimation of a false 
discovery rate for each enriched window. The first step can use several tests to compare window 
distributions to the whole distribution, such as a two-sample Kolmogorov-Smirnov test or χ-
square test on dichotomized data using a specific cutoff, as long as the number of probes in such 
a window is sufficient. In general, sufficient means around ten probes. Depending on the probe 
spacing, which averages somewhere between 50 and 100 bp for most modern microarrays, this 
means a window size of between 500 and 1000 bp. ACME uses the χ-square test approach for 
enrichment finding. A downside of this approach is that a cut-off is required, which the authors 
suggest be between 90th and 95
th
 quantile of the data. Although sufficient for exploratory data 
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analysis, this hampers the ability to detect smaller changes in enrichment, which is essential for 
DNA methylation microarray data. We therefore developed a similar approach using a two-
sample Kolmogorov-Smirnov test that does not require such a cut-off. It compares the distribution 
of a set of probes in a window to the distribution of all probes, assessing if the set of probes in the 
window is drawn from a distribution that has a significantly higher mean than the distribution of all 
probes. This enrichment finding can easily be extended to multiple samples, such as replicates, 
taking for each window the probes from all samples and comparing them to the joint distribution 
of all samples. 
 Differential enrichment analysis: Differential enrichment analysis can follow exactly the same 
approach, but instead of using the signal from one condition, we use the ratio of signals between 
conditions. As s second option, it can use the results from enrichment finding on one condition, 
and then compare these results afterwards. That is difficult however, as a score is needed for 
comparison that needs to enable statistical testing. We have developed two approaches for this. 
The first one uses the mean of the probes in a window as a measure of enrichment and 
compares them between conditions. In our experience 6 replicates per condition is sufficient for 
this approach. The second approach uses all the values of the probes in a window, performing an 
ANOVA between conditions using the values of all replicates. This is a more robust approach for 
smaller datasets, but decreases the power to call differences. 
 Biological interpretation: With respect to biological interpretation, there is a clear need for 
sequence retrieval tools. We have created several functions to retrieve promoter sequences, 
sequences of enriched regions and a generic function to get sequences of any region of interest. 
Sequence retrieval is robust. If connection error, it retries. If something fails, it closes all open 
connections before quitting the function. The promoter retrieval tool requires Ensembl IDs, 
because of the use of Biomart. Because NimbleGen uses Entrez Gene identifiers in their 
promoter reports, we created a simple batch converter for Entrez Gene to Ensembl Gene ID.  
Additionally, we created a Gene Ontology enrichment function that only needs a set of Entrez 
Gene IDs of interest.  
 
The enrichR toolkit comprises several functions for DNA enrichment data analysis (table 2). They are split 
into two portions: one set is generic and independent of platform and technology, the other set is specific 
for NimbleGen microarrays. The latter has functions for raw data and functions specialized for NimbleGen 
promoter report data, which is data already analyzed in-house by NimbleGen and the easiest starting 
point for an analysis. All functions require a minimum amount of input from the user and have suitable 
defaults for most common applications. 
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Function 
 
Type 
 
Description 
getPromoterSequence Generic Get promoter sequences from Ensembl 
entrez2synonym Generic Convert Entrez Gene IDs to other 
myGetSequence Generic Retrieve genomic sequences from Ensembl 
write.fasta Generic Write FASTA format sequence files 
toEnsemblGeneId Generic Convert Entrez Gene IDs to Ensembl Gene ID 
GOenrichmentAnalysis Generic Wrapper for easy GO enrichment analysis 
cgiCheck Generic Check a sequence for the presence of a CpG island 
nimbleGetPeakSequence NimbleGen  
Promoterreport data 
Gets peaks sequence 
nimbleReadPromoterReport NimbleGen  
Promoterreport data 
Import NimbleGen promoter report 
nimbleChromPlot NimbleGen  
Promoterreport data 
Create chromosome plot of enriched locations 
nimbleFindCommonPeaks NimbleGen  
Promoterreport data 
Find common peaks in two samples 
nimbleWriteGff NimbleGen  
Promoterreport data 
Creates GFF file 
nimbleReadPos NimbleGen raw data Import NimbleGen probe postion file 
nimbleReadRaw NimbleGen raw data Import NimbleGen raw intensity pair files 
nimbleQC.Raw NimbleGen raw data Creates several QC plots to assess overall quality of the 
arrays 
nimbleQC.Norm NimbleGen raw data Creates several QC plots to assess overall quality of the 
arrays 
nimbleEnrichmentCalc NimbleGen raw data Calculated enrichment for each genomic region 
nimbleDifferentialEnrichmentCalc NimbleGen raw data Calculate differential enrichment between conditions 
nimbleCreateAnnotation NimbleGen raw data Using Biomart, automatically creates microarray annotation 
 
Table 2: An overview of  the functions in the enrichR toolkit. 
Apart from the standard Bioconductor installation [34], several non-default packages are required. The 
most important ones are Ringo [35], RMySQL, RCurl [42], biomaRt [43], topGO [15] and GOsim [44].  
 
The enrichR software, a full description of all functions and required packages is available from 
http://www.bigcat.unimaas.nl/wiki/index.php/EnrichR.  
 
Datasets, analysis & script 
The estrogen receptor α ChIP-on-chip dataset used for the demonstration was published previously [13]. 
The transcriptomics dataset is available from ArrayExpress (accession number E-GEOD-3834). The table 
and script used for the analysis are available from http://www.bigcat.unimaas.nl/wiki/index.php/EnrichR.  
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Abstract 
The combination of chromatin immunoprecipitation with two-channel microarray technology enables 
genome-wide mapping of binding sites of DNA-interacting proteins (ChIP-on-chip) or sites with 
methylated CpG di-nucleotides (DNA methylation microarray). These powerful tools are the gateway to 
understanding gene transcription regulation. Since the goals of such studies, the sample preparation 
procedures, the microarray content and study design are all different from transcriptomics microarrays, 
the data pre-processing strategies traditionally applied to transcriptomics microarrays may not be 
appropriate. Particularly, the main challenge of the normalization of “regulation microarrays” is (i) to make 
the data of individual microarrays quantitatively comparable and (ii) to keep the signals of the enriched 
probes, representing DNA sequences from the precipitate, as distinguishable as possible from the signals 
of the un-enriched probes, representing DNA sequences largely absent from the precipitate. We compare 
several widely used normalization approaches (VSN, LOWESS, quantile, T-quantile, Tukey’s biweight 
scaling, Peng’s method) applied to a selection of regulation microarray datasets, ranging from DNA 
methylation to transcription factor binding and histone modification studies. Through comparison of the 
data distributions of control probes and gene promoter probes before and after normalization, and 
assessment of the power to identify known enriched genomic regions after normalization, we demonstrate 
that there are clear differences in performance between normalization procedures. T-quantile 
normalization applied separately on the channels and Tukey’s biweight scaling outperform other methods 
in terms of the conservation of enriched and un-enriched signal separation, as well as in identification of 
genomic regions known to be enriched. T-quantile normalization is preferable as it additionally improves 
comparability between microarrays. In contrast, popular normalization approaches like quantile, 
LOWESS, Peng’s method and VSN normalization alter the data distributions of regulation microarrays to 
such an extent that using these approaches will impact the reliability of the downstream analysis 
substantially.  
Note: high-resolution figures freely available online at http://www.biomedcentral.com/1471-2164/13/42  
 
Background 
For over a decade, two-channel transcriptomics microarrays have provided a powerful approach to study 
genome-wide gene expression events. Now, continued development of two-channel microarray 
technology has enabled extending our experimentation to the next level: regulation of gene transcription. 
One of the most popular techniques in this field combines chromatin immunoprecipitation (ChIP) assays 
with two-channel microarray technology (ChIP-on-chip [1]). ChIP-on-chip studies are used to detect any 
protein-DNA interaction genome-wide, such as transcription factor binding, but also epigenetic events 
such as histone modifications, as long as a suitable antibody is available. The same approach is used to 
detect DNA methylation, by using either an antibody that interacts with methyl-CpG-binding domain 
(MBD) proteins bound to methylated CpG dinucleotides (MBD-ChIP assay), or an antibody that interacts 
with methylated CpG dinucleotides directly (methylated DNA immunoprecipitation (MeDIP) assay [2]).  
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Even though newer technologies such as ChIP-sequencing (ChIP-seq) are on the rise, two-channel 
microarrays still present a valuable approach to understanding gene transcription regulation events, and 
during the last decade have opened opportunities to identify novel targets and markers in complex 
diseases such as cancer [3,4,5], heart failure [6] and diet-related disorders [7], and psychiatric disorders 
such as depression, schizophrenia and addiction [8]. Since the main appliance of this technology at the 
time being is gene transcription regulation studies – transcription factor and co-regulator binding, DNA 
methylation, and histone modifications – the term ‘regulation microarrays’ will be used for brevity 
henceforth. 
The design and the experimental approach for regulation microarrays are very different from the more 
extensively studied transcriptomics microarrays, which has implications for data pre-processing 
procedures. The key difference is that in transcriptomics microarrays both channels contain amplified 
transcript samples, usually corresponding to two different experimental conditions, while in regulation 
microarrays the channels comprise an experimental sample and a reference sample. The cyanine 3 
(Cy3), or green, channel of regulation microarrays generally contains the total DNA sample that gives the 
reference baseline signal, and the cyanine 5 (Cy5), or red, channel contains an experimentally enriched 
DNA sample, extracted using a specific antibody binding to a DNA-interacting protein (ChIP) or directly to 
methylated CpGs on the DNA (MeDIP). Hence, while the log-ratio between the channel signals 
represents the differential expression between two conditions in transcriptomics studies, for regulation 
microarrays it is used as a measure of enrichment: the higher the log-ratio of a probe or set of tiling 
probes, the higher the likelihood that the corresponding region in the genome has a high level of 
methylation or is targeted by a DNA-interacting protein.  
 
Another important assumption in regulation microarrays is that a DNA-interacting protein is either bound 
or not bound (for ChIP) and that a target sequence is either methylated or not (for MeDIP). Regardless, 
depending on binding affinity, mean time of residence and other factors, the fraction of cells with bound 
protein or a particular methylation status is not an all-or-nothing condition, especially in heterogeneous 
tissues. Combined with the characteristics of the data distribution surrounding a site of interest (figure 1) 
and probe effects [9], this produces a continuous log-ratio distribution. However, the characteristics of the 
samples hybridized to the channels force a dichotomy upon the log-ratio distribution, which is comprised 
of two components (figure 2) commonly referred to as an enriched and an un-enriched component [10]. 
The enriched component corresponds to the probes to which the experimental DNA has hybridized and 
the un-enriched component to the probes whose targets are largely absent from the experimental DNA 
sample. Hence, contrary to transcriptomics microarray data, where low log-ratio values are meaningful as 
long as the differences between conditions are statistically significant, when interpreting ChIP-on-chip and 
DNA methylation microarray data, the upper quantile is of most interest, as it generally comprises mostly 
enriched probes. Based on this assumption, enrichment finding algorithms like ACME [11], will test if a set 
of tiling probes is significantly more likely to be a sampling of this upper quantile than of the rest of the 
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data, assuming that if this is the case, this set of tiling probes corresponds to a protein binding site or 
methylated region. A better separation between the enriched and un-enriched components hence 
increases the power to identify enriched regions. Thus, a crucial aspect in regulation studies is that any 
separation between the enriched and un-enriched components present in the data before normalization, 
should be kept afterwards. Apart from conserving this separation, other aspects need to be taken into 
account when normalizing regulation microarray data.  
 
 
Figure 1: The birth of an enrichment signal around a binding site (ChIP-on-chip). Since DNA 
fragmentation through sonication can be modeled as a Poisson process [1], the DNA fragment length 
distribution follows a Poisson distribution and adjacent probes on the genome have a correlated log-ratio, 
resulting in the hybridization pattern shown here. Each blue column represents a probe hybridization site. 
Black-outlined bars represent their log-ratio. Green lines are sonicated immuno-precipitated DNA 
fragments corresponding to the binding site. 
 
Normalization is a process that is applied at multiple levels connected to spatial [12], probe [13,14,15] and 
dye or intensity dependent biases [16]. Additionally, differences in print quality, differences in ambient 
conditions when the plates were processed or changes in the scanner settings can cause scaling 
differences between microarrays. Most of the assumptions underlying the process of correcting for these 
biases are identical for transcriptomics microarrays and regulation microarrays. The exception is the 
correction for intensity dependent bias, for which the most common approaches in use for transcriptomics 
microarrays are LOWESS normalization [12,17,18] and quantile normalization [19].  Both methods are 
based on the assumption that the majority of probe signals are unchanged between channels and 
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microarrays, which generally holds for transcriptomics studies [12,20,18]. In regulation studies however, 
this assumption does not hold since the samples comprising the two channels differ to a large extent.   
Based on these observations, the main challenge of the normalization of regulation microarrays is (i) to 
make the signals of individual microarrays quantitatively comparable and (ii) to retain the separation 
between the enriched and un-enriched components present in the data. Programs like CoCAS [21] offer a 
range of normalization methods for regulation microarrays, including quantile normalization [19] and 
variance stabilizing normalization [22], and R/Bioconductor [23] offers many more popular choices, which 
may not all be suitable for this challenge. Hence, we here assess the efficacy in removing technical 
biases and in preservation of the separation between the enriched and un-enriched components, for six 
two-channel microarray normalization methods (VSN [22], LOWESS [12,16], quantile [19], T-quantile [19], 
Tukey’s biweight scaling, Peng’s method [24]) applied to five published ChIP-on-chip and MeDIP-on-chip 
datasets on the NimbleGen platform.  
 
 
Figure 2: An example of a two-component distribution fitted on ChIP-on-chip data of dataset #1 (see 
Methods section for dataset description and numbering). 
 
Results 
To determine the efficacy in correcting for technical biases and improving comparability between 
microarrays, quality control and bias assessment was performed on all datasets before and after 
normalization for each of the six normalization approaches. Complete results are available from 
http://www.bigcat.unimaas.nl/userfiles/adriaens/arrayQualityMetrics/. In all datasets scaling effects 
between microarrays and intensity dependent bias within microarrays are present, visible from the 
microarray data distributions. All tested normalization methods are able to correct for the observed 
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biases, where from a technical standpoint, normalization approaches that normalize channels together 
(VSN, LOWESS, Peng’s method, quantile) equalize the data distributions to a larger extent than 
normalization approaches that normalize the channels separately (T-quantile, Tukey’s biweight scaling). 
In the latter category, T-quantile normalization enhances overall comparability to a larger extent than 
Tukey’s biweight scaling. 
 
 
 
Figure 3: Density distributions of the control probes and gene promoter probes of the raw log-ratio data 
of all individual microarrays and corresponding ROC curves for dataset #1 (a), dataset #2 (b), dataset #3 
(c), dataset #4 (d) and dataset #5 (e). AUC values of each ROC curve are reported in the legend. 
 
To evaluate the separation between the enriched and un-enriched components, the gene promoter probe 
and the negative control probe log-ratio distributions were assessed using ROC curves before and after 
normalization with each of the six normalization approaches (figure 3). The raw data from dataset #1 
(see Methods section for dataset details and numbering) shows largely overlapping control probe and 
gene promoter probe distributions (figure 3a). Between individual microarrays, the distributions show 
larger differences, also resulting in more variation in both the area under the curve (AUC) as well as the 
A B 
C D 
E 
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shape of the ROC curves, indicating that comparability between microarrays is hindered by lack of 
normalization.  
The results of the combined data of the individual microarrays from the six normalization approaches 
(VSN, LOWESS, quantile, T-quantile, Tukey’s biweight scaling, Peng’s method) show equal performance 
of all approaches for dataset #1 (figure 4a), resulting in ROC curves with similar shape and comparable 
AUC values. Based on the AUC values, separation between components is best when using Peng’s 
method.  
 
 
 
Figure 4: ROC curves of the control probe and gene promoter distributions of the combined log-ratio 
data, for each normalization approach of dataset #1 (a), dataset #2 (b), dataset #3 (c), dataset #4 (d) and 
dataset #5 (e). AUC values are reported in the legend. TBW = Tukey’s biweight scaling, Q = quantile 
normalization, TQ = T-quantile normalization. 
 
Dataset #2, the second ChIP-on-chip dataset gives different results (figure 3b and 4b). Separation 
between components is preserved best when using T-quantile or Tukey’s biweight scaling normalization 
(figure 4b). The other approaches, including Peng’s method, alter the ranking of probes resulting in the 
control probe and gene promoter probe distributions becoming superimposed. VSN normalization 
appears to scale the distributions, enforcing a larger spread compared to the data acquired through the 
other normalization approaches (figure 5). 
A B C 
D E 
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Figure 5: Density distributions of the control probes and gene promoter probes of the normalized 
combined log-ratio data of dataset #2 (ChIP-on-chip). Results are shows for (from left to right, top to 
bottom) VSN, LOWESS, quantile (Q) , T-quantile (TQ), Tukey’s biweight scaling (TBW), Peng’s method. 
 
Tukey’s biweight scaling and T-quantile normalization appear to perform comparably with respect to 
conserving the component separation. Tukey’s biweight scaling adjusts the log-ratio data with a scaling 
factor for each microarray in the dataset individually, which means that the ROC curves will be identical to 
those of the raw data, and that the distributions will be the same as those before normalization save for a 
shift. This may explain the variability observed in the individual ROC curves and AUC values of the 
Tukey’s biweight scaling normalized data. T-quantile normalization reduces the variability between the 
data distributions of individual microarrays, resulting in ROC curves that are more comparable in both 
shape and AUC (figure 6).  
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Figure 6: Density distributions of the control probes and gene promoter probes of the normalized log-ratio 
data of each individual microarray and corresponding ROC curves of dataset #2 (ChIP-on-chip). Top: 
Results for T-quantile (TQ) normalized data. Bottom: Results for Tukey’s biweight scaling (TBW) 
normalized data. AUC values of each ROC curve are reported in the legend. 
 
The results of the MeDIP-on-chip datasets support the conclusions reached for the ChIP-on-chip 
datasets: separation of the components present before normalization (figure 3c, 3d and 3e) are 
preserved best with T-quantile and Tukey’s biweight scaling approaches (figure 4c). LOWESS, quantile, 
VSN and Peng’s normalization alter the distributions and eradicate the separation. In dataset #3, the 
differences between the normalization approaches is less striking, illustrated by similarly shaped ROC 
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curves and AUC values (figure 4c). Dataset #4 shows a larger heterogeneity between individual 
microarrays than both dataset #3 and #5. For both dataset #4 and #5 Tukey’s biweight scaling and T-
quantile normalization produce higher AUC values for these approaches (figure 4d and 4e). Both 
methods appear to perform comparably with respect to conserving the component separation. However, 
as in dataset #2, the differences between both approaches are highlighted by the distributions of the 
individual microarrays: Tukey’s biweight scaling adjusts each microarray individually, whereas T-quantile 
normalization is applied between microarrays. T-quantile normalization thereby results in ROC curves 
with less variation in shape and AUC (figure 7) than those of the raw data and the Tukey’s biweight 
scaling normalized data. 
 
 
 
Figure 7: Density distributions for the control probes and gene promoter probes of the normalized log-
ratio data of each individual microarray and corresponding ROC curves of dataset #4 and #5. Top left: 
Results for T-quantile (TQ) normalized data of dataset #4. Top right: Results for Tukey’s biweight scaling 
(TBW) normalized data of dataset #4. Bottom left: Results for T-quantile (TQ) normalized data of dataset 
#5. Bottom right: Results for Tukey’s biweight scaling (TBW) normalized data of dataset #5. AUC values 
of each ROC curve are reported in the legend. 
 
Any appropriate normalization method should preserve the biological information present in the raw data. 
Assessing the distributions of the negative control probes and the gene promoter probes is a global 
indicator of this conservation of biological information. In addition, three datasets with suitable positive 
controls were used to assess the impact of the normalization approaches on the power to identify 
significant enrichment for specific genomic regions. ACME [11] was used for all enrichment calculations. 
For dataset #1, 33 validated ER-a targets were used as positive controls [25,26]. The results are reported 
in table 1 for all normalization approaches and for several enrichment p-value cut-offs (0.05, 0.10, 0.20 
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and 0.50). T-quantile and quantile normalization in general result in identification of more targets at each 
cut-off.  
 
  
Number of ER-a targets found (out of 33) 
Normalization approach 
Enrichment p-value 
< 0.05 
 
< 0.10 
 
< 0.20 
 
< 0.50 
VSN 7 8 11 23 
LOWESS 6 7 10 25 
Quantile 8 9 12 25 
T-quantile 9 10 14 24 
Tukey’s biweight scaling 7 8 11 23 
Peng’s method 5 5 9 23 
 
Table 1: Number of validated estrogen receptor α targets found significantly enriched in the estrogen 
receptor α ChIP-on-chip dataset (dataset #1). This table contains for each of the tested normalization 
approaches the number of validated estrogen receptor α targets [25] found significantly enriched in the 
estrogen receptor α ChIP-on-chip dataset (dataset #1). Results for four enrichment p-value cut-offs are 
given (0.05, 0.10, 0.20 and 0.50). 
 
For dataset #3 enrichment of the HOXA group of developmental genes was calculated. HOXA genes are 
located in a cluster on chromosome 7 and are known to be switched off and moderately to highly 
methylated in most tissues [27]. The negative 
10
log-transformed enrichment p-values plotted along the 
HOXA region are shown in figure 8 (top). Using Tukey’s biweight scaling or T-quantile normalization 
results in identification of several enriched loci, most of which are moderately methylated. Less loci are 
found when using VSN, quantile or LOWESS normalization. Peng’s method results in identification of only 
a few loci with moderate enrichment.  
For dataset #4 enrichment was determined for the Dlk1-Gtl2 cluster on chromosome 12, a region 
reported in the original results [28] to be highly enriched. For all normalization approaches in dataset #4 
the same area in this region is identified as very highly enriched (figure 8 bottom). 
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Figure 8: Genome plots of negative 
10
log-transformed enrichment p-values, for the HOXA cluster on 
human chromosome 7 (top) and the Dlk1-Gtl2 cluster on mouse chromosome 12 (bottom). Red vertical 
lines are given at values corresponding to p-values of 0.05 (top line) and 0.20 (bottom line). Regions with 
values above the top line are highly enriched, while values between the lines are a sign of moderate 
enrichment. The total number of identified enriched regions are reported in the legend. TBW = Tukey’s 
biweight scaling, Q = quantile normalization, TQ = T-quantile normalization. 
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Discussion 
Two-channel transcriptomics and regulation microarrays should not be pre-processed in the same 
manner. Appropriate normalization strategies for regulation microarrays are characterized by their ability 
to retain the separation between the enriched and un-enriched components present in the data whilst 
enhancing comparability between microarrays. Six normalization methods were tested by (i) assessing 
the separation between the control probe and gene promoter probe distributions before and after 
normalization using ROC curves and (ii) by verifying whether known enriched genes and regions could be 
identified as such after normalization. We have shown that the result of each approach depends heavily 
on the situation before normalization, specifically the amount of enriched and un-enriched probes and the 
separation between the corresponding components in the raw data. These two characteristics are 
different for each experiment, depending largely on the biological system studied and the applied assay.    
In the ChIP-on-chip datasets used here, the distributions of the control probes and gene promoter probes 
overlap to a large extent before and after normalization. This may be explained by the small proportion of 
the genome generally covered by the potential binding sites of a DNA-interacting protein and the resulting 
small contribution of the enriched component. Hence in general, the lower the amount of binding sites, 
the more similar the control probe and gene promoter distributions, and the more comparable the 
performance of the normalization approaches, based on ROC curves of both distributions before and 
after normalization. However, in some cases VSN can cause a sizeable rescaling of the distributions, and 
to a spurious control probe distribution with a higher mean and spread than the gene promoter probe 
distribution. This renders gene promoter probes in the upper quantile of the data indistinguishable from 
random data, strongly impacting the biological interpretation.  
In DNA methylation microarrays the amount of enriched probes and un-enriched probes is of the same 
order, since in general the proportion of methylated CpG di-nucleotides in a genome is substantial. We 
have shown that for such microarrays, the choice for a normalization procedure will be crucial for the 
downstream analysis. All three MeDIP-on-chip datasets show a large degree of separation between the 
gene promoter and control probe distributions. The separation is lost when using normalization methods 
that normalize channels together, such as VSN, LOWESS, Peng’s method and quantile normalization. 
Using LOWESS approaches on MeDIP-on-chip data has been reported elsewhere to result in increased 
bias, because the underlying assumption that the log-ratio should be independent of the average 
individual channel signals does not hold for this type of data. DNA methylation levels are related to CpG 
and GC density, while signal intensity is also known to be influenced by GC content. Forcing the log-ratio 
to be independent of the average signal intensity using LOWESS normalization thus introduces bias 
instead of removing it [9]. 
T-quantile normalization, applied separately on the channels, and Tukey’s biweight scaling are the only 
approaches that are able to preserve the component separation in all example datasets. In dataset #1, 
individual microarrays already showed comparable distributions before normalization; hence for this 
dataset, Tukey’s biweight scaling would be sufficient. In contrast, dataset #4 for example showed a large 
heterogeneity between individual microarrays, in which case between-microarray normalization is better 
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suited to improve the overall comparability and enable quantitative data comparison. This can be 
achieved either by doing an additional normalization step after scaling, but ideally by using a between-
microarray normalization approach from the beginning, such as applying T-quantile normalization as 
demonstrated here.  
 
In regulation microarrays the sequence content of the input DNA sample and the experimental DNA 
sample always differs to a large extent. There are also instances for transcriptomics microarrays, such as 
dedicated microarrays designed for a specific biological context, where the assumption that the majority 
of genes are not differentially expressed does not hold, hence requiring adapted normalization strategies. 
Most of these strategies involve the use of invariant genes, either present on the slide [29,30] or 
determined from the data [31]. Selecting invariant probes in ChIP-on-chip and DNA methylation data is 
difficult however, even when selecting the control probes used in the analysis presented here, because 
this would implicate a normalization based on un-enriched probes. Since the sequences meant to 
hybridize to these probes are largely absent from the experimental sample, they essentially measure 
background noise in the channel containing the experimental sample. Variation in log-ratio values of 
these un-enriched probes between microarrays therefore reflects methodological effects rather than 
biology, which compromises their usability. To avoid the use of invariant genes in transcriptomics 
microarrays, a three-component mixture model has been proposed [32]. The normalization parameters 
are estimated independently in the groups of up-regulated, down-regulated and unchanged genes and 
normalized separately. Such a model in adapted form can be fitted on regulation microarray data and 
used conjointly with enrichment finding. It has been shown that for DNA methylation studies using specific 
reference samples, such as a fully methylated total DNA sample, it is possible to make robust estimates 
for methylation percentages when using such a model [9, 33, 34].  
The research described herein is limited to the normalization of replicate microarrays. In many cases 
however, a study will consist of multiple conditions, such as different tissues, or treatment and control 
samples as demonstrated in dataset #1. In these cases, the experimental DNA samples may differ to a 
large extent between treatment and control groups, warranting application of normalization to each 
condition separately. However, when only a relatively small amount of loci is expected to be differentially 
enriched and the total amount of enrichment can be assumed constant between conditions, normalization 
approaches applied to the dataset as a whole are more appropriate. This holds for experiments such as 
DNA methylation studies on the same tissue treated with a micronutrient [35], where only a projected 
limited amount of important regulatory regions with substantially altered levels of methylation is of 
interest.  
 
The results of known targets and enriched regions show consistent differences between the various 
normalization approaches. When looking at the Dlk1-Gtl2 cluster for the DNA methylation data of dataset 
#4, a region reported to be highly enriched in the original findings, it is clear that such highly enriched 
49 
regions will be identified as such regardless of the chosen normalization approach. This is not the case 
when studying moderately enriched regions, as illustrated by the results of the HOXA cluster in dataset 
#3, where the degree to which this region is identified as being enriched depends strongly on the applied 
normalization approach. Overall, T-quantile normalization and Tukey’s biweight scaling again give the 
best results. A potential cause of the observed difference between the tested normalization approaches is 
observed in the results on global level: the ranking of probes changes when using some normalization 
approaches, increasing the likelihood of un-enriched probes being spread over the whole dynamic range 
of the enriched probe distribution. Ultimately, such changes in the ranking can be destructive on the 
power to call differences in methylation or protein binding. Also, enrichment finding algorithms [11] as 
used for these results, will test if a group of tiling probes is significantly more likely to be part of the upper 
quantile than of the rest of the data distribution, assuming that if this is the case, this group of tiling probes 
shows significant enrichment and thus corresponds to a binding site or methylated region. This upper 
quantile can be defined for each microarray individually after normalization. Hence, it is not the values 
themselves, but the rank in the data distribution which is biologically relevant. Considering this, within 
channel and treatment normalization approaches do not only enable a more robust data interpretation, 
but since for many applications the individual values themselves do not need to be comparable, they are 
also sufficient. 
 
Conclusion 
The main issue of ChIP-on-chip and DNA methylation microarray normalization is to enhance 
comparability between microarrays, while keeping the separation between the enriched and un-enriched 
components present in the data. Within-channel approaches give the best performance, with enhanced 
comparability between individual microarrays for approaches that also normalize between microarrays. 
More specifically, quantile, LOWESS, Peng’s and VSN normalization alter the signal distributions to such 
an extent that it will impact the reliability of the downstream analysis substantially. Better results are 
obtained with T-quantile normalization applied separately on the channels or Tukey’s biweight scaling. 
For all datasets tested, these two methods consistently outperform the other tested methods in 
conservation of separation between the enriched and un-enriched distributions, as well as in identification 
of genomic regions known to be enriched. The T-quantile approach is preferable because it additionally 
yields enhanced comparability between microarrays. 
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Methods 
ChIP-on-chip and DNA methylation microarray dataset selection 
Five published datasets were selected from ArrayExpress. Selection criteria were set to select several 
assay types (MeDIP and ChIP), several species (human and mouse) and cover several research fields. 
Due to the selection criteria, all datasets were chosen from the same microarray manufacturer, 
NimbleGen (table 2). 
Dataset number #1 #2 #3 #4 #5 
ArrayExpress ID not registered E-TABM-529 E-GEOD-17581 E-GEOD-24286 E-GEOD-22831 
Assay type  ChIP-on-chip  ChIP-on-chip  MeDIP-on-chip  MeDIP-on-chip MeDIP-on-chip 
Microarray ID NimbleGen Human 
HGS17 minimal 
promoter  
NimbleGen Mouse 
Tiling 2006-07-17 
MM8Tiling Set17 
NimbleGen Homo 
sapiens 385K CGH 
array 
NimbleGen mouse 
385K Refseq and 
miRNA promoter 
tiling (2-array set) 
NimbleGen 
Nimblegen HD2 
MM8 promoter 
deluxe array 
Species Human Mouse Human Mouse Mouse 
Investigation Identification of  ER-
α target genes in 
breast cancer cells 
Identification of 
histone modification 
profiles in WT and 
Kcnq1ot1  
Methylome analysis 
of congenital ectopic 
thyroids 
Mecp2-dependent 
regulation of 
MicroRNAs in Rett 
Syndrome 
DNA methylation 
analysis in E3.5 
blastocysts, E6.5 
epiblasts and E9.5 
whole embryos 
No of microarrays  8  11 6 8 11 
Microarray content · 3 stimulated 
by 17beta-
estradiol 
· 1 pool of the 3 
stimulated 
· 3 untreated 
· 1 pool of the 3 
untreated 
· 2 Kcnq1ot1 
· 9 wild type 
· Tissues are 
placenta or 
liver 
· 3 orthotopic 
thyroid 
· 3 congenital 
ectopic thyroid 
 
· 2 KO using 
Mecp2 
· 4 wild type 
using Mecp2  
· 2 wild type 
using 5-
methylcytosine 
· 2 E3.5 
blastocysts 
· 3 E6.5 
epiblasts 
· 3 E9.5 whole 
embryos  
· 3 Control 
pooled 
unamplified 
MeDIPs in 
E9.5 embryos 
Microarrays used 
for this study 
3: 2 stimulated + the 
pool of stimulated 
4: H3K27me3 in 
wild-type placenta  
6: all  8: all  8: all except the 
pooled controls 
Data publication 
date 
Article publication: 
15/01/2010  
PMID: 19698761 
08/01/2008 27/10/2010 30/09/2010 
 
01/11/2010 
 
Table 2: Technical information on the ChIP-on-chip and MeDIP-on-chip datasets used for the 
normalization approach comparison. This table contains all relevant the technical information of the ChIP-
on-chip and MeDIP-on-chip datasets used for the normalization approach comparison, including the 
dataset number as used herein, the ArrayExpress ID, the assay type, the microarray ID, species, the total 
number of microarrays in the dataset, the experimental content of the microarrays, a specification of the 
subset of microarrays used for the analyses, and the publication date of the dataset on ArrayExpress. 
Sub-selections of microarrays and experimental groups were made to keep only the microarrays of 
sufficient quality and homogeneous replicate groups of sufficiently large size. In dataset #1, one 
microarray of the 17beta-estradiol stimulated group was removed because the red channel was 
saturated, as reported previously [26]. Instead the microarray containing a pool of stimulated samples 
51 
was included. The microarrays corresponding to the untreated group were left out of the analysis. In 
dataset #2, only the microarrays containing the wild-type placenta H3K27me3 samples were chosen. All 
the microarrays from dataset #3 and #4 were used. In dataset #5 all microarrays were used, except for 
three containing pooled samples. 
Quality control and bias assessment of the raw and normalized data was performed using the 
arrayQualityMetrics package [36]. Individual reports are available online at 
http://www.bigcat.unimaas.nl/userfiles/adriaens/arrayQualityMetrics/.  
 
Removing technical biases through normalization 
Microarray data is subject to multiple sources of variation. The goal of normalization is to remove all 
technical biases from the microarray data, while retaining the biological variation. There are many 
normalization procedures available for two-channel microarray data, but the choice for a specific 
procedure has to be fuelled by the characteristics of the dataset: (i) the procedure should correct all the 
systematic biases in the dataset diagnosed during the quality control process and (ii) the underlying 
assumptions of the particular method must be met. In regulation studies, there is the additional goal to 
retain the separation between the enriched and un-enriched components of the log-ratio distribution.  
To illustrate this, data from five human and mouse ChIP-on-chip and MeDIP-on-chip datasets were 
normalized using six different methods: (i) LOWESS normalization [12,16] applied on each microarray 
individually, which assumes the log-ratio distribution is a normal distribution centered around zero; (ii) 
Quantile normalization [19] applied between microarrays, which equalizes the intensity distributions of all 
channels – green and red – together; (iii) Variance stabilizing normalization (VSN) [22], which is applied 
between microarrays and between channels; (iv) T-quantile normalization [19], which allows for quantile 
normalization of the data in subgroups and here is applied to normalize the red and green channels 
separately; (v) Tukey’s biweight scaling, which scales the log-ratio distribution of each microarray 
individually using a robust Tukey’s biweight estimate of the median; (vi) Peng’s method [24], which 
performs a MA-data rotation step followed by LOWESS normalization.  
NimbleGen uses Tukey’s biweight scaling in-house. It consists of two steps: calculating the log-ratio 
between channels and subsequently correcting these by subtracting the robust Tukey’s biweight estimate 
of the median. For this estimate, each data point is given a weight using a bi-square function. The weights 
assigned by this function are inversely correlated to the distance from the median, so outliers have a 
minimal effect on the estimate. The method developed by Peng et al. [24] makes strong assumptions 
regarding the shape of the MA-plot. In this approach, LOWESS normalization is preceded by a rotation 
step of the MA-data, which is meant to account for major dye trends. This method has been mostly 
applied in Drosophila [24,37,38].  
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Quantifying the effect of normalization on the two-component distribution 
The separation between the enriched and un-enriched components present in the data of two-channel 
regulation microarrays should be conserved after applying normalization. To determine this conservation, 
the log-ratio distribution of negative control probes (which are a measure of non-specific annealing and 
background fluorescence) and the log-ratio distribution of gene promoter probes were assessed before 
and after normalization using ROC curves. For creating the ROC curves, the negative control probes 
represent the negative class of outcomes, while the gene promoter probes represent the positive class of 
outcomes. If there are any enriched probes, the gene promoter probe distribution should extend beyond 
the control probe distribution in the upper quantile and is expected to have a higher mean than the control 
probe distribution. If this separation is retained, the ROC curves are expected to have comparable AUC 
values before and after normalization, while if the separation is not retained, the ROC curves will have 
lower AUC values after normalization.  
Genomic regions known a priori to be enriched were used as positive controls, verifying to what extent 
these regions are identified after using each of the six normalization approaches. To this end, 33 well 
established ER-a targets [25] were chosen as positive controls for dataset #1 [26]. Enrichment of these 
targets was calculated using ACME with default settings and a sliding window of 750 bp [11]. For dataset 
#3 enrichment of the HOXA group of developmental genes was determined, which are located in a cluster 
on chromosome 7 and are known to be silenced and moderately to highly methylated in most tissues [27]. 
Enrichment p-values were calculated with ACME using default settings and a sliding window of 1000 bp. 
For dataset #4 the same approach was used, focussing on the Dlk1-Gtl2 cluster on chromosome 12, a 
region that was identified as highly methylated in the original results [28]. The other datasets lacked 
suitable positive controls. 
Data was imported and analyzed using Bioconductor [23] in the statistical programming language R, 
more specifically using the ACME package [11] for enrichment finding, the limma package [39] for data 
normalization and the Ringo package [40] for data import and handling.  
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Abstract 
Chromatin immunoprecipitation combined with high-throughput sequencing (ChIP-seq) has become the 
state-of-the-art technology for genome-wide mapping of epigenetic modifications. ChIP-seq has a much 
higher resolution than microarray based applications; this impacts on the requirements for analysis tools. 
Here we focus on applying ChIP-seq to study enrichment of tri-methylation of the lysine 27 residue on 
histone H3 (H3K27me3) in dynamic biological systems, where the majority of epigenetic markings are 
different between samples. A number of specific challenges exist with regards to studying histone 
modifications under dynamic conditions. Firstly, ChIP-seq enrichment-finding algorithms are optimized for 
identifying sharp peaks, whereas H3K27me3 marks tend to spread over a large number of nucleosomes 
(blanketing) and cover extended genomic regions. Thus, existing algorithms are unable to reliably identify 
H3K27me3 enriched regions. Secondly, ChIP-seq data requires normalization to enable quantitative 
comparison. In dynamic biological systems, both the total number of marks and their location is variable. 
A suitable normalization approach in this situation involves data-scaling of individual samples to genomic 
regions with relatively stable H3K27me3 marking. Definition of such stable regions depends heavily on 
the biological system. With these difficulties in mind, we have developed a standardized protocol for the 
processing of H3K27me3 ChIP-seq data. The protocol enables robust detection of H3K27me3 blanketing 
and allows for quantitative data comparison. As such, our protocol complements previous efforts to create 
a fully standardized analysis-pipeline for H3K27me3 enriched ChIP-seq data.  
 
Introduction 
High-throughput sequencing (HTS) has enabled the study of biological systems on a greater scale and 
higher genomic resolution than ever before [1] and is prospected to soon replace microarrays as the 
platform of choice. Although the technology is constantly evolving, analysis approaches are lagging 
behind [2]. Most approaches are derivatives of approaches developed for the corresponding application 
on microarrays [3], which are characterized by lower genomic resolution and scale.  
Epigenomics is the genome-wide study of epigenetic modifications, such as DNA methylation and 
modification of N-terminal histone tails, which are heritable but nonetheless variable marks that influence 
gene expression and phenotypic plasticity. Well known examples of histone modifications are tri-
methylation of lysine 4 of histone H3 (H3K4me3), which is associated with open chromatin and 
permissive for gene transcription, and tri-methylation of lysine 27 of histone H3 (H3K27me3), which is 
associated with closed chromatin and gene silencing. Chromatin immunoprecipitation (ChIP) combined 
with HTS technology (ChIP-seq) is a powerful approach to create genome-wide maps of such histone 
modifications. Here we focus specifically on H3K27me3 ChIP-seq data analysis in the context of 
biological systems where many epigenetic changes occur. Cancer cells exposed to fluctuating levels of 
oxygenation exemplify a model for such dynamic effects occurring in response to hypoxia in solid tumors. 
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Sequence sample
Raw read mapping
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Biological interpretation
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with or without input sample
paired-end or single-end sequencing
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paired-end alignment or single-end alignment
relative to input sample
expected fragment length
significance cut-off (p-value)
signal segmentation setting
integration with data from other molecular
levels: systems biology
normalize on invariant/stable regions
normalize on total amount of mapped reads
other approaches
Data summarization
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genic regions (promoter, TSS, gene body,
exons, introns) or intergenic regions
(enhancers, satellite regions)
Step Choices/settings
Output: FASTQ
Input: FASTQ
Output: BAM
Input: BAM
Output: WIG, GFF or BED
Input: GFF or BED
Output: GFF or BED
Input: WIG, GFF or BED
Output: WIG, GFF or BED
Input: WIG, GFF, BED
Output: GFF or BED
I/O data formats
 
Figure 1: Flow diagram of steps involved in the bioinformatics analyses of ChIP-seq data, from raw reads 
to biological interpretation. 
 
The sequential steps involved in ChIP-seq analysis are summarized in figure 1. Each step is paralleled 
by important decisions and specific data formats. This flow scheme concludes with interpretation of the 
data in a biologically relevant context.  
 
Step 1: Sequencing 
The steps before enrichment finding are well established and are independent of the biological system 
studied. Yet a number of important considerations apply to the design of the sequencing experiment. The 
first is whether or not to include an input sample in parallel as a reference for analysis of ChIP-seq data. 
Although including input samples increases overall costs and reduces the number of experimental 
samples in one run, an input sample is absolutely essential for proper correction of background 
anomalies, such as amplified regions and variability in shearing of DNA [4]. Also the choice of sequencing 
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technology, i.e. paired-end or single-end sequencing, requires consideration: paired-end sequencing 
yields paired reads corresponding to the start and the end of a fragment and thus allows for more robust 
alignment. For ChIP-seq experiments, paired-end technology is clearly the preferred method, provided it 
is available [5].  
 
Step 2: Mapping reads 
The next step in the process is the mapping of the raw sequence reads to a reference genome build, 
most commonly performed using Needleman-Wunsch or BLAST algorithms [6]. Some are designed for 
rapid analysis, such as Eland, while others aim for sensitivity, such as Novoalign [7]. Important decisions 
to make at this step include exclusion of non-unique mappings and collapsing duplicate reads caused by 
PCR bias. In most cases, collapsing and proceeding with unique mappings only leads to more reliable, 
unbiased data [7]. Depending on the technology applied, raw reads consist of paired-end reads or single-
end reads. As paired-end sequencing provides two connected DNA end-tags, it enables reliable 
identification of enriched regions. In addition, paired-end sequencing is more powerful in identifying 
enrichment in repeat regions, such as satellite DNA regions near centromeres. Single-end mappings from 
such regions will often be discarded from the analysis, because they do not map uniquely to one defined 
region. In case of paired-end reads, two close mappings, with ideally only one out of two reads mapping 
into a repeat region, prevent loss of such repeat regions. Since several histone modifications are 
associated with such regions and as such are of biological interest [8], paired-end mapping is always the 
algorithm of choice when studying histone modifications [5]. 
 
Step 3: Identifying regions of enrichment 
Several tools are available for enrichment-finding in ChIP-seq data, of which FindPeaks [9], PeakSeq 
[10], USeq [11] and MACS [12] are the most popular. Although these tools produce comparable results, 
FindPeaks is most sensitive in distinguishing enrichment [13]. Enrichment-finding tools work by the 
assumption that regions enriched for a histone modification of interest will yield a higher number of reads 
representing the regions in ChIP samples relative to un-enriched regions. Hence, significantly enriched 
regions can be identified [14] against a null distribution, ideally in the form of a sequenced input sample. 
Additional modulations to support enrichment-finding include modification of the expected fragment-length 
(post-sonication), resetting the significance cut-off (usually in the form of a percentile of the data above 
which a signal is considered enriched; e.g. 95%), and varying the signal-segmentation setting 
(determines when a multi-modal signal should be split into separate peaks). Most of these distinct 
enrichment-finding approaches have been developed for lower resolution cistromics applications on 
microarray platforms. Although they work well for many histone modifications deposited over a small 
number of nucleosomes such as H3K4me3, such approaches are not optimized for detection of 
H3K27me3 enrichment. A potential underlying cause is that H3K27me3 tends to spread over more 
nucleosomes to cover an entire locus, which is known as “blanketing” [15]. This results in data comprising 
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spread-out enrichment signals covering large genomic regions [15,16,17] instead of sharp peaks, which 
hampers their detection by existing peak-finding algorithms.  
 
Step 4: Data normalization 
To compare samples quantitatively, ChIP-seq data requires normalization, because signal intensity 
depends on sequencing depth and mapping efficiency. Several approaches have been developed, of 
which scaling based on the total number of aligned reads is most common [18,19]. This method starts 
with the assumption that there is only a small number of prospected differences between conditions, 
which does not hold for dynamic biological systems; for such systems normalizing on regions with stable 
enrichment seems the only valid approach. However, it is difficult to define a priori genomic regions as 
candidates for such stable enrichment, as this relies heavily on the biological system as well as the 
studied histone modification [18]. 
 
Step 5 & 6: Data summarization and interpretation. 
Although usually complex and mostly dependent on the biological system of choice and research 
question(s) at hand, the biological interpretation of the data is identical to comparable applications in 
microarrays [20]: integration of transcriptomics data is the minimal requirement for a meaningful analysis. 
Since experiments and research questions are extremely diverse, a flexible analysis tool is needed. 
Perhaps not surprising, several open source tools are available to enable robust analysis and biological 
interpretation of ChIP-seq data [21,22,23]. However, the sheer amount of sequencing information 
obstructs straight-forward data interpretation. Hence, most researchers choose to focus on genes and/or 
regulatory regions before committing to the biological interpretation phase. This requires summarization 
of the enrichment in genic and regulatory regions of interest. For H3K27me3 data, such regulatory 
relevant regions have been defined successfully before [15]. 
 
Based on the considerations above, we have developed a protocol to handle H3K27me3 ChIP-seq data 
focused on (i) standardization of the enrichment finding, (ii) data normalization and (iii) data 
summarization steps, while building on the already standardized stages before enrichment finding. 
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Procedure 
(i) Finding regions of enrichment 
 
H3K27me3 is known to “blanket” over large genomic regions. In order to define such broad regions of 
enrichment, while still retaining all the advantages of using an input DNA sample as a reference, 
FindPeaks with adapted settings is used. The primary setting that needs to be changed in the FindPeaks 
algorithm is the expected sequence distribution setting. By increasing the expected fragment size (post-
sonication), the algorithm successfully classifies broad regions of enrichment as peaks (figure 2).  
 
 
Figure 2: Illustration of the effect of increasing the expected fragment length-distribution to enable more 
robust detection of H3K27me3 enriched regions. 
 
Additional settings are tied to the normalization approach: for this method to work, the signal needs to be 
split in as many individual peaks as possible, which is controlled by the signal-segmentation setting. 
Furthermore, the approach requires retention of as much of the signal as possible, which is controlled by 
the significance cut-off setting. Although this will inevitably increase the size of the resulting data files, as 
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the identified peaks will be broader, the signal sampling frequency can safely be decreased as a counter 
measure. 
 
Using the mapped input reads as control sample with flag “-control” and the immunoprecipitated sample 
as the experimental sample with the flag “-input”, we use the following “broad-peak” settings: 
 -aligner sam    (aligner type) 
 -subpeaks 0.5    (signal segmentation) 
 -control_type 0    (control type: input DNA) 
 -alpha 0.2    (significance setting) 
 -wig_step_size 10   (signal sampling frequency) 
 -trim 0.2    (peak trimming) 
 -dist_type 1 285 600 100 (expected sequence distribution) 
 
As an example, using FindPeaks with these settings would lead to the following terminal command: 
 
 
 
 
(ii) Data normalization 
Normalization follows the identification of H3K27me3-enriched signals that are significantly above 
background level. The normalization strategy is based on identifying regions with stable H3K27me3-
enrichment between two or more samples. The cumulative area under the curve (AUC) for all peaks in all 
these regions is determined for each condition, and based on those values, scaling factors are calculated 
relative to the smallest value among the samples (figure 3).  
java -jar  /test/local/analysis/src/findPeaks/fp4.0.16/fp4/FindPeaks.jar   
-aligner sam  
-hist_size 100   
-input ../5.merge.filtered4_256.collapsed.q30.bam  
-name 5.merge.filtered4_256.collapsed.q30.bam.out   
-control ../../../1/novoalign/1.merge.filtered4_256.collapsed.q30.bam  
-output .  
-subpeaks 0.5  
-control_type 0  
-alpha 0.2  
-wig_step_size 10  
-trim 0.2  
-dist_type 1 285 600 100 
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Figure 3: A schematic overview showing the steps involved in the normalization strategy based on 
finding regions with stable H3K27me3 enrichment.  
 
The most straightforward approach is to use the ACME package [14] in R, using the following approach: 
 
 Import the files containing peak data in R, including for each peak at least a genomic location and 
a height or AUC-value (GFF or BED format). 
 Then for all samples/conditions: 
o Create an ACME data object as described in the ACME documentation [14] 
o Run ACME using a window size of at least 20000 bp and a cut-off of 0.90 corresponding 
to the peak height value of the 90
th
 percentile. Peaks with a height above this value will 
be designated positive, those below this value will be designated negative (figure 3). The 
 
65 
window size of 20000 bp is chosen because it is much larger than the observed average 
peak width when using the settings specified in step (i), while being small enough to lead 
to a reasonable specificity.    
o Upon completion of the run, proceed only with regions with a chi-square test p-value 
smaller than 1E-5 in all samples/conditions. This value was shown empirically to yield 
good results.  
 Add up all signals detected within the stable regions for each sample individually. 
 Divide the individual sums by the smallest sum in the batch and use the resulting scaling factors 
to scale the peaks for each sample individually. 
 
(iii) Summarization at gene level 
 
To ease the interpretation of  high-scale datasets such as obtained in ChIP-seq analysis, an excellent 
approach is to summarize the data based on relative location with respect to genes and gene regulatory 
regions. For H3K27me3, such regions have been defined successfully before, with clear associations to 
gene transcription regulation [15]: 
 Promoter region: 3000 bp upstream of TSS to 100 bp upstream of TSS 
 TSS region: 100 bp upstream of TSS to 1000 bp downstream of TSS 
 Gene body: 1000 bp downstream of TSS to end of the last exon 
 
Enrichment for H3K27me3 that covers the entire gene body is associated with gene silencing. Enrichment 
within the TSS region are candidates for so-called bivalency, i.e. nucleosomal regions marked with both 
gene-silencing-associated H3K27me3 and gene-activity-associated H3K4me3. Enrichment in the 
promoter region can be associated with gene silencing as well as active gene transcription, depending on 
the nearby presence of other histone modifications and the cellular context [15].  
Other regions of interest (ROI) may be enhancers, which are known to be susceptible to various histone 
modifications [24]. A potential obstacle with these ROIs is that clear definitions of what constitutes a 
functional enhancer is  not always available, as these are functionally dependent on cellular context. 
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Anticipated results 
We have tested the above protocol extensively on our own and published H3K27me3 ChIP-seq datasets. 
The enrichment-finding approach and the normalization approach are inseparably connected. The broad-
peak settings for FindPeaks produce more returned signal, which is separated into more individual peaks 
(figure 4).  
 
 
Figure 4: Results of the broad-peak settings for FindPeaks compared to the default settings. 
This is required for the normalization-approach to work properly, because it needs to integrate as much 
peak information as possible to reliably identify stable regions of enrichment within the genome. For the 
dataset used to develop the protocol, most of these stable regions were found near centromeres and in 
intergenic regions. It has been observed previously that centromeres are heavily enriched for H3K27me3 
[8,25,26,27]. These regions are also known to contain a large number of repeats. Therefore, repeat 
region reads will inevitably end-up being mapped to these regions, regardless of their origin. Hence, the 
reason for finding high enrichment within these regions may reflect a technical artifact rather than biology. 
It is therefore essential to prevent accumulation of such reads leading to spurious enrichment in these 
regions, by keeping only uniquely mapped reads for normalization analysis.  
We compared the results for our dataset and approach to published results [28]. In figure 5, condensed 
genome tracks are plotted for chromosome 1 and 19, showing very similar profiles, although our 
approach retains more signal. 
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Figure 5: Comparison of published results with our results: a similar “fingerprint” is found, but more signal 
is retained using our H3K27me3 enrichment protocol. 
 
Discussion 
We here report on a straight forward, robust method to delineate non-uniform genomic H3K27me3-
distributions. Our approach integrates a normalization method based on identifying regions with stable 
H3K27me3-enrichment between samples and a cumulative signal-retention strategy, which identifies 
broadly defined epigenetic marks, which would be lost with standard peak-find algorithms. 
With respect to definition of H3K27me3-enrichment in ChIP-seq data multiple approaches are in use, 
which mostly build on limiting the enrichment-finding step to predefined regions and counting the number 
of reads in these regions. Some methods apply this to genic regions only [15,29], some to intergenic 
regions only [27] and others to both [30]. By limiting the enrichment-finding to regions with predefined 
start and end points, however, the enrichment analysis requires redefinition each time when novel regions 
of interest are probed, such as enhancers which are often located in the predefined intergenic regions. 
Moreover, when neither input sample data nor an estimated null-distribution is considered in the 
enrichment–finding strategy, which is the case for some published approaches [29,30], this can result in 
spurious background enrichment, which limits the reliability of quantitative comparisons, regardless of 
normalization. Another downside of many of these approaches is that definition of enrichment is data 
driven, resulting in analytical parameter use that may not be applicable to other studies. 
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Genome-wide enrichment-finding methodology not limited by pre-defined static regions, include, for 
instance, a hidden Markov-model approach. Although some methods compare H3K27me3-enrichment 
between samples in a genome-wide fashion [31,32] and/or apply a genome-wide sliding window 
approach (i.e. summarizing the counts in each window; [33,34]), none of these approaches integrate input 
sample data or an estimated null-distribution to correct for background anomalies. Several studies report 
the use of standard enrichment-finding algorithms, like MACS [35], in combination with input sample data 
[36,37,38]. Using such algorithms without adapted settings, however, will inevitably result in significant 
loss of H3K27me3 signal. 
With regard to data normalization, the most often reported approach is scaling by the total number of 
unique reads of each sample to the sample with the lowest number of reads [15,30,32]. A related 
approach is the dissection of nucleosome-filled genomic portions (or a subset thereof) into non-
overlapping windows, followed by dividing the count-number in each window by the average number of 
counts for all windows [27,29]. Note that both normalization methods start from the assumption that the 
number of (any given) histone modifications does not vary between conditions. Whereas this may be 
satisfactory for specific experimental settings, it does not apply to dynamic biological systems. Strikingly, 
many published reports have omitted any form of data normalization as part of the data summarizing flow 
[33,34,36,37,38]. 
In conclusion, to our knowledge, the herein described approach is the only generic protocol that enables 
genome-wide, quantitative data comparison for H3K27me3 ChIP-seq data, while still retaining the 
robustness of using input sample data for enrichment-finding. Other histone modifications exist with 
similar distribution-profiles as H3K27me3, an example of which is the H3K36me3 modification; 
H3K36me3 is associated with transcription-elongation and typically covers the most if not all of the gene 
body. Hence, while our method is designed and optimized for studying H3K27me3-histone modifications, 
the protocol is readily adaptable for definition of other broad-type epigenetic enrichment profiles. 
 
R scripts are available from the authors upon request. 
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Abstract 
Biological pathways are abstract and functional visual representations of existing biological knowledge. 
By mapping high-throughput data on these representations, changes and patterns in biological systems 
on the genetic, metabolic and protein level are instantly assessable. Many public domain repositories 
exist for storing biological pathways, each applying its own conventions and storage format. A pathway 
based content review of these repositories reveals that none of them are comprehensive.  
To address this issue, we apply a general workflow to create curated biological pathways, in which we 
combine three content sources: public domain databases, literature and experts. In this workflow all 
content of a particular biological pathway is manually retrieved from biological pathway databases and 
literature, after which this content is compared, combined and subsequently curated by experts. From the 
curated content new biological pathways can be created for a pathway analysis tool of choice and 
distributed amongst its user base. We applied this procedure to successfully construct high quality 
curated biological pathways involved in human fatty acid metabolism. 
 
Introduction 
In recent years biological pathway analysis has become common in biochemical research. There is a 
plethora of pathway analysis tools available. In general such tools map multidimensional experimental 
data to biological pathways, which are abstract and functional visual representations of existing biological 
knowledge [1]. Pathways help to understand changes and patterns in biological systems of various types 
of organisms on the genetic, protein and metabolic level.  
A pathway may encompass one or several types of biological processes [2], the key ones being 
regulatory processes, metabolic processes, protein-protein interactions and signaling processes. A 
regulatory process may for instance involve transcription factors and the genes whose expression they 
activate or inhibit, an example of which is the regulation of genes involved in fatty acid metabolism by 
peroxisome proliferator-activated receptor alpha (PPAR-α). A metabolic process describes flows of 
physiological reactions, involving subtracts, products and commonly a catalyst, such as the series of 
reactions describing fatty acid β-oxidation. An example of a protein-protein interaction is the binding of a 
ligand to a receptor, which in turn may activate a signaling process like the mitogen activated protein 
kinase (MAPK) cascade. A pathway always shows direction, but it can contain more knowledge than a 
simple network, such as information on the sub-cellular localization of components, regulatory 
mechanisms and connections to other pathways.  
 
Over the last decade several online databases were created to store biological pathways [3]. Each 
database has its own conventions, level of interactivity and storage format, but in the end all of them store 
information covering biological pathways, from the low-level processes of metabolism to high-level 
processes like regulation. Some databases store only a static picture of a biological pathway, such as the 
BioCarta database (http://www.biocarta.com/), while others, such as Reactome [4] and KEGG [5], store 
 75 
extensive annotation for each of the elements in a pathway by using a custom XML format, in addition to 
a graphical layout.  Another growing repository is Science Signaling (http://stke.sciencemag.org/), 
developed by American Association for the Advancement of Science (AAAS), the publisher of Science 
Magazine. It includes more than 60 curated signaling pathways and additionally provides short lists of key 
references and evaluations of the strength of existing evidence for associations within the database. 
WikiPathways (http://www.wikipathways.org/) applies a similar concept. It is a public Wiki platform 
dedicated to the creation, storing and curation of biological pathways by and for the scientific community. 
WikiPathways contains copies of all GenMAPP pathways plus additional pathways in GPML (GenMAPP 
Pathway Markup Language) format. 
GeneGO Metacore [6], GenMAPP [7] and Metacyc (http://www.metacyc.org/) also offer data visualization 
and statistical analysis tools to analyze experimental data on a pathway level. This brings us to the most 
important application of pathways: pathway analysis. 
 
Pathway analysis tools 
Pathway analysis of gene or protein expression data applies genomic information to couple the 
expression data to known biological pathways. Usage of extensive collections of such pathways allows a 
quickly assessable overview of expression results in relation to biological mechanisms, facilitating the 
understanding of gene, protein and metabolite interactions at higher physiological levels. Cavalieri and De 
Filippo [8] reviewed tools that automatically display functional genomics results on biological pathways 
and tools that test for statistical significance of enrichment of genes belonging to a biological pathway. 
Among these tools are several commercial applications, such as GeneGO Metacore, Rosetta Resolver 
and Acuity, which are commonly used for high-throughput data analysis. Open-source programs such as 
GenMAPP with MAPPFinder [9], Cytoscape [10] and DAVID (http://david.abcc.ncifcrf.gov/) also offer the 
possibility of interactively visualizing expression datasets on biological pathways. When large amounts of 
expression data need to be analyzed on a large collection of pathways, a need for automation arises. 
Several statistical methods were developed to assess the significance of changes in gene expression in a 
pathway or a collection of pathways. Pathway analysis programs such as Pathway Miner [11], Eu.gene 
Analyzer [8], MetaCyc (http://www.metacyc.org/) and GenMAPP’s MAPPFinder each have their own 
statistical approaches. An overview of some popular pathway editing and analysis tools is found in table 
1. 
 
GenMAPP is a popular freely available biological pathway analysis tool developed at the Conklin Lab at 
the J. David Gladstone Institutes of the University of California. Several gene properties can be displayed 
on pathways simultaneously by creating a lookup table, linking colours and descriptions to user specified 
criteria that for instance indicate changes in the gene expression level. GenMAPP’s built-in statistical tool 
MAPPFinder enables a pathway-based enrichment analysis. MAPPFinder calculates a statistical p-value 
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for each pathway entity using the hypergeometrical distribution, after which pathways are ranked by 
significance. 
Table 1: Overview of some popular pathway editing and analysis tools. 
a
 For pathway expansion; 
b
 
Through online converter on WikiPathways. 
 
Another popular tools suite is Ingenuity Pathways Analysis (IPA, http://www.ingenuity.com/), an all-in-one 
commercial software application that enables modeling, analysis and understanding of the complex 
biological and chemical systems at the core of life science research. It consists of several tools enabling 
one to easily mine the scientific literature, build dynamic pathway models and quickly analyze high-
throughput experimental data to identify key insights. IPA’s dynamic pathway modeling tool applies 
textmining approaches for construction of novel relations between pathway entities. As a free alternative, 
the textmining tool Bibliosphere by the Genomatix company (http://www.genomatix.de) offers similar 
functionality, combining textmining results from literature with sequence data to more robustly identify 
relations. Bibliosphere is available from the Genomatix website. Likewise, Pathway Studio, a commercial 
 Pathway 
editing 
Pathway 
analysis
 
Licence Textmining
a 
Pathway databases 
Biocarta Yes No Free No Proprietary 
EU.gene Yes Yes Free No Proprietary, WikiPathways
b 
GenMAPP Yes Yes Free No Proprietary, KEGG, 
WikiPathways
b 
Genomatix No Yes Commercial Yes Proprietary 
Ingenuity Yes Yes Commercial Yes Proprietary, KEGG 
MetaCore Yes Yes Commercial Yes Proprietary 
Pathway Studio Yes Yes Commercial Yes ResNet Mammalian Database, 
ResNet Plant, ResNet Targeted 
Databases, KEGG, Science 
Signaling, Prolexys HyNet yeast 
two-hybrid database 
Reactome Yes No Free No Proprietary 
WikiPathways Yes No Free No Proprietary, GenMAPP 
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application suite from Ariadne Genomics, implements textmining approaches to find relationships among 
pathway entities. In addition, Pathway Studio can perform Gene Set Enrichment analysis on sets of 
genes that share a functional, biological or some other relation.  
 
Pathway repositories 
Every pathway analysis tool uses pathways that are created locally or downloaded from a central 
repository. To assess the quality and completeness of such repositories, we extracted and compared the 
pathway content from processes involved in fatty acid metabolism from several free pathway databases. 
We focussed on fatty acid oxidation, fatty acid synthesis and regulation of these processes. These 
pathways are well described in literature. Since most pathway repositories curate their pathways with 
literature, one would expect excellent entries. A full overview is given in table 2. 
 
KEGG stores 33,679 pathways for over a hundred species generated from 269 reference pathways, 
about metabolism, genetic information processing, environmental response, cellular processes, human 
diseases and drug response. Most pathway tools make extensive use of the KEGG database. Although 
generally considered a robust database, some of the fatty acid metabolism pathways in KEGG have not 
been updated in years. The database contains the pathways for fatty acid biosynthesis, fatty acid 
elongation, fatty acid desaturation and fatty acid mitochondrial β-oxidation, but no entries related to the 
regulation of these processes. 
The BioCarta pathway database offers a free collection of pathways and is hosted by a company that 
supplies anti-bodies for entities on several pathways. It contains key information for over 120,000 genes 
from multiple species through a user-friendly interface. The database contains 296 regularly updated 
pathways. Pathways describing mitochondrial and peroxisomal β-oxidation of fatty acids, oxidation of 
odd-numbered chain fatty acids, oxidation of polyunsaturated fatty acids, disease related ω-oxidation and 
a separate pathway of the carnitine mediated transport system are all found in BioCarta. 
GenMAPP stores more than 200 contributed pathways as well as hundreds of pathways derived from the 
KEGG database. The contributed pathways related to human fatty acid metabolism are fatty acid 
synthesis, mitochondrial fatty acid β-oxidation and fatty acid degradation, but these have not been 
updated or checked in years.  
Reactome is an online bioinformatics database of biology described in molecular terms, storing pathways 
as a series of separate biochemical reactions. Most pathways involved in human fatty acid metabolism 
are present. Some pathways, like the oxidation of unsaturated fatty acids, are not found in other 
databases. Several reactions, like the one converting palmitate to long-chain fatty acids, are only 
mentioned, whereas other databases give a complete set of reactions. 
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A pathway curation workflow 
Biological pathway content varies greatly among the tools and databases described above in both quality 
and completeness, even at first glance. Additionally, pathway repositories in general apply different 
storage formats and conventions. Ideally, one would want to integrate all knowledge of a particular 
pathway from the various tools and databases available to create one ‘complete’ pathway. This is 
especially attractive when performing pathway analysis. Yet, researchers that possess the knowledge 
needed to create and curate such an integrated pathway are often discouraged to do so. A possible 
cause is the lack of a general guideline for pathway creation and curation, in addition to the false 
assumption that it is a time consuming process. 
We ourselves apply a general biological pathway curation workflow (figure 1) comprised of four phases 
and three main data sources: online public domain databases, literature and experts. The databases 
used to collect content are KEGG, Reactome, GenMAPP and BioCarta, using the content from Reactome 
as a basis, as its content is the most complete, heavily curated and therefore of the highest quality. 
PubMed (http://www.pubmed.org/) is used to find relevant literature.  
 
 
Figure 1: Pathway curation workflow. This figure shows the outline of the biological pathway curation 
workflow. The workflow applies content from online databases, literature and experts. First, all biological 
information associated with the biological pathways in question is retrieved from Reactome and compared 
to content from KEGG, GenMAPP and BioCarta. Scientific literature is used to fill in the gaps and finally, 
the results are curated with the help of experts to remove ambiguities and inconsistencies. The curated 
content is used to make new digital pathway representations, suitable for analysis in a pathway analysis 
tool of choice. These digital representations are distributed amongst the user base of the pathway 
analysis tool of choice, resulting in additional curation feedback. 
 
The first step in this manual workflow is to collect all biological information associated with the biological 
pathways in question by (i) retrieving biological pathway content from several curated and highly regarded 
biological pathway databases, (ii) comparing and structuring content from different databases, (iii) 
searching for scientific literature referring to the processes described in these biological pathways and 
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finally (iv) curating the results with the help of experts to remove ambiguities and inconsistencies. The 
resulting curated content is subsequently used to create new pathways in a format suitable for a pathway 
analysis tool of choice, resulting in additional curation feedback. 
 
Creating high quality curated fatty acid metabolism pathways 
The manual curation process was used to create high quality curated pathways of the key processes 
involved in human fatty acid metabolism: fatty acid oxidation, fatty acid synthesis and regulation of these 
processes. Pathways involved in fatty acid metabolism are essential pathways in nutritional research. 
Curated up-to-date versions of these pathways are therefore in high demand. 
Biological pathways in Reactome are presented as a collection of biochemical reactions and lack a visual 
overview displaying connections between these reactions. Hence, comparing pathway content from 
Reactome to the content found in other databases is a difficult task. To facilitate this process, graphical 
overviews were created manually by starting with the first listed reaction, connecting its product as the 
substrate of the second reaction and so on, creating a series of  representations of all the reactions 
involved in human fatty acid metabolism. Once these representations were created, differences with 
pathway content found in the biological pathway repositories described above were annotated and 
simultaneously literature was searched to check everything found up to that point. Some of the pathways 
involved in human fatty acid metabolism were found to be incomplete or completely missing in the various 
biological pathway repositories. The results are best discussed on a pathway to pathway basis, 
highlighting the differences in completeness and accuracy between databases (summarized in table 2). 
 
 Biosynthesis Fatty acid 
degradation
 
Transport Regulation Fatty acid 
elongation 
Fatty 
acids 
Triacyl 
glycerid 
β 
ox 
M 
β 
ox 
U 
β 
ox 
P 
ω 
ox 
Carnitine 
shuttle 
Synthesis Degradation Elongation 
Reactome i c c c m m m i m m 
KEGG c m c m m m m m m c 
GenMAPP c m i i m m i m m m 
BioCarta m m c c i c c i m m 
 
Table 2: Fatty acid metabolism pathway content of selected pathway repositories. c = complete pathway 
in database, m = missing in database, i = present but incomplete in database, β-ox M = mitochondrial β-
oxidation, β-ox U = mitochondrial β-oxidation of unsaturated fatty acids, β-ox P = peroxisomal β-oxidation. 
 
Fatty acid biosynthesis has three major functions: the storage of excess energy intake, synthesis of fat 
from carbohydrates or proteins if the quantity of fat in the diet is low and synthesis of fat for lactation [12]. 
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Reactome gives a good overview of the transport of citric acid from the mitochondria to the cytosol, where 
the citrate lygase catalyzes the production of acetyl-co-enzym A (acetyl-CoA) from citrate, to the creation 
of long-chain fatty acids. This pathway is followed by the triacylglycerol biosynthesis pathway.  
Several essential parts of the fatty acid metabolism were found to be missing from the Reactome 
database. No details are given regarding the reaction that transforms palmitate into long-chain-fatty-acid 
and there is only a schematic overview of the reaction which transfers butyryl-acyl carrier protein (butyryl-
ACP) into palmitoyl-ACP. Pathways involved in fatty acid elongation and desaturation are missing 
entirely.  
The elongation of fatty acids proceeds through a repeated cycle of reactions. This cycle starts by the 
conversion of acyl-CoA to 3-ketoacyl-CoA, which is catalyzed by acetyl-CoA C-acyltransferase. The 3-
ketoacyl-CoA intermediate undergoes the same three reactions that form the basis of β-oxidation, only in 
reverse order. Reduction of the keto-group is followed by dehydration to form a double bond. Reduction 
of the double bond results in an acyl-CoA that is two carbons longer than the acyl-CoA in the beginning of 
the cycle [13]. The desaturation takes place after elongation in the endoplasmic reticulum and is 
catalyzed by acyl-CoA desaturase. 
KEGG describes the elongation cycles in detail and in addition gives all the enzyme codes of the different 
fatty acid synthases. GenMAPP has MAPPs describing fatty acid elongation and desaturation, but the 
reactions are not visualized in a cyclic manner.  
 
There are several processes involved in the degradation of fatty acids, with β-oxidation being the most 
important [14]. Β-oxidation is the process by which fatty acids are degraded in the mitochondria. The 
carnitine shuttle [15] is essentially the first step of mitochondrial fatty acid β-oxidation. It is involved in 
transport of long-chain fatty acids through both mitochondrial membranes, from the cytosol to the 
mitochondrial matrix where β-oxidation takes place [16]. 
Collecting and comparing the information on the several fatty acid degradation processes showed that 
Reactome does not contain any information on reactions related to the fatty acid carnitine transport 
system (the transport of fatty acid into mitochondria) or fatty acid cell transport system (the transport of 
fatty acid into the cell). The KEGG database refers to the carnitine O-palmitotransferase enzyme in the β-
oxidation pathway, but fails to clarify the uptake into mitochondria. GenMAPP and BioCarta give a full 
overview of the carnitine shuttle, but disagree on some minor details concerning the sub-cellular location 
of each step in the process. These ambiguities were clarified using literature [15, 16].  
Mitochondrial fatty acid β-oxidation of saturated and unsaturated fatty acids is well described in 
Reactome. In KEGG, β-oxidation of unsaturated fatty acids is missing. GenMAPP gives an abbreviated 
description and BioCarta gives a small overview. Both BioCarta and GenMAPP do not detail the seven 
different cycles of the β-oxidation process, falsely assuming a reiteration of one general cycle.  
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Peroxisomal β-oxidation [17] applies the same mechanism as mitochondrial β-oxidation, but the 
peroxisomal fatty acid β-oxidation system is only able to shorten fatty acids chains and cannot degrade 
fatty acids to completion. The shorter chains are transported as carnitine-ester from the peroxisomes to 
the mitochondria, where the degradation is completed. Specific information on peroxisomal β-oxidation is 
missing from most databases. Reactions describing the process are present, but incomplete in the 
Reactome database. BioCarta gives a short but otherwise complete overview.  
 
Another form of fatty acid oxidation is ω-oxidation [17]. Ω-oxidation is a minor process that takes place in 
the endoplasmic reticulum, but only occurs when the β-oxidation processes are somehow impaired by 
disease or fasting. Information on ω-oxidation is only found in BioCarta. Ω-oxidation was not mentioned in 
any other database. Additions were found in literature [17].  
 
There are five main regulatory proteins involved in the regulation of fatty acid synthesis: liver X 
receptor/retinoid X receptor (LXR-α/RXR-α) heterodimer, nuclear transcription factor Y (NF-Y), sterol 
regulatory element binding protein 1 and 2 (SREBP1, SREBP2) and carbohydrate regulatory element 
binding protein (ChREBP) [21-26]. The main regulator in the regulation of β-oxidation is peroxisome 
proliferator activated receptor alpha (PPAR-α) [18-20].  
Regulation of fatty acid synthesis by ChREBP [21-26] has an entry in the Reactome database, but 
transcriptional activation of the synthesis via SREBP1 and LXR-α/RXR-α heterodimer and NF-Y is 
absent. The regulation of fatty acid degradation is not mentioned in Reactome. 
BioCarta contains pathways describing regulation of fatty acid synthesis by SREBP1 and SREBP2 and 
the regulation of genes involved in fatty acid β-oxidation by PPAR-α. LXR is only mentioned in 
conjunction with FXR in a pathway on the regulation of cholesterol metabolism. Likewise, RXR 
degradation is mentioned, but there is no entry describing the relation to the regulation of fatty acid 
synthesis.  
GenMAPP and KEGG do not contain any pathways describing regulation of processes involved in human 
fatty acid metabolism. Content from Reactome and BioCarta was expanded with the help of literature [18-
26].  
 
After all content was collected, it was passed on to experts in the field of fatty acid metabolism. New 
pathways describing fatty acid synthesis, triacylglyceride synthesis, fatty acid β-oxidation (saturated and 
unsaturated) and fatty acid ω-oxidation were created from this curated content. Pathways are available 
from WikiPathways (http://www.wikipathways.org/). Downloading the pathways from this location ensures 
that you have the most up-to-date version. WikiPathways has the option to export to formats suitable for 
analysis in Cytoscape, EU.gene Analyzer and GenMAPP. This resulted in constructive feedback from the 
large user base of these tools.  
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Conclusion 
Biological pathway databases are far from comprehensive. We have used a rapid pathway curation 
workflow to collect all content of biological pathways involved in human fatty acid metabolism. At the time 
of writing, these improved fatty acid metabolism pathways are among the most widely used biological 
pathways in GenMAPP and as such have become part of the standard MAPP archive. The suggested 
workflow can be seen as a general guideline for anyone looking to create novel high quality curated 
biological pathways. The choice for a particular pathway editing tool however, is up to the user.  
Additionally, we use public domain databases only. Although content that comes with commercial tools is 
often derived from public databases and literature, those tools are in many cases well developed and 
have convenient user interfaces, which makes their usage beneficial for pathway developers that do have 
access to such tools. 
A downside of the presented manual curation workflow is that it will generally not yield novel pathways 
when using database content as the starting point. This can be addressed by consulting experts first, 
which in most cases will result in a ‘raw pathway’. Literature and database content can then be used to 
polish this raw pathway. Finding relevant literature is an arduous task, however, as querying articles for 
single reactions yields excessive amounts of hits. A possible solution for this issue is text mining, which 
can be used to generate an exhaustive list of relevant literature and networks of possible connections 
between queried components, for instance based on co-citation in Pubmed abstracts. These networks of 
inferred relations are then integrated into one or several pathways. The content should then still be 
curated by experts, as textmining will in general yield a large amount of false positives. In a similar 
fashion to manually extracted content from databases and literature, this content may then be transcribed 
into novel pathways. Textmining is already used in several pathway analysis tools (see table 1) as an 
alternative to pathway analysis using known curated pathways. 
 
Using the presented workflow, it is possible to create a small collection of curated pathways within 20 
man-hours, of course depending on expert availability. This is not fast enough to fill a repository with all 
known pathways. But this is not the purpose of the presented workflow. Anyone can make a small 
pathway in half an hour, but this does not imply that the information contained within the pathway is of 
high quality or even correct. Curation is the key. Pathway curation can normally take months, leading to 
out-of-date and incomplete content. The presented pathway curation workflow, although possibly less 
thorough, is faster and founded on the principle of public demand. Hence, it is a suitable workflow for 
creating key pathways. A community effort is needed to create a more robust set of pathways in a similar 
manner, as demonstrated by the Science Signaling and WikiPathways initiatives. 
Still, to improve speed, partial automation of the curation process could be implemented, starting with 
content extraction from Reactome and ending at novel pathways in a suitable exchange format. There are 
two data flows at the moment, an overview of which can be seen in figure 2. Once the content is in 
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GPML format, the pathways are easily converted to Cytoscape, EU.gene Analyzer and GenMAPP 
formats through the WikiPathways interface. 
 
Only one connection between Reactome and GPML is readily available, implementing an intermediary 
EBI created comma-separated text format. There is another suggested connection through the BioPAX 
level 2 format [27]. BioPAX Level 2 is a suitable exchange format for biological pathway content, but at 
the moment does not store the additional graphical layout information that is required for transparent 
conversion of pathway representations from pathway analysis tools such as GenMAPP and Cytoscape. 
Reactome offers the option to export all its pathways and reactions as BioPAX level 2 compliant files, 
which can then be directly imported into the java-based Cytoscape application and converted to GPML.  
 
 
 
Figure 2: Reactome to GPML pipeline. This figure shows two possible connections between Reactome 
and GPML. Each wave block is a data type; each parallelogram is a software application. One connection 
uses an EBI created comma-separated text format and a novel converter to create a GPML file, a format 
suitable for both WikiPathways and GenMAPP. Additionally, Reactome offers the option to export all its 
pathways and reactions as BioPAX level 2 compliant files, which can then be directly imported in the java-
based Cytoscape application and converted to GPML. 
 
Pathway curation is a Sisyphean task, as new discoveries constantly lead to novel additions and 
adaptations to a pathway. Also, the ‘beginning’ and ‘end’ of a pathway are arbitrary definitions. This latter 
difficulty can be overcome by creating so-called meta-pathways, covering several separately defined 
pathways and their respective biochemical and biological connections, similar to the Reactome sky map.  
The former challenge can be met by adaptation of standard exchange formats for biological pathways, 
enabling automated pathway data acquisition and comparison in a network analysis tool. With such 
additions in place, the road to curated pathways will become less long and winding. 
 
Acknowledgements 
We would like to thank Sander Kersten and Jochum Plat, who we consulted as experts in the field of fatty 
acid metabolism, and Marjan van Erk, Rachel van Haaften, Peter d’Eustachio and Bernard de Bono for 
their valuable advice and support. 
 84 
References 
1. Cary, M.P. et al. (2005) Pathway information for systems biology. FEBS Lett, 579 (8): 1815-20. 
2. Bader, G.D. et al. (2006) Pathguide: a pathway resource list. Nucleic Acids Res 34(Database issue): 
D504-6.  
3. Galperin, M.Y. (2008) The Molecular Biology Database Collection: 2008 update. Nucleic Acids Res 
36 (Database issue), D2. 
4. Vastrik, I. et al. (2007) Reactome: a knowledge base of biologic pathways and processes. Genome 
Biol 8 (3), R39. 
5. Kanehisa, M. et al (2008) KEGG for linking genomes to life and the environment. Nucleic Acids Res 
Vol. 36(Database issue), D480-D484. 
6. Ekins, S. et al. (2007) Pathway mapping tools for analysis of high content data. Methods Mol Biol 
356, 319-50.  
7. Salomonis, N. et al. (2007) GenMAPP 2: New Features and Resources for Pathway Analysis. BMC 
Bioinform. 8, 217. 
8. Cavalieri, D. and De Filippo, C. (2005) Bioinformatic methods for integrating whole-genome 
expression results into cellular networks. Drug Discov Today 10(10), 727-34. 
9. Doniger, S.W. et al. (2003) MAPPFinder: using Gene Ontology and GenMAPP to create a global 
gene-expression profile from microarray data. Genome Biol, 2003. 4(1): p. R7. 
10. Cline, M.S. et al. (2007) Integration of biological networks and gene expression data using 
Cytoscape. Nat Protoc 2 (10), 2366-82.  
11. Pandey, R. et al. (2004) Pathway Miner: extracting gene association networks from molecular 
pathways for predicting the biological significance of gene expression microarray data. Bioinformatics 
20(13): p. 2156-8. 
12. Kuhajda, F.P. (2000) Fatty-acid synthase and human cancer: new perspectives on its role in tumor 
biology. Nutrition 16(3), 202-208. 
13. Garrett, R.H. and Grisham, C.M., eds (1999). Biochemistry, 2nd edition. Brooks & Cole. 
14. Vockley, J. and Whiteman, A.H. (2002) Defects of mitochondrial β-oxidation: a growing group of 
disorders. Neuromuscular Disorders 12(3), 235-246. 
15. Rubio-Gozalbo, M.E. et al. (2004) Carnitine-acylcarnitine translocase deficiency, clinical biochemical 
and genetic aspects. Molecular Aspects of Medicine 25(5-6), 521-532. 
16. McClelland, G.B. (2004) Fat to the fire: the regulation of fatty acid oxidation with exercise and 
environmental stress. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular 
Biology 139(3), 443-460. 
17. Wanders, R.J.A. (2004) Peroxisomes, fatty acid metabolism, and peroxisomal disorders. Molecular 
Genetics and Metabolism 83(1-2), 16-27. 
18. Kota, B.P. et al. (2005) An overview on biological mechanisms of PPARs. Pharmacological Research 
51, 85-94.  
 85 
19. Mandard, S. et al. (2004) Peroxisome proliferator-activated receptor alpha target genes. Cell. Mol. 
Life Sci. 61, 393–416. 
20. Rastinejad, F. (2001) Retinoid X receptor and its partners in the nuclear receptor family. Current 
Opinion in Structural Biology Volume 11(1), 33-38.   
21. Joseph, S.B. and Tontonoz, P. (2003) LXRs: new therapeutic targets in atherosclerosis? Current 
Opinion in Pharmacology 3(2), 192-197. 
22. Dentin, R. et al. (2005) Carbohydrate responsive element binding protein (ChREBP) and sterol 
regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and 
fatty acid synthesis in liver. Biochimie 87, 81–86.  
23. Uyeda, K. et al. (2002) Carbohydrate responsive element-binding protein (ChREBP): a key regulator 
of glucose metabolism and fat storage. Biochemical Pharmacology 63, 2075-2080.  
24. Matuoka, K. and Chen, K.Y. (2002) Transcriptional regulation of cellular ageing by the CCAAT box-
binding factor CBF/NF-Y. Ageing Research Reviews 1(4), 639-651. 
25. Brown, M.S. and Goldstein, J.L. (1997) The SREBP Pathway: Regulation of Cholesterol Metabolism 
by Proteolysis of a Membrane-Bound Transcription. Cell 89 3(2), 331-340. 
26. Edwards, P.A. et al. (2000) Regulation of gene expression by SREBP and SCAP. Biochimica et 
Biophysica Acta (BBA) - Molecular and Cell Biology of Fatty acids 1-3, 103-113.  
27. Strömbäck, L. and Lambrix, P. (2005) Representations of molecular pathways: an evaluation of 
SBML, PSI MI and BioPAX. Bioinformatics 21 (24), 4401-7. 
  
 86 
 
Chapter 6 
Identification of novel ER-α target genes in breast 
cancer cells: gene- and cell-selective co-regulator 
recruitment at target promoters determine 
response to 17β-estradiol and tamoxifen 
 
 
 
 
 
Andrea Romano
1,2,a
, Michiel Adriaens
3
, Sabine Kuenen
1,2
, Bert 
Delvoux
1,2
, Gerard Dunselman
1,2
, Chris Evelo
3
, Patrick Groothuis
1,2,4
 
 
 
 
 
 
 
1
GROW, School for Oncology and Developmental Biology,  Maastricht University, Maastricht, The 
Netherlands. 
2
 Department of Obstetrics and Gynaecology, Maastricht University, Maastricht, The Netherlands. 
3
 Department of Bioinformatics – BiGCaT, Maastricht University, Maastricht, The Netherlands. 
 
Keywords: 17β-Estradiol, estrogen receptor-α, co-activators, co-repressors, tamoxifen. 
 
Publication: Romano, A., M.E. Adriaens, S. Kuenen, B. Delvoux, G. Dunselman, C.T.A. Evelo and P. 
Groothuis (2010). "Identification of novel ER-alpha target genes in breast cancer cells: gene- and cell-
selective co-regulator recruitment at target promoters determines the response to 17beta-estradiol and 
tamoxifen." Mol Cell Endocrinol 314(1): 90-100. 
88 
Abstract 
Tamoxifen and 17beta-estradiol are capable of up-regulating the expression of some genes and down-
regulate the expression of others simultaneously in the same cell. In addition, tamoxifen shows distinct 
transcriptional activities in different target tissues. To elucidate whether these events are determined by 
differences in the recruitment of co-regulators by activated estrogen receptor-alpha (ER-alpha) at target 
promoters, we applied chromatin immunoprecipitation (ChIP) with promoter microarray hybridisation in 
breast cancer T47D cells and identified 904 ER-alpha targets genome-wide. On a selection of newly 
identified targets, we show that 17beta-estradiol and tamoxifen stimulated up- or down-regulation of 
transcription correlates with the selective recruitment of co-activators or co-repressors, respectively. This 
is shown for both breast (T47D) and endometrial carcinoma cells (ECC1). Moreover, differential co-
regulator recruitment also explains that tamoxifen regulates a number of genes in opposite direction in 
breast and endometrial cancer cells. Over-expression of co-activator SRC-1 or co-repressor SMRT is 
sufficient to alter the transcriptional action of tamoxifen on a number of targets. Our findings support the 
notion that recruitment of co-regulator at target gene promoters and their expression levels determine the 
effect of ER-alpha on gene expression to a large extent. 
 
Introduction 
Upon ligand activation, estrogen receptor-  (ER- ) binds to the promoters of responsive genes, 
interacting directly with estrogen response elements (EREs) or indirectly via interactions with other 
transcription factors (reviewed in: [1]). Numerous mechanisms participate in the fine-tuning of estrogen 
regulatory actions in target cells. These mechanisms allow estrogens to exert opposite transcriptional 
actions on different genes in the same cell type, or act as agonists in one cell type and as antagonists in 
another cell type. The same mechanisms may also be responsible for the unwanted side effects that have 
been observed during the use of estrogens and selective estrogen receptor modulators (SERMs) in 
medical treatments. The SERM tamoxifen, for instance, acts as an ER-  antagonist by inhibiting 
proliferation in breast cancer cells [2, 3], but is a partial agonist in the endometrium and increases the 
incidence of endometrial hyperplasia and cancer [4, 5]. The same mechanisms may also explain the 
resistance to tamoxifen of breast cancer patients [3, 6] and the patient-dependent therapeutic efficacy of 
tamoxifen to treat ovarian cancer [7]. 
There is increasing evidence that the gene- and cell-specific actions of estrogens depend largely on the 
presence of co-regulators. These proteins either bridge the ER-α / target-promoter-complex with the 
transcriptional machinery (co-activators such as CBP, p300, SRC family) or impair it (co-repressors; 
SMRT, NCoR; [1, 8]. Several recent studies have indicated that the agonistic or antagonistic action of a 
SERM is determined by the cellular availability of co-regulators in different cell types. For example, the 
agonistic action of tamoxifen in endometrial cancer cells is the consequence of high expression of the co-
activator SRC-1 [9]. In breast cancer cells, down-regulation of co-repressor NCoR turns tamoxifen into an 
inducer of proliferation and over-expression of co-activator SRC-3 (AIB1) is predictive of resistance to 
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tamoxifen in breast cancer patients and is associated with malignancies in the endometrium [3, 6, 10]. 
However, the direct effect of co-regulators on gene transcription in distinct cell types has been 
demonstrated for a limited number of ER-  targets only [9, 11, 12] or by means of reporter gene assays 
[13, 14]. In addition, it remains difficult to understand how estrogens induce the expression of specific 
genes and repress the expression of others in the same cell type [15-21]; [22]. 
In the present study, we aimed at examining whether differential co-regulator recruitment (i) determines 
different transcriptional actions of one ligand on distinct target genes in the same cell type and (ii) 
determines the opposite transcriptional regulation of the same genes in different cell types treated with 
the same ligand. To this end, we applied chromatin immunoprecipitation (ChIP) together with promoter 
DNA array hybridisation (ChIP-chip) and identified 904 ER-α target promoters in T47D breast cancer 
cells. On a selection of newly identified target genes, we show that the transcriptional stimulatory or 
inhibitory effects of 17β-estradiol or OH-tamoxifen, the active metabolite of tamoxifen, closely correlate 
with the recruitment of co-activators or co-repressors, respectively. Moreover, recruitment of distinct co-
regulators correlates with the opposite transcriptional responses observed in T47D and endometrial 
cancer cells (ECC1). To further support this notion, we show that over-expression of co-activator SRC-1 
intensifies OH-tamoxifen response, while over-expression of co-repressor SMRT inhibits this response, 
both irrespective of cell context. 
 
Materials and Methods 
Cell lines and culture. The human breast cancer cell line T47D and human endometrial cancer cell line 
ECC1 were purchased from the American Type Culture Collection (ATCC; Rockville, Md. USA) and 
maintained as described [23]. For all experiments involving hormonal stimulation, cells were cultured for 
five days prior to, and during the experiment in RPMI without phenol-red (Invitrogen, Life Technologies, 
Inc., Carlsbad, CA) supplemented with 5% hormone-stripped serum (c.c.pro GmbH, Neustadt, Germany). 
 
Steroid hormones. 17β-estradiol and OH-tamoxifen were purchased from Sigma-Aldrich Chemie BV 
(Zwijndrecht, The Netherlands). ICI-164384 was a gift from Schering-Plough (Oss, The Netherlands). 
  
RNA extraction and cDNA synthesis. RNA was isolated using the Trizol reagent (Invitrogen, Life 
Technologies, Inc., Carlsbad, CA) as recommended by the manufacturer. Complementary DNA (cDNA) 
was synthesised using the M-MLV reverse transcriptase (Invitrogen, Life Technologies, Inc., Carlsbad, 
CA) as described earlier [23].  
 
Oligonucleotides. Oligonucleotides used for linear amplification of immunoprecipitated chromatin prior to 
ChIP-chip and used for PCR were purchased from MWG-Biotech AG (Ebersberg, Germany) and are 
listed in Supplemental Table S-III. 
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PCR and real time PCR (RT-PCR). PCR was performed with the Taq DNA polymerase (Fermentas 
GMBH, St Leon-Rot, Germany) as recommended by the manufacturer. Semi-quantitative PCR was 
performed by stopping PCR reactions every three cycles and by evaluation of band intensity on an 
agarose gel. RT-PCR was performed using the Syber-green ABGene system (ABGene Limited, Epsom, 
United Kingdom), as recommended by the manufacturer and the BioRad MyIQ apparatus.  
 
Chromatin immunoprecipitation (ChIP). ChIP was performed as described elsewhere [23]. Briefly, T47D 
or ECC1 cells were grown to 80% confluence (165 cm
2
 culture flasks) treated with vehicle-only (ethanol) 
or with ligand for 50 minutes, fixed (1% formaldehyde, 10 minutes) and scraped in 1 ml of cold PBS 
supplemented with Complete
TM
 protease inhibitor (Roche, Mannheim, Germany). After cell lysis, nuclei 
were pelleted, lysed and chromatin was sonicated. Chromatin-protein complexes were 
immunoprecipitated (IP) with protein-G/A magnetic beads (Dynal, Invitrogen Life Technologies, Inc., 
Carlsbad, CA) and 2 g of specific antibodies: HC-20 against ER- , H-224 against RNA-Pol-II, C-20, N-
15 and A-22 against co-activators SRC-1, p300 and CBP, and antibodies sc-1609 and H-300 against co-
repressors NCoR and SMRT (Santa Cruz Biotechnology, California, USA). After IP, bead washing and 
reverse crosslinking, DNA was purified using the Qiaquick reaction clean-up kit (Qiagen GmbH, Hilden, 
Germany). Binding of the RNA-Pol-II to the GAPDH promoter was used as positive control of the ChIP 
procedure and it was assessed using primers ChIP-positive (Supplemental Table S-III). ER-  binding to 
the TFF1 promoter was used as a positive control for ChIP with ER-  antibody and it was assessed using 
primers in Supplemental Table S-III. ChIP PCR signals were normalised with an unspecific negative 
control, using primers ChIP-negative (Supplemental Table S-III) that flank cytogenetic location 12p13.3 
where no transcription factors bind. All additional primers used to assess ER-  and co-regulatory protein 
binding are listed in Supplemental Table S-III. 
 
ChIP-chip. ChIP in T47D cells using ER-  antibody was performed as described above. Successful ChIP 
was confirmed by assessing ER-  binding to the promoter of the estrogen responsive gene TFF1. 
Isolated DNA fragments were subsequently subjected to a linear-amplification as follows: a) 7.5 l of DNA 
were denatured, amplified with 1.5 U of Sequenase
TM
 T7 DNA-polymerase (Invitrogen, Life Technologies, 
Inc., Carlsbad, CA) using primer LA-0 (Supplemental Table S-III) in the recommended buffer (1X) for 8 
minutes at 37 C. This step was repeated once. b) 15 l of this reaction were amplified by Taq 
polymerase (Fermentas GMBH, St Leon-Rot, Germany) using primer LA-1 (Supplemental Table S-III) in 
0.1 mM dNTPs, 1X recommended buffer, 1.5 mM MgCl2 in 100 l final volume. Aliquots (5 l) were taken 
at 25, 30, 35, 40 cycles to determine the number of cycles necessary to enter the exponential phase 
(which was determined based on the intensity of the smeared-DNA visualised on an agarose gel). A 
second round of amplification using the Taq polymerase was performed. Amplified DNA was purified 
using the Qiaquick reaction cleanup kit (Qiagen GmbH, Hilden, Germany). Enrichment of the TFF1 
promoter was confirmed at intermediate steps of the amplification and at the end of the amplification 
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(Figure 1a). This quality control guaranteed that the amplification of signals in the ChIP-DNA did not 
reach saturation and therefore did not result in loss of enrichment of target promoters. 
Samples were generated from three independent experiments (T1, T2 and T3). In each experiment, cells 
were treated with 17β-estradiol or vehicle for 50 minutes. In addition, a reference pool (P) was created by 
pooling equal amounts of the amplified DNA from the 17β-estradiol and vehicle-treated samples of T1, T2 
and T3. The ChIP-DNA fragment was labelled with Cy-5, while the input-DNA, the DNA purified from 
fragmented chromatin non-subjected to IP reaction and processed through the same linear-amplification 
as the ChIP-DNA, was labelled with Cy-3. Labelled ChIP- and input-DNA fractions from the eight samples 
(four treated and four untreated) were subsequently hybridised to the Nimblegen HGS17 genome build 
promoter microarray containing 1500 bp of promoters from 24,134 human genes. Labelling and 
hybridisation were performed in-house by Nimblegen (Madison, USA). The promoter regions on the array 
are covered by 50- to 75-mer probes with approximately 100 bp spacing. The log-ratio of Cy-5 and Cy-3 
intensities was subsequently calculated to assess enrichment of specific promoters  of the ChIP-DNA 
compared to the input-DNA, suggesting binding of ER- . The hybridisation efficiency of the samples from 
experiment T3 did not meet the quality criteria and these samples were excluded from further analysis.  
 
Statistical analysis. Two different methods were evaluated for the identification of ER-  targets. Method 
(i), a within-array analysis, searches for four or more probes in each 1500 bp promoter whose signals are 
above a specified cut-off value. This analysis was performed using the proprietary software of Nimblegen. 
Method (ii) is a between-array analysis, employing positive (treated replicate samples) and negative 
controls (vehicle-treated samples) at probe level, which was performed in the statistical programming 
language R. This latter method is expected to produce a statistically more robust set of potential ER-  
targets. First, the log-ratio between ChIP-DNA and input-DNA intensities is calculated separately for each 
array. Next, all probes are ordered according to genomic location and dichotomised using a threshold 
around twice the estimated standard deviation of the log-ratio. Probes with log-ratio values above this 
threshold are designated as positive, those below the threshold negative. Next, for each array, a sliding 
window of a variable number of base pairs is moved over all probes, calculating a p-value for each 
window with a Yates corrected chi-square test. To determine whether a promoter shows true significant 
enrichment, the promoter has to contain at least one window that shows significant enrichment in at least 
two treated samples (positive controls) and the same window or windows should not show significant 
enrichment in more than one untreated sample (negative controls). To minimise false positives, an 
adaptation of the Benjamini and Hochberg method [24] is applied to calculate false discovery rates (FDR).  
Both methods showed over fifty percent consistency when a FDR threshold of 20 % was applied. We 
compared the list of target genes obtained with the two methods with a list of already known targets [25]. 
Given that at the same FDR, method (ii) retrieved a larger number of known target promoters when 
compared to method (i) and considering the greater robustness of a between-array approach, method (ii) 
was used to generate the list of targets used for further analysis. 
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To identify our 904 promoters, we combined results using two FDR cut-off points. We first identified a 
suitable cut-off point able to retrieve as many previously found targets [25] as possible. Using a FDR cut-
off of 20 % we identified most known targets (i.e. CTSD, BRCA, c-Myc, ADORA1, AGT, HSPB1, LCN2) 
and only few more (TGFA, TERT) were retrieved when cut-off points with lower stringency (FDR cut-offs 
higher than 20 %) were used. Therefore, 20 % FDR was fixed as the upper limit for the stringency of our 
statistics. Subsequently, a low stringency (FDR 20 %) was used to identify ER-  targets common in the 
arrays of the independent experiments (T1 and T2 or T1, T2 and P). A high stringency (FDR 5 %) was 
used for targets that were common in one of the T arrays and the P array, as those areessentially 
technical replicates.  
The promoter regions were scanned for occurrence of EREs using the Genomatix MatInspector software 
[26] and the Genomatix transcription factor motif database (www.genomatix.de). We also scanned 
promoter sequences of a validated sub selection of ER-α targets for the presence of potential tethering 
domains for EREs (AP1, NF B and SP1 binding sites), using the same approach. 
  
Cell transfection, luciferase assay and immunocytochemistry. Plasmids used for transfection were 
previously described: ERE-TK-luciferase (2X ERE-TK-LUC) containing the estrogen responsive promoter-
luciferase reporter [27], was gifted by Prof Scheule. The expression vector for co-activator SRC-1 [14] 
and the co-repressor SMRT [28] were gifts from Prof O’Malley and Prof Evans, respectively. The SMRT 
expression plasmid used in these experiments encodes for a truncated form of the human co-repressor 
SMRT (amino-acids 1032-2517) with a dominant co-repressing action [13]. Plasmid pCNDA3.1 
(Invitrogen, Life Technologies, Inc., Carlsbad, CA) was used as empty vector (when indicated). All 
techniques were previously described [23]. In short, transfection was performed using the jetPEI
TM
 
reagent (Q-Biogene, Heidelberg, Germany) as recommended by the manufacturer. Prior to luciferase 
assays, cells were cultured in two wells of a 12-well plate and were transfected (2 g DNA plus 3 l 
jetPEI
TM
 per well). Sixteen hours after transfection, cells from the two wells were trypsinised, pooled and 
seeded into 12 wells of a 96 well-plate. Eight hours after plating, treatments were applied. Each treatment 
was performed in triplicate (the number of initially transfected wells was scaled up according to the 
number of stimulations needed). In case of RNA isolation, cells were transfected in two 25 cm
2
 flasks (10 
g DNA plus 15 l jetPEI
TM
 per flask) and subsequently cells were pooled and plated in 9 wells of a 12-
well plate. For immunocytofluorescence, cells were cultured on glass cover slips fixed in buffered 
formaldehyde (4% paraformaldehyde in PBS), permeabilised with 0.1% Triton-X-100 in PBS and stained 
with the following antibodies (as indicated in the figures): goat polyclonal C-20 against co-activator SRC-1 
and sc-1609 against co-repressor NCoR (Santa Cruz Biotechnology, California, USA), followed by anti-
goat FITC secondary antibody 705-095-147 (Jackson Immunoresearch/Brunschwig chemie B.V., 
Amsterdam, The Netherlands); rabbit polyclonal H-300 against co-repressor SMRT (Santa Cruz 
Biotechnology, California, USA), followed by anti-rabbit FITC F005401 (DAKO, Glostrup, Denmark). For 
western blot (Supplemental Figure S-1) ER-  was detected with monoclonal antibody F10 (Santa Cruz 
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Biotechnology, California, USA), whereas p300 and CBP with rabbit A-22 and N-15 antibodies, 
respectively (Santa Cruz Biotechnology, California, USA). Mouse antibody AC-15 (Sigma-Aldrich Chemie 
BV, Zwijndrecht, The Netherlands) was used to detect -actin. HRP-conjugated rabbit anti-mouse-
antibodies (DAKO, Glostrup, Denmark) and goat-anti-rabbit-antibodies (Pierce, Aalst, Belgium) and the 
super signal-R West-Femto kit (Pierce, Aalst, Belgium) were used for primary antibody visualisation.  
 
Results 
Identification of genomic binding sites for ER-   
ER-α binding sites in gene promoters were searched genome-wide using the estrogen-responsive T47D 
breast cancer cells. Estrogen-responsiveness was shown by the expression of ER-α, the induction of 
various known estrogen responsive genes (TFF1, c-Myc, CCND1) and by the induction of cell 
proliferation by 17 -estradiol (Supplemental Figures S-1 and S2). T47D cells were incubated with 1 nM 
17β-estradiol for 50 minutes, which was shown to result in maximal ER-  binding to the TFF1 promoter 
[16, 29]; this study, results not shown). After chromatin immunoprecipitation (ChIP) using an ER-α 
antibody, two rounds of nucleic acid amplification were performed to yield sufficient DNA for array 
hybridisation to the Nimblegen promoter arrays. In order to assure adequate quality of the amplified DNA 
fragments, enrichment of the TFF1 promoter was confirmed after each amplification round (Figure 1a). 
Three independent experiments, each consisting of a 17 -estradiol and a vehicle treated sample, were 
performed (T1, T2 and T3). Given that the hybridisation performance of the T3 samples was poor, data 
from experiment T3 were not used for subsequent analyses. An additional sample was included (referred 
to as the pool, P) created by combining equal amounts of amplified DNA material from T1, T2 and T3. 
We applied robust statistical procedures (see ‘Materials and Methods’), which allowed us to retrieve 
several previously known ER-  target promoters (i.e. CTSD, BRCA, c-Myc, ADORA1, AGT, HSPB1, 
LCN2; [25]. With this method, 904 potential ER-  binding sites were identified in total (Supplemental 
Table S-I), some of which are common to recent genome-wide screenings for ER-  targets 
(Supplemental Table S-II). The 904 binding sites are equally distributed over all chromosomes 
(Supplemental Table I), excluding the Y chromosome, as the T47D line is derived from a woman. Only 
one site was found on chromosome Y and is not included in the list of 904 targets. 
 
ChIP-chip validation and target promoter features 
To validate the findings of the ChIP-chip, standard ChIP assays were performed on additional 
independent experiments (two or more) and ER-  binding was confirmed for a selection of 12 promoter 
regions (Figure 1b). Enrichments were not seen for three non-target locations (PGR gene exons 4 and 6 
and chromosome region 12p13.3).  
To demonstrate that ER-α binding to the promoter regions is functional, the effect on mRNA expression 
was studied with RT-PCR (Figure 1b). The expression of most genes is induced by 17β-estradiol, with 
the  
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Figure 1. ChIP-chip: quality control, validation and prevalence of EREs 
A. Prior to ChIP-chip hybridisation, immunoprecipitated (IP) DNA fragments were amplified (linear 
amplification). As a quality check, binding of ER-  to the TFF1 promoter was confirmed after each 
amplification round (shown for each experiment at the end of the amplification, just prior to labelling and 
hybridisation). ChIP-DNA = IP DNA. Input-DNA = non-IP- chromatin amplified similarly to the ChIP-DNA. 
B. ER-  targets identified by ChIP-chip and validated by standard ChIP. For all ChIP experiments, cells 
were treated for 50 minutes; control = vehicle treated cells; E2 or 17β-estradiol: 1 nM. IgG = ChIP with 
non-specific antibodies; ER-  = ChIP with an ER-  antibody. Column on the right: mRNA level of the 
corresponding gene after 17β-estradiol (1 nM) induction. mRNA was assessed (RT-PCR or semi-
quantitative PCR – semiQ-PCR) after different periods of hormone stimulation (up to 24 hours) in 
triplicate. Results in column signify that the considered mRNA is significantly regulated in the indicated 
direction (p < 0.05 compared to time point zero) at one time point at least (results not shown). ND: not 
determined. 
C. Prevalence of ERE in the promoters of the entire group (n = 904) of ER-  target genes as determined 
by Genomatix MatInspector (http://www.genomatix.de). Promoters were scanned using a family of ERE 
consensus matrices [26]. A specification of EREs present in the group of 904 targets is given in the 
Supplementary Table S-IV. 
 
exception of DKFZ p762E1312, which is down-regulated, and FANCM, which does not respond despite 
ER-  binding to its promoter (Figure 1b). In addition, we evaluated the transcriptional response of six 
target genes for which ChIP reactions were not set-up, CCNE2, IGF1-R, FBP-1, BCL2, MALL and CA2 
(Supplemental Figure S-3). All genes, except CA2, are induced by 17β-estradiol. MALL and CA2 are 
induced by OH-tamoxifen, whereas BCL2 and CCNE2 expression is reduced by OH-tamoxifen.  
Binding sites for ER-  are present both upstream and downstream of the transcription start site (TSS) 
and are evenly distributed along the promoter regions with respect to the distance from the TSS (results 
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not shown). Seventy four percent of the 904 target promoters contain an estrogen-response element 
(ERE; Figure 1c) in silico, determined with the Genomatix MatInspector software. 
 
Selective recruitment of co-regulators determines the ER-  mediated transcription 
Both 17β-estradiol and OH-tamoxifen can simultaneously up- and down-regulate the transcription of 
different genes in the same cell. To verify whether differential co-regulator recruitment (i.e. co-activators 
versus co-repressors) accounts for these opposite transcriptional responses in the same cells, we 
performed ChIP with antibodies directed against ER- , co-activators p300, CBP and SRC-1 or co-
repressors SMRT and NCoR after exposing T47D cells for 50 minutes to 1 nM 17β-estradiol or to 1 M 
OH-tamoxifen. These co-regulators were selected because they are expressed in T47D cells 
(Supplemental Figure S-1) and all three co-activators are efficiently recruited at the promoter of TFF1 
after 17β-estradiol induction (results not shown). It should be noted that we did not aim at identifying 
which specific co-regulator binds to one region, but rather whether co-activators or co-repressors are 
recruited. CBP / p300 are general mediators, which bridge the basal transcriptional machinery to the ER-
 complex with additional co-activators, irrespective to which specific protein is present (SRC1, SRC2 or 
SRC3; [30, 31]. Therefore, in order to immunoprecipitate all DNA sequences interacting with co-activators 
simultaneously, we pooled the antibodies against p300, CBP and SRC-1. For the same reasons, we 
pooled co-repressors NCoR and SMRT antibodies. 
The expression of TFF1, DDX-27, ZNF-228 and ZWINT is up-regulated by 17β-estradiol and down-
regulated by OH-tamoxifen (Figure 2), which correlates well with the recruitment of co-activators and co-
repressors, respectively. In contrast, the expression of FLNA, SYMPK, KGFLP1 and BCL2L1 is induced 
by both 17β-estradiol and OH-tamoxifen (Figure 3). In these cases, recruitment of predominantly co-
activators is observed, although for some gene-promoters a non-significant recruitment of co-repressors 
can be seen as well (BCL2L1 after 17β-estradiol treatment and FLNA, SYMPK, KGFLP1 after OH-
tamoxifen treatment). Expression of DKFZ p762E1312 is suppressed by both 17β-estradiol and OH-
tamoxifen (Figure 4a). In the presence of 17β-estradiol, ER-  recruits co-repressors only; however, in the 
presence of OH-tamoxifen, co-activators are recruited as well (Figure 4a). This could be explained by the 
fact that OH-tamoxifen induces the transcription of DKFZ p762E1312 at later time points (Supplemental 
Figure S-3). Also in case of the transcription up-regulation by 17β-estradiol of EPHA4 (Figure 4b), ER-  
recruits co-activators at the EPHA4 promoter. No recruitment of co-regulators is observed for this gene in 
response to OH-tamoxifen (Figure 4b) and its transcription is not altered, even though ER-  binds to the 
promoter.  
 
Differential recruitment of co-regulators determines cell-specific transcriptional activities of ER-  
We examined whether co-activators and co-repressors are recruited to selected ER-α target genes in 
accordance with their opposite transcriptional responses to OH-tamoxifen in T47D breast cells versus 
ECC1 endometrial cancer cells (ECC1 cells are ER-α / co-regulator positive - Supplemental Figure S-1 -  
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Figure 2. Co-regulator recruitment at targets induced by 17β-estradiol and repressed by OH-
tamoxifen in T47D cells 
A. Transcriptional responses of the indicated target genes (RT-PCR) after treatment with 17β-estradiol, 
OH-tamoxifen (1 nM and 1 μM, respectively) in T47D. Mean ± standard deviation (SD), n = 3. Asterisks: p 
< 0.05 compared to time point zero. Expression data were reconfirmed in at least one extra independent 
experiment. 
B. ChIP assessing binding of ER- , co-activators (p300, CBP and SRC-1) or co-repressors (SMRT and 
NCoR) to the corresponding promoter (E2 = 17β-estradiol. Tam = OH-tamoxifen. No treatment: treatment 
with vehicle only (ethanol)). Cells were treated for 50 minutes before ChIP. 
C. Quantitative evaluation (estimated by agarose-gel band intensities) of chromatin enrichments after 
ChIP with ER- , co-activator (ACT) or co-repressor (REP) antibodies. Mean ± SD; n = 2 or 3. Asterisks: p 
< 0.05 compared to the IgG control. ChIP experiments were reconfirmed in at least one additional 
independent experiment. The ChIP negative control for these assays is shown in Figure 4c. 
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Figure 3. Co-activators are recruited at genes induced by both 17β-estradiol and OH-tamoxifen in 
T47D cells 
A. Transcriptional responses in T47D to 1 nM 17β-estradiol or 1 μM OH-tamoxifen (RT-PCR and semiQ-
PCR for KGFLP1). Mean ± SD, n = 3. Asterisks: p < 0.05 compared to time point zero. Expression data 
were reconfirmed in at least one independent experiment. 
B. ChIP assessing binding to the corresponding promoter of ER- , co-activators or co-repressors (50 
minutes after induction start: E2 = 17β-estradiol. Tam = OH-tamoxifen. No treatment: induction with 
vehicle only). 
C. Quantitative evaluation of chromatin enrichments after ChIP with ER- , co-activator (ACT) or co-
repressor (REP) antibodies. Mean ± SD; n = 2 or 3. Asterisks: p < 0.05 compared to IgG control. ChIP 
experiments were reconfirmed in at least one additional independent experiment (ChIP negative in Figure 
4c). 
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Figure 4. Co-regulator recruitment by activated ER-  at DKFZ p762E1312 and EPHA4 in T47D cells 
A. On the left: transcriptional responses of the DKFZ p762E1312 gene (repressed by both 17β-estradiol - 
1 nM - and OH-tamoxifen - 1 μM) in T47D (RT-PCR). Mean ± SD, n = 3. Asterisks: p < 0.05 versus time 
point zero. RNA data were reconfirmed in at least one extra independent experiment. Middle: ChIP 
assessing binding to the DKFZ p762E1312 promoter of ER- , co-activators or co-repressors. ChIP was 
performed 50 minutes after induction start: E2 = 17β-estradiol. Tam = OH-tamoxifen. No treatment: 
vehicle only. Right: quantitative evaluation of chromatin enrichments after ChIP with ER- , co-activator 
(ACT) or co-repressor (REP) antibodies. Mean ± SD. Asterisks: p < 0.05 versus IgG control, n = 2 or 3. 
B. EPHA4 gene is induced by 17β-estradiol (1 nM) but is not influenced by 1 μM OH-tamoxifen (on the 
left; mean ± SD, n = 3. Asterisks: p < 0.05 versus time point zero). RNA data were reconfirmed in at least 
one extra independent experiment. Middle and right: ChIP assay and quantitative evaluation of the ChIP 
experiments (mean ± SD based on at least two independent experiments. Asterisks: p < 0.05 versus IgG 
control). C. ChIP negative control (cytogenetic location 12p13.3). 
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and estrogen-responsive - Supplemental Figure S-2). In ECC1 cells, KGFLP1, DDX-27 and FLNA are 
induced by 17β-estradiol and OH-tamoxifen, whereas TFF1 is induced by 17β-estradiol only. ER-α 
preferentially recruits co-activators to up-regulate these genes (Figure 5). In contrast, the transcriptional 
inhibitory effects of 17β-estradiol (for BCL2L1) or OH-tamoxifen (for TFF1, BCL2L1 and EPHA4) are 
associated with the recruitment of co-repressors after ER-α binding (Figure 5). 
Interestingly, OH-tamoxifen and 17β-estradiol reduce the expression of BCL2L1 in ECC1, but induce it in 
T47D cells (Figures 5b and 3, respectively). In contrast, the expression of DDX-27 is induced in ECC1 
and reduced in T47D cells by OH-tamoxifen (Figures 5b and 2, respectively). These opposite 
transcriptional effects are clearly related to the recruitment of different co-regulatory proteins in the two 
cell contexts: co-activators in case of induction, and co-repressors in the case of inhibition of transcription. 
The same is evident for EPHA4. This gene is induced by 17β-estradiol in T47D cells, under which 
condition ER-α recruits co-activators (Figure 4b). However, EPHA4 is not responsive to 17β-estradiol in 
ECC1 cells, and in this cell context, binding of ER-α to the corresponding promoter is not accompanied by 
further co-regulator recruitment (Figure 5b). The opposite is observed with OH-tamoxifen, which inhibits 
EPHA4 expression in ECC1 cells but has no effect T47D cells. In T47D cells, no co-regulators are 
recruited by ER-α (Figure 4b), whereas in ECC-1 cells, binding of ER-α is followed by recruitment of co-
repressors (Figure 5b). The recruitment of distinct co-regulators at the promoters of DDX-27 and BCL2L1 
in T47D and ECC1 after induction with OH-tamoxifen was confirmed by real-time PCR (Figure 5d). 
 
Over-expression of SRC-1 and SMRT alters the response of target genes to OH-tamoxifen 
If the regulation of the aforementioned genes is truly dependent on co-regulators, it should be expected 
that, as previously shown [13, 14], modification in the level of some of these proteins modifies the 
response of the target genes. Therefore, to confirm the association between up- or down-regulation and 
recruitment of co-activators or repressors, we over-expressed co-activator SRC-1 or co-repressor SMRT 
by transient transfections in T47D and ECC1 cells (Figure 6a). To proof that these transfections had 
significant and measurable effects, we assessed the activity of the estrogen-responsive construct ERE-
TK-luciferase after co-transfection with SRC-1 or with SMRT. As expected, SRC-1 over-expression 
enhances the 17β-estradiol-induced luciferase activity, whereas SMRT reduces it (Figure 6b). To confirm 
the transfectability of T47D and ECC1 cells we also measured GFP expression after transient transfection 
with a GFP expression plasmid (Supplemental Figure S-4). 
Figure 6c shows the effect of SRC-1 or SMRT over-expression on a number of identified target genes. In 
T47D cells, BCL2L1 transcription is normally up-regulated by OH-tamoxifen. Over-expression of the co-
activator SRC-1 enhances this effect, whereas over-expression of the co-repressor SMRT changes OH-
tamoxifen into an inhibitor of transcription (Figure 6c). In ECC1, BCL2L1 is normally repressed by OH-
tamoxifen, but over-expression of SRC-1 changes OH-tamoxifen into an inducer of transcription. 
With regard to the expression of EPHA4, over-expression of SRC-1 in T47D cells turns OH-tamoxifen into 
an inducer of transcription, whereas this gene is unresponsive under normal conditions. In ECC1 cells,  
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Figure 5. mRNA level and co-regulator recruitment in ECC1 cells 
A and B. Transcriptional responses (RT-PCR and semiQ-PCR for KGFLP1) after 17β-estradiol or OH-
tamoxifen stimulation (1 nM and 1 μM, respectively) in ECC1 (left side of panels A and B). Mean ± SD, n 
= 3. Asterisks: p < 0.05 versus time point zero. RNA expression data were reconfirmed in at least one 
additional independent experiment. ChIP assays (50 minutes of induction) showing binding of ER- , co-
activators (SRC-1, CBP and p300) and co-repressors (NCoR and SMRT) to the corresponding promoter 
are shown on the right of each A and B panels (E2 = 17β-estradiol. Tam = OH-tamoxifen. No treatment: 
vehicle only). ChIP experiments were reconfirmed in at least one additional independent experiment. 
A. The transcriptional response of these genes in ECC1 (shown in panel) is similar to the response 
observed in T47D cells (shown in Figures 2a and 3a) and ChIP indicates that the same kind of co-
regulators are recruited at gene promoters in the two cell lines (ECC1, shown in this figure, and T47D 
cells, Figures 2 and 3). 
B. The transcriptional response of these genes in ECC1 (shown in panel) is opposite compared to the 
response observed in T47D cells (shown in Figures 2, 3 and 4) and ChIP indicates that the distinct co-
regulators are recruited at gene promoters in ECC1 (shown in panel) and T47D cells (Figures 2, 3 and 4). 
C. ChIP negative control (cytogenetic location 12p13.3). 
D. Relative enrichments of ER- , co-activators (ACT) or co-repressors (REP) at the promoters of DDX-27 
and BCL2L1 in T47D and ECC1 cells after OH-tamoxifen induction (50 minutes). OH-tamoxifen induces 
DDX-27 and BCL2L1 in opposite directions in T47D and ECC1 cells. The direction of the mRNA 
regulation is indicated by the arrows. ChIP reactions were measured by real-time PCR (mean ± SD based 
on two replicates. Asterisks: p < 0.05 versus IgG control). 
  
101 
 
 
Figure 6. Over-expression of SRC-1 and SMRT modifies OH-tamoxifen responses 
A. Over-expression of co-activator SRC-1 and co-repressor SMRT in T47D and ECC1 cells after transient 
transfection (immunocytofluorescence). Empty arrow-heads: endogenous expression level. Solid arrow-
heads: over-expressing cells.  
B. Induction of the ERE-TK promoter after co-transfection of ECC1 cells with the 2X ERE-TK-LUC 
construct (containing the luciferase reporter) along with either the expression plasmid for co-activator 
SRC-1 (increasing amounts of plasmids used for transfection) or the plasmid expressing co-repressor 
SMRT. Cells were transfected as described in material and methods in 12-well plates using 2 g of total 
plasmid DNA: 1 g of 2X ERE-TK-LUC combined with variable amounts (0 – 1 g of SRC-1). Total 
amount of transfected DNA was kept constant using the empty vector. For induction (n = 3 per treatment 
± SD) and luciferase assay, transfected cells were re-plated on a 96 well-plate. Similar results are 
obtained in T47D cells (not shown). 
C. Transcriptional responses of BCL2L1, DDX-27, EPHA4 (RT-PCR) and KGFLP1 (semiQ-PCR) after 
stimulation with 1 μM OH-tamoxifen or with vehicle only (no treatment) for 5 hours in T47D and ECC1 
cells transiently transfected with the empty vector, SRC-1 expression plasmid or SMRT expression 
plasmid. Cells were transfected as described in material and methods in 25 cm
2
 flask (10 g DNA) and 
re-plated for induction and RNA isolation in 12-well plates. Bars indicate mean ± SD, n = 3. 
 
 
EPHA4 transcription is inhibited by OH-tamoxifen and SRC-1 over-expression impairs this repressive 
activity. Also in case of the transcriptional activation of KGFLP1 in both T47D and ECC1 cells, SMRT 
over-expression is sufficient to reverse (in T47D cells) or impair (in ECC1 cells) this response (Figure 6c). 
Transcription of DDX-27 is suppressed by OH-tamoxifen in T47D and induced in ECC1 cells. Over-
expression of SRC-1 does not affect the inhibitory action of OH-tamoxifen in T47D, but over-expression of 
SMRT in ECC1 cells turns OH-tamoxifen into a repressor of transcription (Figure 6c).  
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The response to OH-tamoxifen of other validated genes (TFF1, FLNA, SYMPK, DFFZ p762E1312, 
ZWINT and ZNF-228) and the responses to 17β-estradiol in general, were not significantly influenced by 
modifications of the level of SRC-1 and SMRT (data not shown), suggesting either a promoter-specificity 
or a cell-specific modification of co-regulators as a mechanism behind the distinctive interaction with the 
gene promoters of these genes. 
 
Discussion 
The aim of the present study was to elucidate the role of co-regulators in (i) the opposite transcriptional 
actions mediated by ER-  on different target genes and (ii) the tissue specific actions of OH-tamoxifen 
(and 17 -estradiol) in breast and endometrial cancer cells. To this end, we first identified ER-  target 
promoters genome-wide by ChIP-chip and subsequently we examined whether co-activators or co-
repressors are recruited by activated ER-  at the promoters of a number of newly-identified targets. 
Though some past studies have focussed on the genome-wide identification of ER-  binding sites in 
breast cancer cell lines [15, 16, 18-21, 29, 32-34] none have further considered the role of co-regulators 
on the transcriptional regulation of these ER-  targets. Up to now, this knowledge has been generated by 
means of reporter gene assays [13, 14] or by studying a low number of estrogen responsive genes only 
[9, 11]. 
In the present study, we identified 904 promoters targeted by ER-  using ChIP-chip. These results were 
validated by standard ChIP, by the estrogen responsiveness of the corresponding genes at the mRNA 
level, and by the high prevalence of EREs among target promoters (Figure 1). 
 
Co-regulator recruitment at target promoters determines gene- and cell-specific responses to ER-
 ligands 
In line with previous studies [9, 11, 12], activated ER-  binds to gene promoters, recruits co-activators or 
co-repressors, which determine the subsequent transcriptional up- or down-regulation, respectively 
(Figures 2, 3 and 4). In one cell type, all determinants of the ER-  action (like ligand concentration, level 
and activation of ER-  and co-regulators) are identical, except for the promoter, which therefore must be 
responsible for the recruitment of different co-regulators. A number of studies have already shed light on 
the roles of ERE-motifs and additional cis-regulatory elements (AP1, Sp1, NF B binding sites) in the cell- 
and ligand-specific regulation of ER-  and ER-  [35-37]. The main features of the genes analysed in the 
present study (EREs and binding sites for additional transcription factors) are given in Supplemental 
Table S-IV. Alternatively, it is possible that co-regulators are modified post-translationally in a cell-specific 
manner, resulting in altered interactions at gene promoters in the distinct cell contexts. 
In one case only (DKFZ p762E1312), transcription repression by OH-tamoxifen was associated with 
recruitment of both co-repressors and co-activators. We explained this effect with the ability of OH-
tamoxifen to induce DKFZ p762E131 transcription at later time points. However, it should also be noted 
that the dynamics, the sequential and combinatorial assembly of co-activators and co-repressors at target 
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promoters have not been addressed in the present investigation. Nevertheless, these events are 
important for the action of nuclear receptors [38, 39].  
 
Differential co-regulator recruitment also explains the opposite transcriptional response observed at a 
number of target genes in response to OH-tamoxifen (DDX-27, BCL2L1 and EPHA4) or 17β-estradiol 
(BCL2L1 and EPHA4) in breast cancer (T47D; Figures 2, 3 and 4) and endometrial cancer cells (ECC1; 
Figure 5). These results confirm a previous finding  for a number of known estrogen responsive genes (c-
Myc, IGF-I, EBAG9 and CTSD; [9]. The present study extends this mechanism of action to potentially all 
ER-  target genes. 
 
To further substantiate the association between transcriptional regulation and co-regulator recruitment, 
we over-expressed either co-activator SRC-1 or co-repressor SMRT. In a number of cases, the 
transcriptional response to OH-tamoxifen in T47D or ECC1 cells could be modified or inverted by over-
expression of these co-regulators (BCL2L1, KGFLP1, EPHA4; Figure 6). 
The transcription of other genes in response to OH-tamoxifen was not influenced by SRC-1 or SMRT 
over-expression (TFF1, FLNA, SYMPK, DFFZ p762E1312, ZWINT and ZNF-228). In some cases, as 
observed for DDX-27, the inducing action of OH-tamoxifen could be impaired in ECC1 after over-
expression of SMRT, but the opposite inhibitory action of OH-tamoxifen observed in T47D cells could not 
be changed by SRC-1 over-expression. As shown by others [13, 40], each promoter interacts with a 
limited number of co-regulators only and therefore each co-regulator modulates the expression of a 
limited number of genes. These events explain why co-regulators have distinct physiological functions 
[41-44]. In our case, it entirely possible that SRC-1 cannot be efficiently recruited at the DDX-27 
promoter, whereas neither SRC-1 nor SMRT can be efficiently recruited at the promoter of other target 
genes, whose transcription was not influenced by these two co-regulators. 
 
Conclusions 
Complex events determine the action of ER- , including histone modifications [45], distal and proximal 
cis-regulatory elements [16], ligand independent signalling and indirect DNA binding mediated by 
additional transcription factors. Our results suggest that at least for direct ER-  targets distinct co-
regulator recruitment is one of the key modulators of hormonal response. 
In case of important drugs like tamoxifen, ER-  is necessary but not sufficient to mediate its actions. The 
direction of the hormonal response is for a large part dependent on co-regulators. Aberrations in the 
functions mediated by these proteins may lead to endocrine related cancers, to innate and developed 
drug-resistance in breast tumours [3, 6, 10] or to poor therapeutic response of ovarian tumours [7]. 
Unravelling the expression and activation patterns of co-regulators in estrogen-dependent tumours may 
be the next step in predicting drug response and  personalized endocrine therapies for responsive 
patients. 
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Supplemental figures and tables 
 
Supplemental Figure S-1. Expression of ER-  and co-regulators in breast cancer T47D and endometrial 
cancer ECC1 cells. The expression of ER-α, co-activators CBP, p300 and SRC-1 and co-repressors 
NCoRand SMRT in T47D and ECC1 was assessed by western blot analysis (A) or immunocytochemistry 
(B). For western blot, anti ER-α monoclonal F10, anti p300 (rabbit, A-22) and anti CBP (rabbit, N-15) 
antibodies (Santa Cruz Biotechnology, California, USA) were used. Mouse antibody AC-15 (Sigma-
Aldrich Chemie BV, Zwijndrecht, The Netherlands) was used to detect β-actin. For visualization of bound 
antibodies, HRP-conjugated rabbit anti-mouse-antibodies (DAKO, Glostrup, Denmark) and goat-anti-
rabbit-antibodies (Pierce, Aalst, Belgium) in conjunction with the super signal-R West-Femto kit (Pierce, 
Aalst, Belgium) were used. For immunofluorescence, cells were cultured on glass cover slips fixed in 
buffered formaldehyde (4% paraformaldehyde in PBS), permeabilised with 0.1% Triton-X-100 in PBS and 
stained with goat polyclonal C-20 against co-activator SRC-1 and sc-1609 against co-repressors NCoR 
(Santa Cruz Biotechnology, California, USA), followed by anti-goat FITC secondary antibody 705-095-147 
(Jackson Immunoresearch/Brunschwig chemie B.V., Amsterdam, The Netherlands); rabbit polyclonal H-
300 against co-repressors SMRT (Santa Cruz Biotechnology, California, USA), followed by anti-rabbit 
FITC F005401 (DAKO, Glostrup, Denmark). Nuclei were stained with 4'-6-diamidino-2-phenylindole 
(DAPI); nuclei are also indicated by the dashed circles in the antibody staining. Additional technical 
information are described in the ‘Materials and Methods’ paragraph or were previously published in 
Romano et al. (2007) J Mol Endocrinol 38, 331-350. 
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Supplemental Figure S-2. Response to estrogen stimulation in T47D and ECC1 cells. A. Induction of 
some known estrogen responsive genes measured by real-time PCR in T47D and ECC1 cells. 
B. FACS analysis of T47D cells treated for the indicated period of time with different ER-  ligands: 
vehicle-only; 17β-estradiol (1 nM); 17β-estradiol and OH-tamoxifen (1 nM and 1 M, respectively); 17β-
estradiol and ICI-164384 (1 nM and 1 M, respectively). The percentage of cells in the S-phase under 
each indicated condition is shown and indicate that T47D cells proliferate with increased rate when 
treated with 1 nM 17 -estradiol and this effect is impaired by treatment with the SERMs OH-tamoxifen 
and ICI-134384 (ER- -antagonists in breast cells). FACS analysis was performed as previously described 
(Romano et al. 2007, J Mol Endocrinol 38, 331-350) and cell-cycle was analysed by WinMDI and 
cylchred. Mean ± SD is based on three replicates. 
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Supplemental Figure S-3. mRNA level of a number of ER-α targets identified by ChIP-chip. mRNA level 
for each indicated gene was assessed by real-time PCR (RT-PCR) or semiquantitative PCR (semiQ-
PCR) after induction with 1 nM 17β-estradiol or 1 μM OH-tamoxifen for different periods of time (indicated 
on the X). Mean ± SD is based on three replicates. Asterisks indicate p < 0.05 compared to time point 
zero. 
 
Supplemental Figure S-4. Transfection efficiency in ECC1 and T47D cells. The transfectability of ECC1 
and T47D cells was confirmed by observing cells expressing the green fluorescence protein (GFP) after 
transfection with a GFP reporter plasmid. 
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Supplemental Table I. Number of ER-  binding sites per chromosome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional supplemental tables S-I, S-II, S-III and S-IV available from 
http://www.sciencedirect.com/science/article/pii/S0303720709004122  
  
Chromosome number of sites Chromosome number of sites 
1 79 13 17 
2 51 14 33 
3 45 15 31 
4 36 16 27 
5 36 17 54 
6 61 18 12 
7 41 19 41 
8 35 20 31 
9 43 21 12 
10 25 22 21 
11 83 X 34 
12 56   
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Abstract 
Trimethylation at histone H3 lysine 4 (H3K4me3) and lysine 27 (H3K27me3) has been linked to gene 
activity and repression, respectively. Distinctive H3K4me3 and H3K27me3-enrichment at specific target-
genes in embryonic stem cells and more committed cell lineages reflects spatio-temporal epigenetic 
control over developmental processes and demonstrates that genomic distribution of both epigenetic 
marks is subject to dynamic change. How H3K4me3 and H3K27me3 respond to changes in the 
microenvironment is relatively unknown. Based on the biochemical dependency of the Jumonji-class 
histone demethylases, we hypothesized that genome-wide histone trimethylation enrichment will be 
dynamically affected by changes in cell oxygenation. We have determined the relationship between 
epigenomic and transcriptomic reprogramming in a model for fluctuating oxygen tension within the tumor 
micro-environment. To this end, we have combined chromatin-immunoprecipitation and deep-sequencing 
analysis of H3K4me3 and H3K27me3-enrichment with expression array data of MCF7 breast cancer cells 
subjected to changes in oxygen tension (i.e. acute hypoxia, chronic hypoxia and reoxygenation. We 
observed a rapid global increase of both H3K4me3 and H3K27me3-marks at specific sites throughout the 
genome, which was reversed upon reoxygenation. Normoxic H3K4me3-profiles at marked genes were 
only marginally affected by hypoxia.. Acquisition or loss of H3K4me3 at target genes correlated with 
increased or reduced gene expression, respectively. In sharp contrast, de novo genic H3K27me3-
marking was found to accumulate around transcription start sites (TSS) during hypoxia, and was 
transitory in nature and did not correlate with transcriptional repression. Thus, under conditions of oxygen 
deprivation, H3K4me3-occupation was identified as the most important epigenetic marker of 
transcriptional regulation. As many TSS loci were already H3K4me3-marked, acquisition of H3K27me3 
resulted in increased bivalent marking. Hypoxia-induced bivalency revealed substantial overlap with 
embryonal stem cell-associated bivalency and was retained at numerous loci upon reoxygenation. This 
suggested strict control over histone (de)methylation at these sites. Our data show for the first time that 
oxygen availability dynamically regulates the epigenetic state of the genome. The possible repercussions 
of hypoxia-induced bivalency in the context of acquisition of stem cell-like epigenomic marking and tumor 
plasticity is discussed.   
Introduction 
Cancer cells in solid tumors are often exposed to fluctuating oxygen tension resulting from inadequate 
blood supply due to poorly developed vasculature [1]. Transcriptional changes in hypoxic cancer cells are 
influenced through several well understood hypoxia response pathways, including stabilization ad 
activation of hypoxia-inducible factor 1a (HIF-1a) [2, 3]. Transcriptional modulation of genes involved in 
glycolysis, angiogenesis, pH homeostasis and apoptosis (i.e. anti-apoptotic genes) enable cancer cells to 
survive and adapt to the hypoxic environment. Repeated oxygen deprivation and reoxygenation also has 
been hypothesized to promote tumor stem cell properties, metastasis, and patient prognosis. The 
phenotypic changes induced by adaptive responses to oxygen deprivation, in combination with other 
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mutational changes in cancer, severely decrease the effectiveness of both ionizing radiation and 
chemotherapy [4, 5].  
Epigenetic regulation of gene expression is coordinated at the level of DNA methylation, covalent histone 
modifications and expression of non-coding RNAs. Their concerted action affects transcriptional 
regulation by influencing both access and binding of regulatory factors to chromatin as a result of 
changed chromatin-compaction, repositioning of nucleosomes and/or recruitment of regulatory factors 
(i.e. by acting as a scaffold). These principles also apply to other DN-templated processes such as 
replication and repair [6, 7]. Recent data has demonstrated that epigenetic regulation can also mediate 
adaptation to changes in the micro-environment and this feature constitutes a major underlying 
mechanism in development, maintenance of cellular diversity, phenotypic plasticity and homeostasis [8]. 
The epigenetic status of the genome, including all chemical modifications of DNA and histone proteins, is 
often referred to as the epigenome [9]. Histone methylation, acetylation and phosphorylation are well-
documented covalent chemical modifications that occur on N-terminal tails of core histones that constitute 
the nucleosomal units in chromatin [7]. Histone acetylation is firmly connected to gene activation. In 
contrast, histone methylation is associated with active gene transcription as well as gene repression: H3 
lysine 9 (H3K9), H3K27 and H4K20 trimethylation (me3) are generally associated with gene silencing, 
whereas H3K4, H3K36 and H3K79 me3 are linked to transcriptional activation [6, 7]. 
 H3K27me3 and H3K4me3 states have been intensely studied in the context of development in relation to 
transcriptional regulation [10-13]. H3K27 is trimethylated by Polycomb Repressive Complex 2 (PRC2), 
which comprises the histone methyl transferease EZH2 [14]. The reverse process (i.e. H3K27-
demethylation) is accomplished by the histone demethylases UTX and JMJD3 [15]. H3K4me3 marks are 
installed by MLL-proteins that belong to the Trithorax Group (TrxG) of epigenetic modifiers, which 
functionally counteract PRCs [16, 17]. JARID1A-D catalyse H3K4 demethylation [18]. Although in 
terminally differentiated cells most H3K4me3 and H3K27me3 marks appear mutually exclusive, bivalent 
marking at key developmental control genes is observed in embryonic stem cells (ESC) [10-13]. 
Epigenomic comparison between ESC and committed and/or fully differentiated cell types has shown that 
bivalent marking is resolved to monovalency (or loss of both marks) at some stage during lineage 
commitment and differentiation. Eventually this results in lineage-specific H3K27me3 and H3K4me3-
profiles, which are stably transmitted during cell division [13, 19]. As such, PRCs and TrXG play a 
fundamental role in the establishment and maintenance of lineage-specific gene expression [16, 17].
Current knowledge on the distribution dynamics of H3K27me3 and H3K4me3 beyond embryonic 
development is relatively limited. We therefore studied the dynamics of histone methylation in the context 
of microenvironmental change. As a relevant physiological model, we used cellular adaptation to hypoxia 
and subsequent reoxygenation. Acute and chronic hypoxia are known to induce major transcriptomic 
changes [20]. Furthermore, hypoxia was reported to induce global changes in histone methylation [21]. 
However, a systematic profiling of H3K27me3 and H3K4me3 in relation to hypoxia induced gene 
expression is lacking. Relevantly, removal of histone trimethylation states is directly coupled to cell 
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oxygenation: the Jumonji C-terminal domain histone demethylases (JHDM) use Fe2+, -ketoglutarate 
and oxygen as co-substrates to remove all methylation states by hydroxylation [22-26]; as such the 
regulation of of -ketoglutarate-dependent demethylases under low oxygen is expected to be very similar, 
if not identical to that of the prolylhydoxylase HIF-PH which targets hypoxia-inducible factor 1a (HIF1a) 
[27, 28]. We therefore hypothesized that oxygen affects the activity of JHDMs and will increase global 
repressive and/or activating histone trimethylation-marking. Since HIF1a targets transcription of a subset 
of responsive genes, it is expected that constitutive transcriptional activity is required at corresponding 
genic areas and that these need to be exempted from silencing.  
To study the relation between epigenomic and transcriptomic changes, we employed chromatin- 
immunoprecipitation (ChIP) followed by deep-sequencing (ChIP-seq) [29, 30] and combined this with 
expression array analysis. We charted the distribution of both histone marks as a function of time cultured 
under low oxygen and correlated their distribution profiles to our gene expression data. Of relevance, we 
also included reoxygenation in our measurements, as cancer cells are subject to constantly changing 
oxygen tension in the tumor microenvironment. As H3K27me3 is known to cover large chromosomal 
regions instead of sharp defined peaks [31, 32], we also developed a standardized protocol to define and 
summarize H3K27me3-enrichment using deep-sequencing analysis. A detailed description of the protocol 
and the scripts used are published elsewhere [33]. 
Methods 
Cell Culture, expression vectors and viral infections 
MCF7 (human mammary adenocarcinoma) and DU145 (human prostate carcinoma) cells (ATCC) were 
cultured at 37°C, 5% CO2, 100% humidity in Dulbecco's Modified Eagle Medium:Nutrient Mixture F-12 
(DMEM/F12 1:1; MCF7) and DMEM McCoy’s 5A medium (DU145). The culture medium was 
supplemented with 10% fetal calf serum (FCS), 200 mM L-glutamine and antibiotics For hypoxic 
exposure, cells were transferred to a MACS VA500 microaerophilic workstation (Don Whitley Scientific, 
Shipley, UK) for the indicated duration. The atmosphere in the chamber consisted of <0.02% O2, 5% H2, 
5% CO2, and 74% N2. For reoxygenation, cells were transferred back to the regular tissue culture inhibitor 
containing ambient oxygen levels (21%). RNA interfering HIF1a sequences were obtained from Sigma 
(clone TRCN0000010819). Plasmids and lentiviral work Knock-down of HIF1alpha was achieved using 
lentiviral shRNA constructs. Lentiviral particles were generated by co-transfection of 293T cells with 
packaging plasmids pCMVdR8.74psPAX2 and pMD2.G together with shRNA vector pLKO.1. Virus 
supernatant was harvested 48 and 72 hrs post transfection. MCF7 cells were transduced with lentiviral 
supernatant in the presence of 8 microg/ml polybrene. Infected cells were selected for 2 days in 2 
microg/ml puromycin containing media.  Efficiency of plasmid constructs was verified by immunoblotting.  
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Protein isolation and Western blot analysis 
Cells were grown to around 70% confluency before they were transferred to the hypoxic chamber. Protein 
extraction was carried out using RIPA buffer supplemented with protease and phosphatase inhibitors. 
Lysates were further processed and protein concentrations were determined. Immunoblotting (IB) was 
performed as described previously, using antibodies raised against HIF1a ( ), H3K4me3 (Ab8580; 
Abcam, Cambridge, UK), H3K27me3 (07-449; Upstate Biotechnology/Millipore, Waltham, MA, USA), 
H3K9/K14ac (Abcam, Cambridge, UK), H3 (ab1791; Abcam, Cambridge, UK), b-Actin (C4, 69100, MP 
Biomedicals, Solon, OH, USA),. For more details, see Supplementary Methods.  
Chromatin immunoprecipitation (ChIP) assays 
MCF7 cells were transferred to hypoxic culturing conditions for the indicated durations and immediately 
fixed to avoid reoxygenation. Cells were disrupted by sonication, yielding genomic DNA fragments 
ranging from 200-1000 bp, with a bulk size of 200-500bp. For each immunoprecipitation 10-20 million 
cells were used. 1% of the cell suspension was kept aside as input DNA to use as a reference. ChIPs 
were performed and analyzed as described previously with minor adjustments [31], see supplementary 
materials and methods. Antibodies used include: H3K4me3 (Ab8580; Abcam), H3K27me3 (07-449; 
Upstate), CBX8 (LAST; courtesy Klaus Hansen, Copenhagen, Denmark) and HA as a negative control 
(sc-805; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The immunoprecipitated DNA was checked 
for enrichment using real-time PCR and quantified by fluorescence detection using Quant-iT™ 
Picogreen dsDNA Reagent (Molecular Probers/Invitrogen, Eugene, OR, USA) before deep sequencing 
was applied.  
Deep sequencing 
Input and ChIP samples were further processed and sequenced at the Ontario Institute for Cancer 
Research using the Illumina next generation sequencing platform. Processing involved size selection to 
enrich for mononucleosome-sized fragments, linker annealing and PCR amplification. Each resulting 
library was subsequently loaded onto individual lanes of a flow cell and sequenced using the 36 
bp paired-end protocol on the Illumina Genome Analyser IIx (GAIIx).  
In order to obtain sufficient sequencing depth additional lanes were sequenced if necessary.All data 
obtained from each individual sample was pooled. Data sets will be made publically available.
Genome alignment, normalization, background correction; identification of enriched regions 
Image processing and base calling was performed using Illumina software tools provided by the 
manufacturer). Subsequent paired-end genome alignment was performed using Novoalign with Human 
Genome 18 (HG18) used as a reference genome. Only uniquely aligned reads were used for further 
analysis. To remove PCR artifacts all data were collapsed prior to peak calling. H3K27me3 data sets 
were normalized based on identification of regions with stable H3K27me3-enrichment between all 
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samples analyzed; the cumulative area under the curve for all peaks within these regions was scaled 
relative to the smallest value among the samples; the normalization strategy will be outlined in detail 
elsewhere [33]. After normalization, a single cut-off value for all samples was set at the enrichment level 
(peak height; estimated by input sample data) above which H3K27me3 signal correlates with a known 
H3K27me3-binding protein under normoxic conditions (t=0; data not shown). Signal intensities below this 
cut-off were not considered biologically relevant. To identify enriched regions in the ChIP samples relative 
to the input control, the peak caller Findpeaks (version 4.0) was used. For H3K4me3 the default settings 
were used, whereas for H3K27me3 the settings were adjusted in order to detect blanketing enrichment 
next to sharply defined peaks [33].
Microarray
RNA for microarray application was isolated using RNeasy mini kit (Qiagen, Hilden, Germany) according 
to manufacturer’s protocol. Isolations were performed in triplicate. Total RNA samples were analysed 
using the Affymetrics expression array platform (Affymetrix Gene Chip 1.0 ST). After scanning, data 
preprocessing and data analysis were done with R (http://www.R-project.org; version 2.12) using the 
Bioconductor (http://www.bioconductor.org; version 2.7). Data were background-corrected and 
normalized using gcRMA [34]. Microarray data will be made available at Gene Expression Omnibus 
(GEO; http://www.ncbi.nlm.nih.gov/geo/).
Integration with gene expression; gene ontology analysis
To enable integration of expression data with our enrichment data, all Affymetrix prob IDs were converted 
into ENSEMBL gene identifiers. The expression level of an individual gene is defined as the average of all 
probe sets representing this gene on the array. Genes were considered expressed if expression exceeds 
100 for at least one independent time-point. Genes were called regulated if genes are expressed (>100 
for 1 or more time-points) and the fold change between 2 independent time-points is  2. All genes which 
were not represented on the micro-array were not included for further analysis. For the identification of 
enriched genes, we defined a gene as the region between its 5’ (most upstream TSS) and 3’ (last exon) 
end plus 5 kb regulatory regions up and downstream respectively. A gene was called marked when there 
was a peak present within this region as determined by the enrichment finding procedure. Gene Ontology 
enrichment analysis was performed using topGO [35, 36]. Comparative GO analysis with embryonal stem 
cell bivalent markers was based on published data [12]. 
Data visualization 
For data visualization several plots were created in R, including histograms, gene tracks, genome plots, 
pie charts, TSS plots, boxplots, scatter plots and pie-charts. For the TSS plots all genes were considered 
in the same orientation (from 5’ to 3’ end), and the average signal intensity was depicted for a region 
defined in number of base pairs surrounding the TSS, as indicated. Box-plots show the 25
th
 and 75
th
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quartile (as indicated by the box), the median (indicated as a line within the box), and the whiskers 
indicate the 5% and 95% percentile respectively. Notches in box-plots indicate confidence intervals (5-
95%) of the median.
Data summarization  
To study different enrichment profiles for H3K27me3, each gene was assigned to the Promoter, the TSS 
or the Broad class in analogy to published analysis [37]. To properly classify all genes, each gene was 
first divided into three regions: the promoter region (-3000/-100 base pairs (bp) in relation to the TSS), the 
TSS region (-100/1000 bp), the broad region (+1000 bp to the last exon). Genes shorter than 4000 bp 
were excluded from the analysis, as they were too small to reliably assign them to either profile. Genes 
were allocated to the different classes based on which of the three regions contained the largest amount 
of signal scaled to the size of each region, provided it contains a peak which showed at least 25% more 
enrichment compared to any other peak within the gene (Promoter and TSS class), or it contains a 
enrichment above the average enrichment at more than 35% of the region (Broad class). Genes allocated 
to either region which did not meet above criteria, were not considered for profile analysis.  
Results 
Reversible oxygen-dependent global changes of H3K4me3 and H3K27me3 levels 
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	 we 
exposed MCF7 breast cancer cells to severe hypoxia (<0.02%) and measured global changes in 
H3K4me3 and H3K27me3 levels by immunoblotting at 8 and 24 hours of hypoxia  compared to normoxic 
cells (t=0). Cancer cells are subject to repetitive fluctuation of oxygen availability in situ (i.e. hypoxia and 
reoxygenation); reoxygenation may affect cells through specific stress responses that that involve 
epigenetic change. For this reason we also determined H3K4me3 and H3K27me3 levels in response to 
reoxygenation. Trimethylation of H3K4 (1.7 fold) and H3K27 (2.2 fold) was increased after 8 hours 
culturing at low oxygen tension; the elevated trimethyl-state was sustained up until 24 hours of culturing 
under hypoxic conditions (Figure 1A). We observed this in multiple cell lines, suggesting that the 
epigenomic remodeling was dictated by oxygen-status and occurred independent of cellular context 
(Figure S1A). Importantly these initial observations are consistent with our original hypothesis. 
Conversely, restoration of oxygenation induced an initial sharp decline of global histone H3K4 and K27-
trimethylation that transiently dropped below levels in normoxic cells and returned to baseline at 
approximately 12-24 hours after reoxygenation, depending on the cell type used; concomitantly, 
H3K9/K14-acetlyation (H3K9/K14a) increased in response to oxygen stress. (Figure 1A, Figure S1A). 
To establish that demethylation activity is reduced because of loss of oxygen, and not by changes in 
protein levels of the responsible molecular machineries, histone lysine demethylase (HKDM) and histone 
lysine methyl transferase (HKMT) mRNA levels were measured. Expression of a number of relevant 
HKMDs including JARID2, JARID3 and JMJD3, show significantly increased expression in hypoxic cells  
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(Figure S1B). In contrast, the H3K27me3-HMT EZH2 as well as numerous confirmed and putative 
H3K4me3 HMTs declined in response to oxygen deprivation or remained unaltered (Figure S1C). Hence, 
changes in levels of responsible writers or erasers could not explain the global increase in both activating 
and inactivating marks; instead the data is consistent with changes in enzymatic activity of KDM. 
Moreover, the sudden drop in H3K4me3 and H3K27me3 levels following reoxygenation is in agreement 
with activation of accumulated HKDM protein by molecular oxygen.  
Previous studies have shown that expression of HKDM is controlled by HIF1a [38-40]. To determine 
whether the effects of altered oxygenation on global trimethylation levels were dependent on HIF1a, 
HIF1a-depleted MCF7 cells were exposed to hypoxia and analyzed for global changes in H3K4me3 
(Figure S1D). No obvious differences with respect to hypoxia-induced increased histone trimethylation 
were observed between control and shHIF1a cells, indicating that the global epigenetic changes occurred 
in a HIF1a-independent fashion (data not shown). Combined, these data suggest that hypoxic stress 
induces a reversible increase in histone H3 trimethylation which is HIF1a-independent.  
We next aimed to determine whether changes in oxygen regulate epigenetic states at specific genes. To 
this end ChIP-seq analysis was performed on H3K4me3 and H3K27me3-enriched sequences in normoxic 
(t=0), hypoxic (t=8 and 24 hrs) and reoxygenated cells (t=+8 hrs); the latter condition was considered as a 
transition point to restoration of the original epigenomic state under ambient conditions (21% oxygen). In 
parallel, RNA samples were collected for analysis at all four time points. ChIP-seq analysis confirmed 
enhanced global trimethylation of H3K4 and H3K27 in response to hypoxia, consistent with the 
immunoblotting findings: the total amount of H3K4me3 and H3K27me3 peaks had increased ±2.6 and 1.4 
fold, respectively, at 24 hours hypoxia (Figure 1B, cf. genome plots Figure S2A,B). Conversely, 
reoxygenated samples revealed a steep drop in the global number of trimethylation peaks: both the 
number of H3K4me3 and H3K27me3 peaks fell ±2.5 fold at 8 hours reoxygenation (t=+8) to 0.98 and 
0.62 fold their original normoxic values, respectively (Figure 1B, cf. genome plots Figure S2A,B). 
Representative genome tracks illustrate examples of individual genes that displayed loss, gain or 
unchanged H3K4me3 and/or H3K27me3 levels in response to altered oxygenation (Figure 1C). 
Consistent with the global decline of H3K4me3 and H3K27me3 (cf.,Figure 1A) enhanced trimethylation 
was lost upon reoxygenation at most of these loci. Reciprocal correlation analysis revealed a substantial 
overlap between enriched loci (for both H3 marks) under normoxic vs. hypoxic conditions (corr.coeff. at 
t=0 vs t=24 hrs: 0.45 H3K4me3, 0.53 H3K27me3) and vice versa (corr.coeff. at t=24 vs t=0 hrs: 0.77 
H3K4me3, 0.60 H3K27me3). This data indicated that pre-existent (normoxic) H3K4me3 and K27me3-
marking was generally retained under hypoxic conditions and that the increased enrichment was derived 
from hypoxia-induced de novo trimethylation. These findings validated the reliability of the comparative 
histone me3-marking analysis. H3K4me3-enrichment (i.e. sequences associated with peaks) returned to 
the normal situation normal (corr.coeff. at normoxia vs. reoxygenation and vice versa: 0.82). In contrast 
H3K27me3-marks show poor correlation between t=0 and t=+8 hrs (corr.coeff: 0.19 norm vs. reox and 
0.11 reox vs. norm) indicating that normoxic H3K27me3-distribution has not been restored at 8 hours  
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after reoxygenation. Although a number of densly trimethylated genomic regions were relatively resistant 
to demethylation at reoxygenation, combined, these findings showed that hypoxia causes an overall 
reversible global increase of H3K4me3 and H3K27me3 and establishes that oxygen is required for 
constitutive activity of HKDM and maitenance of the basal epigenetic state in a large number of genomic 
regions.  
Preferred gain of histone methylation at genic regions   
The above findings provided us with a basis for comparative epigenomic and transcriptomic analysis. To 
relate epigenomic changes to transcriptional states, we first differentiated enriched sequences into genic 
(i.e. “genes” +/- 5000 bp) and intergenic regions. Under control conditions, trimethylation was highly 
associated to genic regions: 88% of all H3K4me3 peaks located to genes compared to 47% for 
H3K27me3 peaks (Figure 1B). In normoxic cells, 46% of all genes carried H3K4me3-marks, whereas 
significantly less genes (9%) were H3K27me3-enriched (Figure 2A,B/a). Intergenic H3K4me3-
association increased from ±10% to ±30%; the relative genic/intergenic H3K27me3-distribution did not 
change as a result of oxygen deprivation (±50%; Figure 1B). Although overall H3K4me3-peaks 
associated to genic regions decreased from 88% to 69% in low oxygen conditions (Figure 1B), the 
number of genes H3K4me3-associated genes increased from 46% to 56% under at 24 hours hypoxia
(Figure S2Aa). In contrast to the rather stable relative number of  H3K27me3 peaks associated with 
genic regions (48% at normoxia vs 49% at 24 hours hypoxia; Figure 1B), the percentage of genes 
associated with H3K27me3 nearly doubled at 16% after 8 hours of oxygen deprivation (Figure 2Ba). 
Thus, although the percentage of marked genes increased for both methyl marks (Figure 2A,B/a), the 
relative increase of H3K4me3-peaks was higher in intergenic regions, whereas relative gain H3K27me3 
occurred mostly in genic regions (Figure 1B; Figure S3A,B). Alignment of all trimethylation-associated 
sequence tags to genic or intergenic regions, showed that the majority (>98%) of trimethyl-marks was 
directed towards genic regions, irrespective of oxygen tension (Figure S3C,D). The combined above data 
confirms that genomic decoration with H3K4me3 and H3K27me3 relates to gene regulation and indicates 
that H3 trimethylation does not occur in a random fashion but is strongly directed towards genic regions. 
Upon reoxygenation the overall number of trimethyl-marked genes reverted to that measured in normoxic 
cells (15752 genes, normox; 31919 genes, 24 hrs hypox vs. 15236 genes, reox, respectively) (Figure 1B, 
Figure 2A-B/a). The intergenic:genic ratio of trimethyl-mark distribution of H3K4me3 was nearly fully 
restored to that initially observed at ambient oxygen levels (0.14, t=0; 0.45, t=24 vs. 0.16, reox); in 
contrast, a relative genic-enrichment H3K27me3 was apparent at the 8 hours reoxygenation time point 
(49% vs. 61%) (Figure 1B). This data is consistent with the poor H3K27me3-peak correlation between 
normoxic and reoxygenated samples (noted above) and shows that hypoxia-induced H3K27me3-marking 
at genic regions is relatively resistant to restored HKDM activity.  
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Epigenetic profiles correlate with transcriptional state  
To profile the oxygen tension-induced enrichment of H3K4me3 and H3K27me3 at genic regions in more 
detail, enrichment data were visualized using TSS-centered plots. Under control conditions, H3K4me3 
was prominently enriched around the TSS with a distinctive signal-depletion directly over the TSS; this 
finding is consistent with earlier reports showing reduced nucleosome presence at this site (Figure 2Ab) 
[41]. In sharp contrast, H3K27me3-marking at normoxia coincided mainly within gene body-enrichment, 
consistent with the reported “blanketing” enrichment of H3K27me3 (Figure 2Bb) [31-33]. The H3K4me3-
enrichment profile did not significantly change as a result of hypoxia or reoxygenation (Figure 2Ab), 
whereas H3K27me3-enrichment was selectively enhanced over and around the TSS during oxygen 
deprivation (Figure 2Bb). Taken together, this data confirmed the genic bias of histone H3 trimethylation 
at K4 and K27 and revealed a pronounced TSS-directed hypoxia-induced increase of H3K27me3  
To correlate H3K4 and H3K27-trimethylation to gene transcription, the ChIP-seq data were compared to 
expression data of corresponding genes. Expression array analysis revealed that a significant number of 
transcripts was down-regulated in response to upon hypoxic exposure (Figure S4A). Gene ontology (GO) 
classification confirmed regulation of expected processes in response to hypoxia (Figure S4C), 
consistent with published data [20]. H3K4me3-marked genes were significantly higher expressed at all 
individual time points (Figure 2Ac), whereas H3K27me3-marked genes were transcribed at substantially 
lower levels as compared to non-marked genes, except for the reoxygenation time point (Figure 2Bc). 
H3K4me3-enrichment showed a positive correlation with gene expression level at all time-points analyzed 
(data not shown). There was no apparent correlation between relative H3K27me3-enrichment and gene 
expression/repression at any time point suggesting that despite the overall increased H3K27me3-
enrichment during oxygen deprivation, H3K27me3-enrichment was not repressive per se.  
Reoxygenation only partially restored the hypoxia-induced epigenetic marking and expression levels, 
indicating that although many cellular processes are affected by reoxygenation, cells are at a transition 
phase at the 8 hours reoxygenation time point (Figure S4B,D). Consistent with the earlier noted 
sustained H3K27me3-marking during reoxygenation, the TSS-associated H3K27me3-enrichment profile 
was not immediately reversed at t=+8 hours (reox), confirming that specifically the K27me3 signal-
distribution at the TSS was relatively resistant to the effects of reoxygenation compared to overall 
H3K27me3-marking. The loss of genic H3K4me3-marking at reoxygenation, despite increase overall 
expression suggested functional uncoupling of epigenetic marking and gene expression in response to 
acute reoxygenation stress.  
Hypoxia induces bivalency 
As 46.3% of genes (22732) was already H3K4me3-enriched at normoxia (Figure 2Ab) and H3K27me3-
enrichment specifically increased around the TSS (Figure 2Bb), the hypoxia-induced increase in 
trimethylation was likely to increase the frequency of co-occurrence of both trimethyl marks. Therefore, 
we selectively examined genes that showed double marking during hypoxia and calculated the Pearson
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correlation coefficient (pcc) at different time points to determine co-occurrence of trimethyl marks. 
Pearson correlation analysis in control samples (normoxia) indicated a negative correlation between 800 
bp up- and downstream of the TSS, corresponding to H3K4me3 enrichment and H3K27me3 depletion 
around the TSS (Figure S5A, cf. Figure 2Ab). Regions more distant (up- or downstream) from the TSS 
and the TSS itself showed a positive pcc, which correlated with low presence of both marks (TSS) and 
absence of H3K4me3 (distant). H3K4me3-monovalency around the TSS at t=0 was lost during hypoxia, 
consistent with the increased H3K27me3-enrichment around the TSS in response to hypoxia (Figure 
S5A, cf. Figure 2Bb). Restoration of ambient oxygen tension correlated with a sharp pcc decline at the 
TSS, correlating with a relative loss of one of two me3-marks at the TSS itself (Figure S5A, cf. Figure 
2Ab,Bb).  
To study the co-occurrence of H3K4me3 and H3K27me3 in further detail, all genes which were enriched 
for both trimethyl marks were plotted for each time point separately.  We detected an almost 3 fold (821 
genes, t=0 to 2200, t=24) increase in the number of double-marked genes as a result of hypoxia. 
Remarkably, double-marking was maintained at more than 70% of genic loci upon reoxygenation (t=24 
hrs vs. reox; Figure S5B). This data demonstrated that hypoxia increases co-occurence of H3K4 and 
H3K27-trimethylation marks, and suggested that this epigenetic state was selectively maintained upon 
reoxygenation despite global loss in trimethylation.  
Transcription at bivalent genes is primarily determined by H3K4me3 
Expression of double-marked genes was marginally affected by hypoxia: 16% of double-marked genes 
were actively expressed in control samples vs. 15% and 13% at 8 and 24 hours hypoxia, respectively. To 
determine the consequences of dynamic epigenetic change, including the co-occurrence of H3K4me3 
and H3K27me3, for gene-expression, genes were grouped based on their enrichment profile at normoxia 
(i.e. non-marked, K4me3 only, K27 only, double marked); genes were then compared for changes in 
average expression levels in relation to changes in epigenetic marking. 90% of genes which were 
H3K4me3-marked at normoxia showed persistent H3K4me3-marking well into hypoxia (t=24 hrs) and 
remained transcriptionally active (Figure 3A). Notably, loci at which H3K4me3 was lost (single H3K27+ or 
non-marked at t=24 hrs) were transcriptionally silenced. In sharp contrast, H3K4me3 genes which gained 
K27me3+ (K4/K27+ at t=24h) maintained their averages expression level. Genes that carried both 
trimethyl marks at t=0 had an intermediate expression level compared to H3K4me3-marked (high 
expression) and H3K27me3 or non-marked genes (low expression) (Figure 3A-D; right panels). 
Approximately 20% of the double-marked genes either lost H3K4me3 or H3K27me3-enrichment in 
response to oxygen deprivation, while the majority of genes retained both marks. Loss of H3K27me3 did 
not affect gene-expression, but loss of H3K4me3 clearly reduced expression. In contrast, the H3K27me3-
only pre-marked genes showed a strong shift toward gain of H3K4me3 in hypoxic conditions (±55%; 
Figure 3C). However, gain of H3K4me3 did not parallel increased gene expression as all genes 
remained transcriptionally silent. Of all non-marked genes (t=0) ±81% maintained this status after 24 
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hours of hypoxia; genes that gained H3K4me3-single or both me3-marks (around 15% in total) displayed 
slightly elevated median expression of H3K4me3/single-marked genes; this mirrored the effect of 
H3K4me3-marking under oxygenated conditions, albeit with substantially lower expression levels (Figure 
3D).  
In the context of reoxygenation, the majority of H3K4me3-marked genes maintained some level of 
H3K4me3-marking, and gene expression was not changed upon acquisition of H3K27me3 (Figure 3E); 
non-marked genes (t=24 hrs) were slightly induced upon gain of H3K4me3 (independent of simultaneous 
gain of K27me3; Figure 3H). The double-marked and the H3K27me3-only marked genes showed the 
most significant loss of H3K27me3 upon reoxygenation: 56% and 87%, respectively, which paralleled the 
global loss of H3K27me3 (Figure 3F,G, cf. Figure 1B). Approximately 30% of the double-marked genes 
was significantly expressed at t=+8 hours (Figure S5B). Double-marked genes that lost H3K4me3 (30% 
and/or H3K27me3) showed a concomitant reduction of gene expression (Figure 3F). Remarkably, genes 
that maintained their double–marked status, showed higher transcription levels, whereas those that 
retained H3K4me3-only did not change their expression (Figure 3F), suggesting that gain of H3K27me3 
is regulatory. H3K27me3–only enrichment (t=24 hrs) correlated with a transcriptionally silenced status 
that did not change in response to reoxygenation (Figure 3G).  
Thus, at any given time point H3K27me3-only or no-marking generally correlated with transcriptional 
silencing, whether the condition was pre-existent or acquired, and gain of H3K4me3 at these sites did not 
meaningfully change expression. H3K4me3 pre-marked genes were generally transcriptionally active, 
and maintained their expression level independent of gain of H3K27me3, as long as K4 marking was not 
lost. Changes of H3K4me3-trimethylation primarily control transcription in the context of adaptation to 
altered oxygenation. In combination with H3K4me3, the H3K27me3-mark represented an important 
exception to the general trend that H3K27me3-marking correlates with silencing. The combined data 
identify H3K27me3 as the most transitory mark in response to hypoxia/reoxygenation appeared to be 
H3K27me3. 
Normoxic trimethylation profiles correlate with transcription status
Since the (re)distribution of H3K27me3-enrichment appeared most affected by hypoxia/reoxygenation, we 
next determined the relation between the specific intragenic location of H3K27me3-marks and 
transcriptional regulation. For this purpose, the enrichment–profile of all genes was differentiated into 
three separate regions: promoter (promoter; -3000/-100 bp TSS), transcription start site (TSS; -100/+1000 
bp), and gene-body (broad; +1000/last exon) as was defined before [37]. Genes were then assigned to 
one of three classes at each time point based on their H3K27me3-enrichment (Figure S6A/a): a distinct 
H3K27me3 peak upstream of the TSS (promoter class), ii) a distinct peak at the TSS (TSS–class) or iii) 
no peak, but instead the typical Polycomb-repression-associated ‘blanketed’ distribution over the gene 
body (broad class; Figure S6Aa). In control samples (normoxia) the majority of genes (±55%) displayed 
the broad (gene body/blanketing) enrichment, whereas the TSS (±22%) and promoter (±23%) class were 
128 
equally represented (Figure 4Aa). Hypoxia induced a 1.7 fold increase in H3K27me3-enrichment (total), 
and a clear shift toward TSS-class marking (±22%, t=0 to ±33%, t=8), whereas relative promoter–class 
marking decreased (±23%, t=0 to ±14%, t=8); this relative distribution was maintained for the duration of 
hypoxic exposure (Figure 4B,C/a). TSS-class marking decreased in response to reoxygenation (±31% to 
±16%), whereas the percentage of H3K27me3-blanketed genes increased to ±75% (±55%, t=0, 24) 
(Figure 4Da). This data indicated that hypoxia induces a reversible selective increase of H3K27me3-
marking at transcription start sites. 
To gain insight into the biological relevance of H3K27me3-marking, average gene expression 
measurements were plotted for each individual subclass, and compared to the overall expression of all 
H3K27me3-enriched genes and non-marked genes. Distinctive TSS-marking and gene body-enrichment 
correlated with low expression/repression, compared to the total pool of H3K27me3-marked genes 
(Figure S6A-D/b). Promoter H3K27me3-enrichment was associated with a significantly higher average 
gene expression level, compared to the total H3K27me3-marked gene population, and equaled 
expression levels of non-marked genes; consistent with the absence of transcriptional repression, gene 
body H3K27me3-marking was low at promoter-marked genes (Figure S6Aa,b). A similar correlation was 
observed between intragenic enrichment-profile and expression at acute or chronic hypoxia (Figure S6B-
C/a,b).  
We next asked whether the presence of specific H3K4me3-enrichment within these 3 H3K27me3-classes 
could explain the observed increased expression at these loci. To this end, all H3K27me3-marked loci 
were divided into two categories: HK4me3-negative and H3K4me3-marked loci (Figure 4A-D/a). At 
normoxic conditions, all three H3K27me3-classes contained bivalent genes; the highest number of 
double-marked genes (377; ±40%) was found in the gene body H3K27me3-class; whereas within the 
promoter-class loci, nearly 2/3
rd
 of all loci was marked (253 genes) (Figure 4Aa). Expression within these 
H3K27me3-classes positively correlated with the presence of the H3K4me3-mark (Figure 4Ac; red boxes 
marked “all”), and with relative H3K4me3/TSS-enrichment (promoter and gene-body class; Figure 4Ab); 
TSS-double marked genes showed the lowest median expression. Under hypoxic conditions, the number 
of double-marked genes increased substantially in each H3K27me3-class (Figure 4B,C/a), yet the 
normoxic expression-ratio was maintained (i.e. promoter class > gene body class > TSS class), despite 
progressive reduction of H3K4me3-marking at the TSS in all three H3K27me3-classes (Figure 4B-C/b,c). 
The association between intragenic H3K27me3-marking and transcriptional regulation was lost in the 
context of reoxygenation stress (Figure S6Da,b; cf. Figure 2Bc); of note: even silenced loci (TSS-peak 
or blanketing-type distribution; repressed at t=0 and during hypoxia), showed a sudden rise of 
transcriptional activity (Figure S6Db). Loss of repression under these conditions was not explained by 
quantitative changes in H3K27me3-enrichment (data not shown). Following reoxygenation, expression 
was induced at all H3K4me3-marked loci irrespective of H3K27me3-subclass, but not at 
H3K27me3/single-marked loci (Figure 4Da-c). Of note, the relatively highest increase of H3K4me3- 
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occupation within the H3K27me3/TSS-class correlated with the highest median expression induction (3,7 
fold change; t=24 vs. reox).  
Thus, our comparative analysis of intragenic marking and gene activity identified H3K4me3-marking as 
the dominant determinant of expression of a locus. The data suggested that transcriptional status under 
hypoxic conditions was refractory to gain of H3K27me3-enrichment and revealed a clear association 
between defined promoter-type H3K27me3-marking and a transcriptionally permissive state (vs. TSS or 
gene body-enrichment and transcriptional repression) under normoxic and hypoxic conditions. 
Reoxygenation induced massive transcriptional deregulation, irrespective of the H3K27me3-status of loci. 
Hypoxia-induced bivalency partially overlaps with bivalent genes in ES-cells 
More than 800 genes were classified as bivalently marked under normoxic conditions, based on co-
occurrence of H3K4me3 and H3K27me3-marks within genic regions (Figure 3B,F). To determine 
whether bivalent genes specifically mapped to any of the intragenic H3K27me3-profile subclasses, we 
analyzed the promoter, TSS or gene body H3K27me3-marking groups for H3K4me3-presence. 
Approximately 80% (345 genes) of H3K27me3/promoter-enriched genes was also enriched for H3K4me3 
in hypoxic samples (cf. Figure 4A-D/a). The broadly H3K27me3-enriched genes showed a relatively 
lower H3K4me3-enrichment (±64%,1064 genes; t=8 hrs) compared to promoter or TSS-class genes (758 
genes); of TSS-H3K27me3 genes ±72% was associated with H3K4me3, (cf. Figure 2Ab); the presence 
of H3K4me3 around the TSS (fig cf. fig 2) determined gene expression status, independent of the 
intragenic location of K3K27me3. Consistent with the earlier observed transcriptional deregulation at 
reoxygenation, like H3K27me3, H3K4me3-occupation failed to correlate with transcriptional status. This 
data indicated that bivalent genes are strongly represented among H3K27me3/TSS and promoter-marked 
genes.  
To determine how bivalency was accomplished, the original epigenetic status of the bivalently marked 
genes (at t=8 hrs hypoxia) was traced back to normoxia and displayed as a function of time spent at low 
oxygen. We first selected the TSS-associated bivalency (H3K4me3 and H3K27me3 at TSS) genes for 
further analysis. Bivalency increased approximately 3 fold (758 to 2157 genes) in response to loss of 
oxygen (Figure 5Aa). Gain of H3K4me3 appeared under-represented in regards to acquisition of 
bivalency, due to the fact that a many TSS genes had pre-existent H3K4me3-marking at baseline. More 
than half of the bivalent genes (±54%; 1173 genes) at 8 hours of hypoxia had acquired H3K27me3-
marking alone or in combination with H3K4me3-marking in response to oxygen withdrawal (Figure 5Aa). 
During prolonged hypoxia (t=8 to t=24 hours) or at reoxygenation, again more than ±50% of acquired 
bivalent loci showed gain of H3K27me3 (Figure 5Ba); this finding is in good agreement with the above 
proposed notion that H3K27me3-marking is most prone to dynamic modulation.  
Expression levels of genes with acquired bivalency, largely reflected those corresponding to their original 
epigenetic status: for instance, genes that gained H3K27me3 were significantly higher expressed 
compared to stable bivalent genes (Figure 5Ac,Bc). Although a possible contribution of mRNA stability  
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could formally not be excluded, transcriptional changes should be detectable over an 8 hrs interval and, 
moreover, we observed a similar trend for genes that gained H3K4me3.  
Upon reoxygenation many bivalent genes were lost, and despite a substantial gain of bivalency, the 
number of bivalently marked loci dropped to ±75% compared at t=24 and was still 2 fold higher compared 
to normoxia: more than 500 loci displayed bivalent epigenetic marking at the reoxygenation time point, 
suggesting that somehow these genes were shielded from acute HKDM activity (Figure 5Ca). Compared 
to loss of H3K4me3-marking in response to reoxygenation (±9% of H3K4me3/single-marked genes; t=24 
hrs vs. reox), H3K27me3 was considerably less stable (±87% at H3K27me3/single-marked genes). At 
bivalent loci, the loss was relatively larger for H3K4me3 (±29%), whereas H3K27me3-loss was 
substantially less (± 56%) compared to single-marked genes.  
In conclusion, hypoxia induces epigenetic bivalency, which correlates best with a TSS-specific increase of 
H3K27me3. Bivalent genes show transcriptional activity which overall resembles their original 
expressional status under normoxia. 
Bivalency in embryonal stem cells (ESC) coincides with genomic CpG-content (i.e. CpG islands) [42]. To 
verify whether this applied to bivalent epigenetic marking in MCF7 cancer cells as well, the prevalence of 
bivalently marked genes in high CpG-content promoter/enhancer regions (HCP) versus intermediate and 
low CpG-regions (ICP and LCP, respectively) was determined. H3K4me3 preferentially localized to HCP 
regions; 5198 HCP, 2775 ICP and 1015 LCP promoters were positive for H3K4me3 at normoxia, 
corresponding to 70% of charted HCPs, 54% of ICPs and 10% of LCPs respectively (Figure 5D). 
Bivalently-marked genes showed a highly similar distribution pattern: 366 HCP, 183 ICP and 72 LCP 
promoters were positive for both trimethyl marks in control cells (t=0). Relatively few promoters showed 
H3K27me3-marking, consistent with the relative H3K27me3-enrichment over gene bodies or at the TSS. 
H3K27me3/promoter distribution was opposite of that of H3K4me3: 310 HCP, 2720 ICP and 577 LCP 
promoters were enriched for H3K27m3; (Figure 5D, cf. Figure 4). Although the overall number of 
H3K4me3, H3K27me3 or H3K4me3/H3K27me3-enriched genes increased in response to hypoxia, their 
relative association to HCP, ICP and LCP was maintained (data not shown).  
In the context of stem/progenitor cells bivalently marked loci are often found among key developmental 
control genes [11-13]. We next examined whether the hypoxia-induced bivalently marked gene set in 
MCF7 cancer cells showed overlap with bivalent genes previously identified in ESC. Approximately 600 of 
the hypoxia-induced bivalent genes in MCF7 cells match a previously identified group of bivalent genes in 
ESC [12] (Figure 6A). Comparative GO analysis of both bivalent gene pools revealed a distinctive 
overlap of functional pathways involved and confirmed the presence of bivalently marked developmental 
genes (Figure 6B). Many of these genes were already bivalently marked at the 8 hour hypoxia time point 
(Figure S7), suggesting that these loci are pre-set targets for bivalent marking under low oxygen. Hence, 
our findings suggest that oxygen deprivation in breast cancer cells induces bivalent epigenetic marking at 
genes which are also bivalently marked in ESC and which control key processes during development. 
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Discussion 
We here report that oxygen deprivation induces massive genome-wide trimethylation at H3K4 and H3K27 
through inhibition of JHDM function. Our data establish that oxygen-sensing by HKDM represents a direct 
link between the micro-environment and epigenetic regulatory mechanisms. Comparative analysis of 
ChIP-deep sequencing and expression array data sets revealed that H3K27me3-occupation at the TSS 
and over the gene body correlates with transcriptional repression, whereas H3K4me3 marking under all 
conditions correlates with gene activity. We establish H3K4me3-enrichment as the most relevant 
determinant of transcription status. H3K27me3-acquisition at the TSS with pre-existent H3K4me3 marking 
does not alter the expression status. We show that a subset of genes acquired bivalency, by gain of 
H3K27me3 (54% 1173 genes). The bivalent subset represents genes previously identified as bivalently 
marked genes in ESC.  
Recent advances in the field of epigenetics suggest that chromatin state is more dynamic than originally 
anticipated. Comprehensive insight into transcriptional reprogramming in response to changing 
microenvironments requires systematical genome-wide mapping of epigenetic marks as a function of cell 
type, differential state and micro-environment [6]. We here studied dynamic changes in histone 
trimethylation in the context of cellular adaptation to changed oxygenation (hypoxic stress, 
reoxygenation). To robustly detect H3K27me3-enrichment, we designed a novel enrichment-finding 
protocol including a normalization/summarization strategy. Importantly, this also allows us to obtain 
quantitative measurements of H3K27me3-marking between samples (time-points). Applying this novel 
strategy we were able to reproduce reported correlation between gene-body associated ‘blanketing’ 
H3K27me3-profile and transcriptional repression, thereby validating our analytical approach [33]. The 
prominent TSS-centered H3K4me3-enrichment at expressed loci, and the marked low nucleosome 
abundance right over the TSS, is also consistent with earlier findings [11].  
We detected a clear positive correlation between TSS/H3K4me3-enrichment and gene expression at all 
time-points studied. H3K27me3 displayed multiple distinct enrichment profiles, in line with previous 
publications [37, 43]. H3K27me3-enrichment across the gene body followed the classical Polycomb-
associated repressive H3K27me3-enrichment profile, which is referred to as “blanketing” [31, 32]. Specific 
enrichment at the promoter region, in combination with a marked depletion of the signal within the gene 
body, overlaps with H3K4me3-enrichment profiles and appears permissive for active transcription; 
consequently bivalently-marked genes are expressed at low levels [12, 13, 31]. Interestingly, we 
observed enhanced H3K27me3-marking upon oxygen deprivation at the TSS, relative to promoter and 
gene-body; this resulted in bivalent marking of a substantial number of genes (±950-1100; t=8 and 24 hrs 
combined). By inference, inhibition of HKDMs is likely to be responsible for the increased bivalency at 
TSS in the absence of molecular oxygen. The co-occurrence of both methyl marks was first described in 
embryonic stem cells and is thought to mark key developmental control genes as “poised” for 
transcriptional activation. We and others found a marked increase of bivalent marking at CpG-rich 
genomic regions [37]. CpG-islands are usually hypomethylated (at the DNA level), but instead are marked 
135 
by trimethylation on histone 3 lysine 4 (H3K4me3) or lysine 27 (H3K27me3) [10, 37]; conversely, bivalent 
domains highly correlate with the presence of CpG-islands, and may reflect a competition between PcG-
recruitment (silencing) and transcriptional activation [44]. A recent study in Xenopus showed that 
bivalency may, in reality, affect different alleles [45]. Hence, to conclusively prove that H3K4me3 and 
H3K27me3 occur on the same chromatin segments and are not merely a reflection of different cell pools, 
sequential ChIP for both marks needs to be performed. 
Enhancers represent an important class of functional domains involved in transcriptional regulation. In 
contrast to promoter regions, enhancers operate as highly tissue-specific elements, and their (functional) 
existence cannot be directly inferred from underlying DNA-sequences [46]. In addition, enhancers may be 
located thousands of base pairs removed in cis from their target genes, or even on a different 
chromosome, which makes it difficult to define and relate such regulatory regions to genes. No public 
MCF7 ChIP-seq data-set is currently available, which includes TF/DNA-binding profiles and/or enhancer-
associated epigenetic regulatory factors (e.g. p300) or associated histone modifications (e.g. H3K4me1 
and H3K27ac). To probe for such histone modifications would be relevant in light of our current findings, 
as it was reported that bivalent promoters are associated to a specific subclass of enhancer elements 
which are H3K4me1/H3K27me3-marked instead of H3K4me1/H3K27ac which is the case for active 
promoters [47]. 
The increased global methylation we observed could either be the result of increased histone methyl 
transferase activity or reduced histone demethylase activity. Transcriptional analysis of candidate 
enzymes involved in histone (de)methylation did not suggest a singular role for any of these factors in this 
respect. Expression of JHDM proteins is known to be controlled by HIF1a; likewise HTM expression is 
controlled by oxygen. Nevertheless, we showed that the hypoxia-increased trimethylation was HIF1a–
independent. Most demethylases depend on molecular oxygen for their activity, making JHDM oxygen 
sensors  
The exact relevance of Polycomb-associated marking and occupation at different intragenic positions is 
currently not fully understood. The H3K27me3-mark is bound by chromobox proteins belonging to 
Polycomb group proteins [48]. PcG proteins were shown to be present at active RPOL2 promoters in 
Drosophila and to interact with basal transcription factors (TF) [49]. Target-gene silencing via distant 
enhancer-looping to gene promoters has been shown in flies and in mammalian systems [50]. In addition, 
PcG complexes associate with splicing factors, revealing an as of yet poorly understood role in regulation 
of gene expression. In the context of our hypoxic-stress model, increased bivalency mostly correlated 
with gain of TSS-H3K27me3. It is also interesting to note that H3K27me3-marking appeared to be the 
most prone to dynamic change. The transcriptional status of the corresponding loci, however, was 
generally maintained; hence, this finding suggests that, once marked for transcription, recruitment of HMT 
activity and concomitant H3K27me3-marking per se is not sufficient for transcriptional repression. 
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Despite the global demethylation following reoxygenation, a substantial number of loci was bivalently 
marked 8 hours into restoration of oxygen levels. It is currently unclear whether these loci are protected 
from HKDM activity and/or selectively methylated by K27-directed HTMs. It is conceivable that some 
other local epigenetic aspect (e.g. inhibitor recruitment of higher-order chromatin structure) prevents 
access and/or shields nucleosomes against demethylation. Of relevance, HKMTs are often found in close 
conjunction with HKDMs for opposing epigenetic marks; together these paired epigenetic modulators are 
thought to reinforce transcriptional decisions (co-stability) [51]. It is tempting to speculate about a causal 
role for similarly cooperative H3K4me3 HMTs/H3K27me3 HDMs in the establishment of bivalency under 
HKDM-inhibitory conditions. Irrespective of the exact underling mechanism, our findings confirmed our 
initial hypothesis and define a novel role for oxygen in epigenetic regulation of stress responses. Future 
experiments should address the question whether loss of UTX/JMJD3 abolishes the increase in 
H3K27me3 levels, both on the global as well as on individual gene level. Although the involvement of 
demethylases was recently addressed in the context of hypoxia-induced increased H3K4me3-marking 
[40], our studies provide additional insight in to the effects of reoxygenation on epigenomic and 
transcriptomic responses.  
Acquisition of bivalency under hypoxic conditions is a phenomenon which may have relevance in the 
context of tumor biology (i.e. plasticity, malignancy). TSS-associated H3K27me3 was previously shown to 
be prominent in embryonic stem cells [37]. As bivalency was proposed to represent an aspect of 
hierarchical differentiation, increased epigenomic bivalency may reflect acquisition of a more primitive 
chromatin state [8, 52, 53]. Of relevance, stem cell niches are known to be hypoxic [54-57]. As cancer 
development is thought to be sustained by cancer stem cells [58-61], it is tempting to speculate about a 
possible role for bivalent marking in re-establishing a ‘poised’ gene status, and that hypoxic 
microenvironment selects for or drives tumor plasticity through acquisition of a less differentiated 
epigenome. In this study, we applied severe hypoxic conditions (<0.02% O2) to achieve a semi-
synchronized cell population response. As tumor cells are subjected to constantly fluctuating oxygen 
concentrations due to poor vasculature, the effect of exposure to varying hypoxic as well as cycling 
hypoxia-reoxygenation conditions on epigenomic remodeling and associated transcriptional changes 
needs to be addressed [62]. Repetitive exposure to hypoxia/reoxygenation-stress may impose a more 
realistic micro-environment and concomitant selection-pressure on a cancer cell population and support 
increased tumor plasticity and malignant progression. Our observations put forward the exciting possibility 
that repeated exposure to hypoxia may promote or select for stem-ness or cancer stem cell phenotypes. 
To our knowledge, our study for the first time combines analysis of dynamic data sets on gene expression 
and histone methylation in the context of adaptation to acute environmental changes. The number of 
studies on altered chromatin states and the role of epigenetic modifiers, e.g. in the context of 
embryogenesis, spermatogenesis, metabolic disorders and tumorigenesis steadily increases [52, 63]. 
Combined epigenomic profiling and detailed analysis of transcriptional reprogramming will be crucial for 
fundamental understanding of pluripotency and clinical application of induced precursor cells. 
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Supplemental Methods 
Chromatin immunoprecipitation (ChIP) assays    
Cells were fixed in Phosphate Buffered Saline (PBS) containing 1% formaldehyde. Cross-linking was 
allowed to proceed for 10 min at room temperature and stopped by a 5 minute incubation with glycine at a 
final concentration of 0.125 M. Fixed cells were washed twice with PBS and harvested in SDS buffer (50
mM Tris at pH 8.1, 0.5% SDS, 100 mM NaCl, 5 mM EDTA), supplemented with protease inhibitors 
(Aprotinin, Antipain and Leupeptin all at 5µg/ml and 1 mM PMSF). Cells were pelleted by centrifugation, 
and suspended in IP buffer (100 mM Tris at pH 8.6, 100 mM NaCl, 0.3% SDS, 1.7% Triton X-100, and 5 
mM EDTA), containing protease inhibitors. Cells were disrupted by sonication, yielding genomic DNA 
fragments with a bulk size of 200-500 bp. For each immunoprecipitation, 1.2 ml of lysate was pre-cleared 
by adding of 35 µl of blocked protein A beads (Protein A-Sepharose/ CL-4B, GE Healthcare, Piscataway, 
NJ, USA; 0.5mg/ml fatty acid-free BSA, Sigma; and 0.2 mg/ml herring sperm DNA in TE), followed by 
centrifugation. 12 µl aliquots of pre-cleared suspension were put aside as input DNA and kept at 4°C. 
Samples were immunoprecipitated overnight at 4°C with primary antibodies. Immune complexes were 
recovered by adding 40 µl of blocked protein A beads (GE Healthcare) and incubated for 4 hours at 4°C. 
Beads were washed three times in 1ml of Mixed Micelle Buffer (20 mM Tris at pH 8.1, 150 mM NaCl, 5 
mM EDTA, 5% w/v sucrose, 1% Triton X-100, and 0.2% SDS), twice in 1 ml of Buffer 500 (50mM HEPES 
at pH 7.5, 0.1% w/v Sodium Deoxycholate, 1% Triton X-100, and 1 mM EDTA), twice in 1 ml of LiCl 
Detergent Wash Buffer (10 mM Tris at pH 8.0, 0.5% Sodium Deoxycholate, 0.5% NP-40, 250 mM LiCl, 
and 1 mM EDTA), and once in 1 ml of TE. Immune complexes were eluted from beads in 250 µl elution 
buffer (1% SDS; and 0.1M NaHCO3) for 2 hours at 65°C with continuous shaking at 1000rpm, and after 
centrifugation, supernatants were collected. 250 µl elution buffer was added to input DNA samples and 
these were processed in parallel with eluted samples. Crosslinks were reversed overnight at 65°C, 
followed by a 2 hours digestion with RNAse A at 37°C and 2 hours proteinase K (0.2 µg/µl) at 55°C. DNA 
fragments were recovered using QIAquick PCR purification columns (Qiagen, Hilden, Germany), 
according to manufacturers’ instructions. Samples were eluted in 75 µl EB buffer and checked for 
enrichment using qPCR before deep sequencing was applied on the immunoprecipitated DNA.  
Protein isolation and Western blot analysis 
For protein extraction cells were washed twice with cold PBS and lysed in RIPA buffer (150 mM NaCl, 1% 
NP-40, 0.5% w/v Sodium Deoxycholate, 0.1% SDS, 50 mM Tris at pH 8.0, 5 mM EDTA) supplemented 
with protease and phosphatase inhibitors (5 mM Benzamidine, 5 µg/ml Antipain, 5 µg/ml Leupeptin, 5 
µg/µl Aprotinin, 1 mM Sodium Vanadate, 10 mM Sodium Fluoride, 10 mM Pyrophosphate, 10 mM ß-
glycerophosphate, 0.5 mM DTT and 1mM PMSF). Lysates were subjected to two freeze-thow cycles in 
liquid nitrogen, followed by sonication on ice with a probe sonicator (Soniprep 150; MSE, London, UK) for 
12 cycli (1 sec ON, 1 sec OFF) with amplitude 5. After 10 min centrifugation at 13.200 rpm (4°C), the 
supernatant was transferred to a fresh tube and protein concentration was determined using a BCA 
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protein assay kit (Pierce/Thermo Fisher Scientific, Rockford, IL, USA) according to the manufacturer’s 
protocols on a Benchmark 550 Micro-plate Reader (Bio-Rad). 
For immunoblotting (IB) equal amounts of protein were boiled in Laemmli buffer for 5 min and loaded on 
9-15% polyacrylamide gels. Following separation by SDS-PAGE, proteins were transferred onto 
polyvinylidene fluoride (PVDF) membranes (GE Healthcare). Ponceau S (Sigma) staining was used to 
check protein transfer. Subsequently, PVDF membranes were blocked with 3.4% non-fat dry milk 
(Protifar; Nutricia, Zoetermeer, the Netherlands) in PBS containing 0.1% Tween-20 (pH 7.5) for 1 hour at 
RT, followed by an overnight incubation at 4°C  with the primary antibody (see Supplementary Table 2). 
After extensive washing with PBS/0.2% Tween-20, membranes were probed with corresponding 
horseradish peroxidase conjugated secondary antibodies for 1 hour at RT: rat-anti-mouse (1:5000; 
DAKO, Glostrup, Denmark) and donkey-anti-rabbit (1:15.000; Jackson Lab, Bar Harbor, ME, USA), to 
detect monoclonal and polyclonal primary antibodies respectively. Signals were detected on 
autoradiograms using enhanced chemoluminescence (ECL; Pierce). Intensity of the bands was quantified 
with Quantity One software (Bio-Rad) and plots were generated using GraphPad Prism, version 4.03 for 
Windows (GraphPad Software, San Diego, CA, USA). Data was statistically analyzed by performing 2-
tailed paired t-tests using Microsoft Excel. Data given is expressed as means ± standard deviation (SD) 
and considered significant at p<0.05. *, ** and *** indicate p<0.05, 0.01 and 0,001, respectively. 
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Chapter 8 
General discussion 
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Introduction 
Fast and comprehensive data processing and enhancing biological interpretation is essential in complex 
systems biology studies. This thesis aims to take on this challenge by constructing standardized 
approaches for epigenomics and cistromics data analysis.  Chapter 2 evaluates the requirements of 
epigenomics and cistromics data analysis tools and shows how the enrichR toolkit can serve as the 
missing link between a variety of other available tools. Chapter 3 shows the importance of finding 
standardized pre-processing approaches for epigenomics and cistromics data stemming from microarray 
technology. Chapter 4 assesses the requirements for the processing of H3K27me3 histone modification 
ChIP-seq data and the power of the standardized protocol derived from this assessment. Chapter 5 
proposes a work flow to integrate existing biological pathway knowledge from several sources to enable a 
comprehensive biological interpretation of newly generated data. And finally, chapters 6 and 7 show the 
power of standardized systems biology approaches when applied to cistromics and epigenomics studies. 
This chapter evaluates the limits of standardization and automation of epigenomics and cistromics 
analysis approaches and addresses the future of systems biology research in general. 
 
Standardization of epigenomics and cistromics analysis approaches 
As the number of data types increases, the number of putative analysis paths increases exponentially. It 
is impossible to know a priori which of these paths will be of interest. This does not only require a certain 
level of expertise, but also non-standard tools. When a bioinformatician creates such a tool, he is 
essentially developing it for other bioinformaticians, which has a large impact on the requirements: it 
should be flexible, modular and extendible. This means that strictly speaking, such a tool is not a 
standard software package, but a set of smaller tools or modules, which bioinformaticians can add to their 
own analysis work flows in a non-obtrusive way. In this context, a bioinformatician is anyone who can 
successfully incorporate these modules. Hence, there are two important requirements for standardization 
of analysis approaches and tools: (i) to maximize code reuse, the tools should be available as open-
source; (ii) the tools should adhere to current design standards of the field, taking standard input data 
formats and generating standard output formats, thereby facilitating their dissemination in the scientific 
community. 
Data from different fields all have their own analysis pipelines (figure 1). Standardized pipelines are for 
the larger part in place for transcriptomics, metabolomics, proteomics and genetics. The tools and 
approaches presented in this thesis in chapter 2, 3 and 4 complete the framework by adding standards 
for epigenomics and cistromics data analysis. Individual pipelines can be integrated into work-flow 
wrappers. In general, such wrappers are automated services where users upload their data and with only 
minimal further input, receive processed data back after some time. An example is arrayanalysis.org [1], 
that automates quality control, data preprocessing, statistical analysis and even biological interpretation of 
transcriptomics data using Pathvisio and Wikipathways [2,3]. Arrayanalysis.org makes use of open-
source standards for bioinformatics analysis tools by employing R and Bioconductor packages [4]. 
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Examples of more generalized frameworks for integrative workflows are Galaxy [5] and GenePattern [6]. 
Both are standardized data integration platforms that aim to make the power of bioinformatics tools 
accessible to scientists that lack the necessary computer programming skills. Galaxy and GenePattern 
put emphasis on small, easy to integrate tools that can be used as building blocks to design reproducible 
analysis pipelines that capture the methods, parameters and data used to produce analysis results.  
  
 
Figure 1: Schematic of systems biology data analysis. Contributions for epigenomics and cistromics as 
presented in this thesis are highlighted on the left. 
 
One of the major threats for any bioinformatics tool is that it loses support, either from their developers or 
from the scientific community. There are numerous examples of online services, such as microarray 
quality control services RACE [7] and AMarge [8], that lost support, became inaccessible and 
subsequently forgotten. The enrichR toolkit presented in chapter 2 has no graphical user interface and as 
such may appear to target a small, specific user base with ample experience with R. However, by having 
as many high-level functions as possible, with suitable defaults, enrichR is able to perform complex tasks 
in just a few lines of code. Additionally, because enrichR is open-source and fully compatible with R and 
Bioconductor, it can be implemented in any framework that is compatible with this open-source standard 
in bioinformatics and biostatistics analysis, including Galaxy, GenePattern and arrayanalysis.org, but it 
can be run locally as a stand-alone tool as well. Although there are no guarantees in life nor in science, 
this should stimulate reusing the functionality of enrichR in future applications. 
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The limits of standardization of epigenomics and cistromics data preprocessing 
Normalization standards are well defined for many single-channel and two-channel platforms and 
applications [9,10,11,12]. For two-channel microarray technology, many of these normalization 
approaches were originally designed for transcriptomics studies. In such studies, the two channels on the 
microarray comprise transcript samples, often corresponding to different conditions between which only a 
small amount of differential gene expression is expected. In contrast, the two channels in epigenomics 
and cistromics studies comprise an enriched sample, containing short DNA sequences of epigenetic 
modification or DNA-interacting protein locations, and a total DNA reference sample, containing short 
DNA sequences corresponding to the whole genome of the investigated biological system. Additionally, 
epigenomics and cistromics microarray data is a convolution of enriched probe and unenriched probe 
signals. These signals arise from sequences that are overrepresented or underrepresented, respectively, 
in the enriched DNA sample, corresponding to regions in the genome that are enriched and unenriched 
for binding of a DNA-interacting protein or presence of a specific epigenetic modification. This means that 
assumptions underlying transcriptomics normalization approaches will in general not hold for epigenomics 
and cistromics microarray data. 
The results of chapter 3 suggest that using normalization approaches that do not take the unique 
structure of two-channel epigenomics and cistromics microarray data into account (LOWESS [12], 
quantile [10] and VSN normalization [13]), lower both sensitivity and specificity of identifying enriched 
regions in the genome compared to methods that do (Tukey’s biweight scaling and T-quantile 
normalization [10]). Interestingly, Peng’s method [14] underperforms, even though it was specifically 
developed for ChIP-on-chip technology and as such would appear to be the method of choice for 
cistromics and epigenomics microarray data. The method was originally developed for studies of male-
specific lethal (MSL) complex in Drosophila [15,16] and worked well for this biological system and the 
microarray design for this species. These results serve as a general warning that firstly, canonical data 
normalization methods are very application dependent and their success depends on the technology and 
the biological system they were originally developed for, and secondly, that incorrect use can severely 
impact the reliability of the biological interpretation of the data. In conclusion, normalization methods can 
be standardized only for a specific technology and application, and since technology is never at a 
standstill, this standardization will remain a continuing effort. 
 
Efforts to standardize pre-processing steps for high-throughput sequencing technology have recently 
yielded standardized work-flows and analysis tools for MeDIP-seq analysis [17] and generic MeDIP-seq, 
ChIP-seq and RNA-seq quality control [18]. In chapter 4, a full standardized protocol is presented for 
H3K27me3 ChIP-seq data analysis, tuned to studies of dynamic biological systems. There are similar 
approaches reported in literature for this specific histone modification, but none are fully standardized. By 
restricting enrichment finding to predefined regions [19,20,21,22], by not taking input sample data or an 
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estimated null distribution into account [20,22,23,24, 25], or by using enrichment finding approaches 
without settings adapted to the specific H3K27me3 enrichment profile [26,27,28], none of them offer a 
robust, genome-wide H3K27me3 enrichment finding approach. Additionally, the majority of the 
approaches skimp on data normalization, opting instead for a qualitative data analysis and comparison 
[24,25,26,27,28].  As such, the presented protocol is the first to enable robust, genome-wide identification 
of enrichment and quantitative data comparison for H3K27me3 ChIP-seq data.  
Since the protocol was developed specifically to study H3K27me3 histone modifications, not all of the 
constructed steps are sufficiently generic to accommodate any ChIP-seq experiment. Alignment of raw 
reads using Novoalign, paired-end mappings and leaving out reads that align to more than one region in 
the genome leads to the most reliable mapping. This mapping is irrespective of the studied biological 
system or histone modification and hence is generic for any ChIP-seq experiment comprising paired-end 
reads. For example, the mappings for the H3K4me3 data presented in chapter 7 were generated using 
the same protocol, despite the fact that it comprises a different distribution, profile and biological function 
than H3K27me3 histone modifications.  
The enrichment finding step in the presented protocol is completely optimized for the blanketing 
H3K27me3 histone modification. When the expected enrichment profile in a ChIP-seq experiment does 
not follow such a blanketing distribution, adapted settings will of course yield more reliable results. 
Similarly, data normalization depends highly on the studied biological system. The approach based on 
finding stable regions of enrichment in the genome is essential when studying dynamical systems, where 
the location and total amount of epigenetic modifications or protein binding sites is highly variable 
between conditions.  Although this approach also works for systems with only a small amount of 
prospected differential sites, it is not the most efficient, especially considering that the definition of when a 
region is sufficiently stable are hard to define [29]. Other normalization approaches are more suited in 
these instances, such as scaling based on the total number of reads, or normalizing based on fitting a 
LOWESS model between different conditions using the number of reads ending up on a large number of 
predetermined genomic locations [29].  
The final step before biological interpretation is summarization of the data ending up in specific regions of 
interest in the genome. For H3K27me3 such regions were defined previously, connecting specific 
regulatory characteristics to these regions in presence of this histone modification [19], but for other 
modifications it may be more difficult. Nonetheless, regions neighboring genic loci are a logical starting 
point for any ChIP-seq experiment where integration with transcriptomics data is essential. 
 
Implications of ChIP-seq data analysis standardization for data storage 
Online data analysis services are meant to automate and speed up those data processing tasks that 
require minimal user input, which leaves more time for the actual biological interpretation of the data. A 
major downside is the enormous impact such services have on the required infrastructure. In the age of 
high-throughput sequencing, especially data storage is a severe issue. The raw reads of a single ChIP-
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seq sample can take up many gigabytes of storage, but after data pre-processing and summarization, 
files are smaller by a factor of at least ten [30]. Hence, it will become important in the future to consider for 
each stage in the work flow whether it is necessary to keep the output data to be able to answer 
questions arising during the biological interpretation. By standardization of high-throughput sequencing 
work flows, there will often be no need to repeat analysis steps once they have been completed using the 
state-of-the-art approach and hence many intermediary results will be redundant.  
Most of the analysis steps described in the protocol for blanketing histone modifications of chapter 4 need 
to be performed only once during the course of a research project. Mappings obtained after aligning raw 
reads using Novoalign [31] are robust and can be considered final, except when a new genome build 
becomes available. Apart from coordinate transformations, the differences between genome builds are 
relatively small in genic regions, since these are well conserved. Hence, aligning to a new or different 
genome build will in most cases have a minimum impact on the biological interpretation of the data and 
unless specific intergenic regions are of interest [21,24], where insertions, deletions or crossovers may be 
added or removed by genome build updates, the alignment step need not be repeated.  
As long as input sample reads are taken into account to robustly account for background anomalies, and 
the broad peak settings presented in chapter 4 are used, the enrichment finding step for blanketing 
histone modification ChIP-seq data also needs be performed only once. The same holds for data 
normalization, where for this type of ChIP-seq data, scaling based on regions with stable enrichment 
between conditions is a robust and deterministic approach. The only step that may have to be repeated is 
the data summarization step, because it depends strongly on the biological system studied. Depending 
on the research question, biological interpretation may be restricted to specific regions of interest, such as 
promoters, thereby lowering the memory and computational footprint. But inevitably, during the 
interpretation phase, it will become necessary to look at other regions as well.  
When the above concepts are applied to the example of the H3K27me3 ChIP-seq data used for the 
results of chapter 4 and chapter 7, only the files containing the genomic location and intensity of 
enrichment peaks are essential to keep for a longer period of time. Even though the H3K27me3 ChIP-seq 
data presented herein is a relatively small set of four samples, this lowers the required storage capacity 
dramatically, illustrating that for larger datasets, removing redundant data becomes absolutely essential. 
 
Using existing biological pathway knowledge in data analysis 
Integrating existing biological pathway knowledge enables a comprehensive biological interpretation of 
newly generated epigenomics and cistromics data. The quality of this knowledge varies greatly between 
online pathway repositories. The example for the fatty acid metabolism pathways in chapter 5 shows that 
none of the tested repositories (BioCarta [32], Reactome [33], KEGG [34] and GenMAPP [35,36]) offer 
comprehensive entries, often being complementary to each other. Although Reactome offers the most 
complete content, it is hampered by the underlying curation process, that is concise but slow in updating 
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that content. Integrating the biological pathway knowledge from all these databases with current literature 
and expert knowledge is therefore crucial for creating canonical, comprehensive biological pathways. 
The method presented in chapter 5 to improve and curate fatty acid metabolism pathways is an 
exhaustive but time consuming approach. Using it to create a complete map of all the processes 
occurring in a biological system is therefore impossible. Thankfully, there have been developments in 
recent years to improve pathway content on a much greater scale. Firstly, there are commercial efforts 
such as MetaCore from GeneGo Inc., that offer proprietary manually curated databases, that are claimed 
to be the most comprehensive in the field. Secondly, there are community driven approaches. Several 
efforts have been made to create such community driven repositories, such as the Pathway Interaction 
Database [37] and the possibility for submitting content to Reactome [33], but arguably the most 
significant one is WikiPathways [3]. WikiPathways uses the community curation principle of Wikipedia to 
form a comprehensive repository of canonical pathways. The plus side is that pathways are constantly 
curated in parallel leading to a much higher rate of improved pathways in a shorter amount of time. A 
downside is that the power of community curation depends largely on the size of the user base, which if 
not sufficiently large, will impact the size and overall quality of the content. Hence to increase support, the 
user-experience and the curation process itself should be as smooth and straightforward as possible. For 
example, future developments in this area for Wikipathways entail automated suggestions for pathway 
content improvement, easing the curation process by presenting information that would have otherwise 
taken considerable effort to salvage. Such suggestions can be retrieved from other content providers, 
generated by literature text-mining or visualized using omics data from public data repositories [38]. 
 
When using omics approaches, we mostly focus on presumably static images of a system under a given 
condition or moment in time. This is of course a simplification, as biological systems are extremely 
dynamic. A growing development taking place in the pathway field is the creation of mathematical models 
to simulate the dynamic behavior of a biological system. The Biomodels database [39] houses a plethora 
of such dynamic models, including models of for example signaling pathways, circadian rhythm and fatty 
acid transport across membranes [40]. Generally such models are created using bottom-up approaches 
instead of omics guided top-down approaches, measuring levels and states of a handful of proteins and 
metabolites of canonical processes in a controlled environment over a period of time to estimate model 
parameters [40]. Especially when studying cistromics, dynamic modeling can lead to new insights. In the 
ER-α study of chapter 5, such a model could for example comprise the ER-α signaling cascade, starting 
with stimulation by an estrogenic compound and ending with activated ER-α entering the nucleus to bind 
to target genes. This model can assist in determining the most suitable point in time to measure both ER-
α binding targets using cistromics as well as gene expression using transcriptomics in a biological system 
stimulated by an estrogenic compound. By tuning the time of measurement, the amount of targets 
identified by cistromics is maximized and the amount of gene expression changes arising from secondary 
effects, i.e. effects unassociated with direct binding of activated ER-α, is minimized. Efforts are underway 
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to create an integrated dynamic model for estrogen signaling in breast cancer cells to improve the 
understanding of their susceptibility or resistance to endocrine therapy, but currently there are only 
preliminary mathematical models available of the basic decision circuits in breast cancer cells [41]. In 
general, dynamic modeling is beneficial for cistromics studies on any signaling cascade, such as insulin 
or MAPK signaling [42], that leads to the activation of a transcription factor or combination of transcription 
factors, and subsequent induction or repression of specific targets. As such, it is a development that will 
become increasingly important for cistromics and systems biology research in the coming years.  
 
Epigenomics and cistromics to study the molecular mechanisms of cancer 
There are many efforts to ease biological interpretation. The most well known is pathway analysis tools 
[2] to analyze data in the context of biological processes. The downside is that the pathway content used 
for such analyses is not always up-to-date with the latest discoveries in the field. Textmining [43] seeks to 
fix this problem by automated mining of the biological knowledge encoded in text documents. Regardless, 
analyzing results in a broad biological context will always require expert supervision. This means that the 
role of a bioinformatician is to develop generic tools that enable a fast and standardized analysis and that 
facilitate the biological interpretation by such experts. Chapters 2, 6 and 7 show applications of such 
standardized systems biology approaches for cistromics and epigenomics in cancer research.  
 
Estrogenic compounds such as 17β-estradiol and tamoxifen, are among the most prescribed drugs to 
treat breast cancer. Both compounds activate estrogen receptor α  (ER-α) which subsequently binds to 
the promoter of target genes, leading to up-regulation of some genes and down regulation of others at the 
same time. Additionally, tamoxifen can lead to different transcriptional effects in the breast compared to 
the endometrium. Both events may be caused by differential co-regulator recruitment. In chapter 2 and 6, 
systems biology approaches prove essential to dissect the molecular mechanisms underlying this 
differential co-regulator recruitment. Using ChIP-on-chip technology, 904 ER-α targets were identified in 
T47D breast cancer cells. Using gene ontology analysis and findings in literature, a sub-selection of these 
targets was created. For this selection of targets, it was verified that indeed up- or down-regulation of 
transcription correlates with the selective recruitment of co-activators or co-repressors, respectively, both 
for 17β-estradiol and tamoxifen stimulation, and both for breast (T47D) and endometrial carcinoma cells 
(ECC1).  
The findings of chapter 6 are complemented by the results of chapter 2. By integrating the original ChIP-
on-chip dataset with a 17β-estradiol stimulated T47D transcriptomics data from an online repository [44], 
we distinguished targets whose transcription is induced and targets whose transcription is repressed 
upon binding of ER-α. Motif analysis of the promoters of these targets showed that up-regulated targets 
were characterized by estrogen response element (ERE) half-sites, while down-regulated targets are 
characterized by full canonical ERE motifs. A gene ontology analysis on this set of targets indicated that 
up-regulated targets are involved in cell cycle and proliferation, in accordance with observations made 
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previously [45], while the down-regulated targets are mostly involved in metabolism and regulation of 
transcription. This suggests that the binding event of activated ER-α on the promoter is different for 
induced targets then it is for repressed targets. Combined, these results support the notion that 
recruitment of co-regulators at target gene promoters and their expression levels determine the effect of 
ER-α on gene expression to a large extent and additionally give a mechanism through which tamoxifen 
can regulate genes in opposite direction in breast and endometrial cancer cells. Applying these findings 
and the developed approaches on other estrogenic compounds, other cancer cell lines and clinical 
samples, may in the future enable predicting the action of novel estrogenic drugs in the human 
endometrium and other tissues and more importantly to identify patients who will benefit from hormonal 
therapies.  
In chapter 7, ChIP-seq analysis of H3K4me3 and H3K27me3 histone modifications are combined with 
microarray expression data in MCF7 breast cancer cells, to study the relation between epigenetic and 
transcriptional changes upon hypoxic exposure and subsequent reoxygenation. Although a rapid global 
increase in both H3K4me3 and H3K27me3 is observed, which is largely reversed by reoxygenation, there 
are many subtle effects occurring on a smaller scale. The H3K4me3 enrichment profile at the transcription 
start sites remained largely stable under hypoxia. In sharp contrast, there is a clear gain of H3K27me3 
marking around the TSS of genes already affected by the H3K4me3 modification, resulting in bivalent 
marking. Genes with hypoxia induced bivalency showed a significant overlap with genes known to be 
bivalently marked in embryonic stem cells, suggesting that hypoxia induced bivalency may result in 
acquisition of stem cell-like epigenetic marking. Most interestingly, this group of genes appeared resistant 
to the global demethylation observed during reoxygenation. Systems biology approaches enabled 
discovery of these subtle effects. 
Epigenomics and cistromics approaches such as described in this thesis have been applied in cancer 
research for a long time. The key motivation is that it has long been known that cancer is characterized by 
system-wide deregulation [46], including disruption of epigenetic mechanisms [47,48]. Epigenetics has 
even become an important cornerstone of modern oncology [49]. Yet, epigenomics and cistromics 
approaches are being increasingly adopted in other fields as well. Although the extent of the impact is a 
gray area, it is well established that a pregnant woman's habits affect the health of her unborn child. 
When such impacts are severe, they may leave their mark on the genome of future generations through 
epigenetic mechanisms. Recent epigenomics studies of the Dutch Hongerwinter and the Great Chinese 
Famine [50] have demonstrated this, identifying small but persistent DNA methylation differences that had 
been passed on to later generations [51]. These small differences are genuine, but due to the nature of 
stable biological systems, the effect on phenotype is expected to be only slight. Hence, also in these 
fields, systems biology approaches are key to distinguish small methylation changes from background 
noise and reliably assess the impact of such changes on the condition of the system. 
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Future implications 
It has been well established that panels of genes contribute to complex traits, with any single gene 
accounting for no more than a few percent of the overall variability of the trait [52]. Although classical 
case-control studies in the order of 1000 individuals are sufficient for identifying the genes in these 
panels, systems biology approaches enhance the process by providing candidate genes with a 
comprehensive biological context, thereby revealing key mechanisms underlying such complex traits. Yet, 
genomics, cistromics and epigenomics are not yet widely adopted in clinical applications. To facilitate the 
progression toward the clinic, standardization and clear documentation of the procedures for data 
preprocessing and interpretation are vital [53]. As such, the approaches presented in this thesis 
contribute to this development. Once such approaches have been applied in a clinical setting, marker 
profiles and novel drug targets can be generated for specific traits. These profiles can then be used as a 
screening tool to identify patients who could potentially benefit from specific treatments, or at an earlier 
stage to identify individuals with an increased risk at specific diseases. A recent development is people 
taking matters into their own hands by having themselves screened using over-the-counter tests. An 
example of a company offering such services is 23andMe, where any individual can submit a saliva 
sample to have it analyzed for over a million genetic variations for a relatively low price.  
Besides offering these services, some companies additionally use the data of customers for research 
purposes. Although this novel way of promoting research participation is an exciting development in 
modern health and medicine [54], it is important to realize the impact of this development. When a subject 
is studied as a system, measuring metabolites and proteins on a large scale and gene expression, 
genetic variation and epigenetic variation genome wide instead of looking at a few individual markers and 
genes, one is prone to uncover results that are beyond the primary research questions but nonetheless 
clinically relevant for the subject. How to handle such incidental findings is not trivial. Services like 
23andMe, mostly give trivial information, like eye color, hair type and genetic similarity to Neanderthals, 
but additionally, several indicators are given showing susceptibility to specific diseases. Although genetic 
variation can impact the risk of developing a serious illness, other factors also have a large influence, like 
nutrition, exercise and other environmental factors: nature versus nurture. It is for instance well 
established that diet and exercise have at least as much impact on the onset of type 2 diabetes as the 
presence of genetic risk factors [55,56]. Giving risk indications for serious conditions based purely on one 
characteristic of a system is not only ethically debatable, it would downright be incorrect and a layperson 
may improperly interpret such results and undertake unnecessary action [57]. The successful regulation 
of these developments [58] will therefore be key to the success of implementing systems biology research 
in everyday life.  
 
Conclusions 
Of all the steps involved in the analysis of epigenomics and cistromics data, the biological interpretation 
will remain the step that requires curation by human experts. The role of a bioinformatician should always 
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be to make that step as smooth as possible for the biologist by creating standardized, biology driven 
approaches. The work presented in this thesis contributes to the standardization of analysis approaches 
in the field of epigenomics and cistromics by providing standardized approaches for data pre-processing 
of ChIP-on-chip and MeDIP-on-chip microarray data, for data pre-processing of blanketing histone 
modification ChIP-seq data, for human expert curation of existing biological knowledge to enable a 
comprehensive biological interpretation, and lastly for the biological interpretation of epigenomics and 
cistromics data. Applying the developed approaches in biological research has yielded new insights in the 
mechanisms behind estrogen-dependent breast cancer and epigenetic reprogramming in hypoxic tumors. 
Future developments should be directed towards automating the methods and making them available as 
services to the scientific community. The work presented in this thesis is only a small part of the field of 
systems biology. All efforts in this field together have revolutionized biological research. And in this age of 
biology, it is only a matter of time before they claim their justly place in the clinic and everyday life as well. 
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Om biologie echt te kunnen begrijpen, moeten we het bestuderen als een systeem. Het vakgebied dat 
zich met dit soort onderzoek bezig houdt heet systeembiologie. Vanuit een technisch perspectief wordt 
een stabiel systeem gekenmerkt door feedback loops en een grote mate van redundantie. Dit dogma 
gaat ook op voor biologische systemen. Het aanbrengen van een kleine wijziging in het biologische 
systeem, zoals een veranderde activiteit van een eiwit als gevolg van een mutatie, zal over het algemeen 
slechts een kleine invloed hebben op het fenotype, maar zal desondanks een heel scala aan biologische 
pathways beïnvloeden. Dit wordt gecompliceerder bij het bestuderen van complexe aandoeningen zoals 
kanker, dat wordt gekenmerkt door een systeemwijde deregulering van genetische en epigenetische 
processen, die op hun beurt weer een heel netwerk van met elkaar verweven biologische pathways 
verstoren. Een huis-tuin-en-keuken voorbeeld is voeding, dat bestaat uit complexe mengsels van 
verschillende bioactieve stoffen, die bij inname een overvloed aan processen activeren. De enige manier 
om dergelijke complexe interacties te ontrafelen, is door gebruik te maken van systeembiologie 
benaderingen. Niet langer gericht op het meten van afzonderlijke biologische entiteiten, omvat modern 
biologisch onderzoek nu metingen op meerdere moleculaire niveaus met behulp van zogenaamde 
“omics” technologie. Dankzij deze technologie, kunnen gentranscriptie, eiwitten en metaboliet niveaus, 
eiwit-eiwit interacties, eiwit-DNA-interacties, genetische variatie en vele andere niveaus in één integratief 
biologisch kader worden geanalyseerd. De komst van deze technologie heeft er niet alleen voor gezorgd 
dat de hoeveelheid data in biologisch onderzoek is geëxplodeerd, maar ook dat de interpretatie van deze 
bergen informatie uitermate complex is geworden. Dit is waar bioinformatica om de hoek komt kijken. De 
grote uitdaging van de bioinformatica is computerprocedures te ontwikkelen om biologie te destilleren uit 
de soep van enen en nullen en is als zodanig uitgegroeid tot een van de belangrijkste hoekstenen van 
modern biomedisch onderzoek. 
Ongetwijfeld de meest succesvolle omics technologie van de laatste tien jaar is transcriptomics, om 
genexpressie te bestuderen in een genoomwijde setting. Maar meer en meer beseffen we dat we niet 
alleen geïnteresseerd zijn in het identificeren van veranderingen in genexpressie tussen de verschillende 
condities, maar ook in de complexe regulatie achter deze veranderingen. In dit proefschrift staat 
gentranscriptie regulatie vanuit het cistroom en het epigenoom centraal. Het cistroom is gedefinieerd als 
de complete genoomwijde set van de cis-werkende sites op het DNA, zoals transcriptiefactor 
bindingsplaatsen, behorende bij een trans-werkende factor, zoals een transcriptiefactor. De complete 
genoomwijde set van epigenetische markeringen staat bekend als het epigenoom. Dergelijke 
epigenetische markeringen zijn erfelijke chromatine modificaties die los staan van veranderingen in de 
onderliggende DNA sequentie, die genexpressie en meer in het algemeen fenotype beïnvloeden. De 
meest bestudeerde epigenetische markeringen zijn DNA methylatie en chemische modificaties van histon 
staarten. DNA methylatie vindt meestal plaats in gebieden met een CpG di-nucleotiden. Loci met een 
grote hoeveelheid CpGs staan bekend als CpG eilanden, die oververtegenwoordigd zijn in die regio's in 
het DNA die gekoppeld zijn aan genen. Wanneer een CpG eiland wordt gemethyleerd, dan wordt door 
belemmering van de binding van de benodigde transcriptiefactoren en co-regulatoren de transcriptie van 
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het nabijgelegen gen onderdrukt. Histonen zijn eiwitten die fungeren als spoelen waar DNA omheen is 
gewonden, daarmee structurele eenheden vormend die nucleosomen worden genoemd. Een histon 
bestaat op zijn beurt uit sub-eenheden, met lange aminozuur ketens die buiten het complex uitsteken. 
Residuen in deze histon “staarten” kunnen chemische modificaties ondergaan die gentranscriptie kunnen 
induceren of belemmeren. Epigenetische markeringen hebben niet alleen hun uitwerking op de conditie 
van een biologisch systeem, maar dankzij hun plastische aard zijn ze ook gevoelig voor externe 
invloeden, zoals ziekte en het milieu. De algemene consensus is dat als dergelijke externe invloeden 
ernstig zijn, zoals bijvoorbeeld tijdens een periode van hongersnood, de epigenetische markeringen 
worden doorgegeven aan toekomstige generaties en op deze wijze bijdragen aan het 
aanpassingsvermogen van organismen. In deze visie worden veranderingen in de epigenetische 
markeringen gezien als "epigenetische littekens": belangrijke gebeurtenissen in het leven drukken hun 
stempel op het genoom van toekomstige generaties.  
 
De studie van de cistroom en epigenoom in biologische systemen in een genoomwijde setting met behulp 
van omics technologie, wordt aangeduid als respectievelijk cistromics en epigenomics. De belangrijkste 
technologie om het epigenoom en het cistroom de bestuderen maakt gebruik van een combinatie van 
chromatine immunoprecipitatie met microarrays (ChIP-on-chip) of meer recentelijk met high-throughput 
sequencing (ChIP-seq). Met behulp van ChIP-on-chip of ChIP-seq technologie in combinatie met 
bioinformatica tools, kunnen we genoomwijde kaarten maken van verrijking voor specifieke DNA-
interagerende eiwitten, histon modificaties en DNA methylatie. Dit proefschrift richt zich op belangrijke 
analyse vraagstukken rond cistromics en epigenomics data in elke stap van het proces, van ruwe 
meetgegevens tot biologische interpretatie. Het belangrijkste doel van dit proefschrift is het verbeteren 
van cistromics en epigenomics data analyse door de implementatie van gestandaardiseerde, integratieve 
systeembiologische methoden. Cistromics en epigenomics lenen zich uitstekend voor verkennende 
analyses, om nieuwe hypotheses te genereren die vervolgens getest kunnen worden in het lab. Voor een 
completere interpretatie, is integratie van verschillende omics technologieën en verschillende 
bioinformatica benaderingen nodig. Aangezien we bij cistromics en epigenomics geïnteresseerd zijn in 
regulatie van gentranscriptie, is voor een zinvolle interpretatie de integratie met transcriptomics data een 
eerste vereiste. Daarnaast zijn we geïnteresseerd in het ontdekken van cis-werkende motieven aanwezig 
in de onderliggende DNA sequenties van de geïdentificeerde verrijkte regio's, die mogelijk de binding van 
DNA interagerende eiwitten sturen. In hoofdstuk 2 wordt besproken aan welke eisen een cistromics en 
epigenomics work-flow moet voldoen en de enrichR toolkit die het mogelijk maakt om dergelijke analyses 
snel en grondig uit te voeren. EnrichR is gebouwd met behulp van Bioconductor, dat bestaat uit een 
uitgebreide, open-source collectie van bioinformatica analyse pakketten, en is zelf ook beschikbaar als 
open-source. 
De eerste stap in elke analyse met behulp van omics technologie is het voorbewerken (pre-processing) 
van de ruwe metingen, om te corrigeren voor variantie van de technische aard. ChIP-on-chip en MeDIP-
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on-chip is over het algemeen gebaseerd op twee-kanaals microarray technologie. Eén kanaal bevat het 
door immunoprecipitatie verrijkte sample, terwijl de andere een totaal DNA sample bevat, dat bestaat uit 
alle stukjes sequentie van het onderzochte organisme. De verhouding in intensiteit tussen de kanalen 
wordt gebruikt als maatregel om verrijkte regio's in het genoom te bepalen, welke overeenkomen met de 
DNA-interagerende eiwit bindingsites of sites met specifieke epigenetische modificaties. Deze opzet is 
anders dan twee-kanaals transcriptomics microarrays, waar beide kanalen transcript samples bevatten, in 
veel gevallen overeenkomend met twee verschillende experimentele condities. De algemene 
veronderstelling in transcriptomics studies is dat het merendeel van de genen qua expressie onveranderd 
zijn tussen condities, en dus de meerderheid van de spots op een microarray een vergelijkbaar signaal 
tussen de kanalen zal hebben. In epigenomics en cistromics studies gaat deze aanname echter niet op 
aangezien de samples in de twee kanalen zo fundamenteel verschillend zijn, hetgeen suggereert dat veel 
data normalisatie benaderingen ontwikkeld voor twee-kanaals transcriptomics microarray data niet 
geschikt zijn. Om te bepalen of dit inderdaad het geval is, hebben we de prestaties van verschillende 
bekende transcriptomics normalisatie strategieën geëvalueerd wanneer toegepast op ChIP-on-chip en 
MeDIP-on-chip data. De resultaten besproken in hoofdstuk 3 laten zien dat sommige normalisatie 
strategieën nog destructiever zijn dan verwacht voor de betrouwbaarheid van de biologische interpretatie.  
In hoofdstuk 4 passen we wat we geleerd hebben van ChIP-on-chip en MeDIP-on-chip technologie toe 
om een optimaal protocol te ontwerpen voor verwerking van H3K27me3 histon modificatie ChIP-seq data. 
De H3K27me3 modificatie onderdrukt gentranscriptie bij aanwezigheid rond de promoter. Er zijn 
specifieke uitdagingen voor het bestuderen van deze histon modificatie, met name in de dynamische 
biologische systemen waar naar verwachting veel veranderingen in de epigenetische markeringen zullen 
plaatsvinden, zowel in locatie als aantal. Ten eerste zijn algoritmes voor het lokaliseren van verrijking 
geoptimaliseerd voor scherpe, sterk gelokaliseerde pieken, maar als gevolg van de specifieke aard van 
H3K27me3 modificaties om zich uit te spreiden over grotere regionen, bestaat de data ook uit meer 
uitgesmeerde verrijkingssignalen. Ten tweede, net als ChIP-on-chip, MeDIP-on-chip en alle andere high-
throughput technologie, vereist ChIP-seq data normalisatie om te corrigeren voor technische variantie en 
het mogelijk te maken om de metingen van verschillende condities kwantitatief met elkaar te vergelijken. 
Bij het bestuderen van dynamische biologische systemen is de enige geschikte normalisatie aanpak 
gebaseerd op regio's in het genoom waar de verrijking stabiel is tussen de condities. Het is echter 
moeilijk om a priori te definiëren wanneer een regio stabiele verrijking vertoont, omdat dit sterk afhankelijk 
is van het bestudeerde biologische systeem. Met behulp van nieuw ontwikkelde, gestandaardiseerde 
procedures voor het lokaliseren van verrijking en data normalisatie hebben we deze problemen opgelost. 
Dit protocol is gebruikt om verrijking voor H3K27me3 histon modificaties genoomwijd in kaart te brengen 
voor borstkankercellen die zijn blootgesteld aan hypoxische condities. 
 
Nadat de ruwe gegevens zijn verwerkt, komt de biologie eindelijk in beeld. Er is reeds een enorme 
hoeveelheid biologische kennis beschikbaar in de biologische databases in de vorm van de interacties 
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tussen bioactieve moleculen. Deze informatie kan worden opgeslagen als individuele biochemische 
interacties of als netwerken van biochemische interacties. Wanneer een dergelijk netwerk een min of 
meer gedefinieerd biologisch proces omvat, waarbij de afzonderlijke onderdelen aansturen op een 
consistent pad dat bij activering van dat proces wordt doorlopen, spreekt men van een pathway. Een 
belangrijke stap in interpretatie van gegevens is het integreren van kennis uit biologische databases. Een 
van de meest voorkomende analyse technieken die van deze kennis gebruik maakt is pathway analyse, 
die gen gerelateerde gegevens, zoals expressie data, visualiseren op de bestaande biologische 
pathways, waardoor een eenvoudige visuele interpretatie mogelijk is. Pathways zijn statische 
representaties van biologische processen. Echter, de kwaliteit van de pathway is sterk afhankelijk van de 
kennis van haar makers en de tijd die is verstreken sinds de laatste update. In hoofdstuk 5 vergelijken we 
de inhoud van een aantal pathways voor vetzuurmetabolisme en beoordelen hun kwaliteit door ze uit te 
breiden met huidige literatuur en vervolgens te laten cureren door experts. Bij deze evaluatie ontdekten 
we grote verschillen tussen de inhoud van databases en hebben daarnaast bijgewerkte, uitgebreide 
pathways van vetzuurmetabolisme gemaakt op WikiPathways. 
De laatste hoofdstukken, 6 en 7, laten biologische toepassingen zien van de benaderingen besproken in 
de voorgaande hoofdstukken. Hoofdstuk 6 beschrijft de analyse en de resultaten van een 
oestrogeenreceptor α (ER-α) ChIP-on-chip dataset gericht op het uitpluizen van de moleculaire 
mechanismen achter de mitogene werking van oestrogeen in het menselijk endometrium en de borst, ten 
einde oestrogeen afhankelijke borstkanker beter te kunnen begrijpen. Hoofdstuk 7 beschrijft de resultaten 
van een ChIP-seq data analyse over de verrijking van activerende H3K4me3 en repressieve H3K27me3 
histon modificaties. De bestudeerde systeem is een MCF7 borstkanker cellijn die is blootgesteld aan 
hypoxische condities, zoals een model van de effecten die optreden in de kernen van solide tumoren. 
Kankercellen worden gekenmerkt door een scala aan epigenetische dereguleringen. Het begrijpen van 
de veranderingen in de histon modificaties in zo'n dynamisch systeem is de sleutel tot het begrijpen van 
de moleculaire mechanismen die ten grondslag liggen aan kanker en voor de ontwikkeling van 
toekomstige behandelmethoden. Deze toepassingen tonen het belang van de ontwikkelde methoden en 
de kracht van de integratie van cistromics en epigenomics technologie in systeembiologie onderzoek. 
 
Van alle stappen in de analyse van epigenomics en cistromics data, zal de biologische interpretatie altijd 
een stap blijven die supervisie door menselijke experts vereist. De rol van een bioinformaticus zou altijd 
moeten zijn om die stap zo soepel mogelijk te laten verlopen voor de bioloog door het creëren van 
gestandaardiseerde maar door de biologie gedreven aanpakken. Het werk gepresenteerd in dit 
proefschrift draagt bij aan de standaardisatie van analyse benaderingen op het gebied van epigenomics 
en cistromics door middel van gestandaardiseerde methoden voor data pre-processing van ChIP-on-chip 
en MeDIP-on-chip microarray data, data pre-processing van H3K27me3 histon modificatie ChIP-seq 
data, voor het integreren en verbeteren van bestaande biologische kennis, en ten slotte voor de 
interpretatie van epigenomics en cistromics gegevens in een biologische context. Toepassing van de 
 174 
ontwikkelde aanpak in biologisch onderzoek heeft geleid tot nieuwe inzichten in de mechanismen achter 
de oestrogeen afhankelijke borstkanker en epigenetische herprogrammering in hypoxische tumoren. Het 
werk gepresenteerd in dit proefschrift is slechts een klein deel van het vakgebied der systeembiologie. 
Alle inspanningen binnen dit vakgebied hebben een revolutie teweeggebracht in biomedisch onderzoek 
en het is slechts een kwestie van tijd voordat deze ontwikkelingen hun weg zullen vinden naar de kliniek 
en ons dagelijks leven. 
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